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Abstract 
Thesis Title: Tailored bio-molecular screening methodologies for selection of improved 
antibody lead clones for diagnostic and therapeutic applications. 
Candidate: Valerie Fitzgerald 
The interrogation of highly diverse repertoires of heterogeneous cell populations on a single 
cell basis increases the likelihood that a cell with unique characteristics will be identified. 
This thesis describes the development of a new single cell analysis system comprising 
millions of bundled sub-nanolitre volume bio-incubation chambers for the identification and 
recovery of target specific antibody secreting cells (ASCs). This Direct Clone Analysis and 
Selection Technology (DiCAST) is a patented antibody discovery technology that can not 
only reduce the time and cost for their discovery but also has the potential to find candidates 
that nobody else can. This newly developed technology is applicable to screening both 
bacterial and mammalian antibody secreting cells. The implementation and feasibility of this 
platform in identifying target specific antibodies from bacterial and B cell libraries is 
investigated in this work. It offers a much enhanced alternative to traditional screening 
approaches in both fields as well as offering drastically improved throughput and multi-
plexing capabilities when compared with competing single cell analysis technologies. In 
addition to development of this enhanced screening approach, complementary methods for 
automated (ELISA-based) and high throughput (SPR-based) screening of the selected 
antibodies were developed and deployed for routine use. These methods can be used to 
further characterise antibodies selected using DiCAST and aim to improve the overall 
screening workflow. 
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Chapter 1 
Introduction
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1.1 Section Overview 
This section serves as a brief overview of the antibody discovery field and the ways in which 
both traditional and novel, emerging techniques are applied to generate best-in-class 
monoclonal antibodies. Each of the experimental chapters also includes a more detailed 
description of the specific areas addressed within the thesis work.  
The key characteristics of antibodies, predominantly their high affinity and specificity for a 
binding partner has led to their utilisation in many varied applications in diagnostic, 
biotechnology and biomedical fields. The introduction of hybridoma technology in 1975 and 
the consequent ability to generate monoclonal antibodies (mAbs) led to a surge in antibody 
research and development. Since then there have been  several additional developments in 
the field such as immortalisation of antigen-specific human B cells, recombinant display 
technologies, the production of transgenic animals and the ability to directly clone the 
immunoglobulin (Ig) genes from single B cells (Wang, 2011). 
 As a result, the field of monoclonal antibody discovery has developed into a thriving 
industry and had a profound impact by providing a diverse source of therapeutic and 
diagnostic and research reagents. The global demand for immunoassay testing was nearly 
$15.6 billion in 2011 and $16.3 billion in 2012. This market is expected to grow to $20.5 
billion by 2017 (BCC Research, 2013) with research antibodies reaching $2 billion in 2013 
and nearly $2.2 billion in 2014 and the market expected to reach nearly $3 billion in 2019 
(BCC Research, 2015b). 
Therapeutic use of mAbs has become a major part of treatments in various diseases 
including transplantation, oncology, autoimmune, cardiovascular, and infectious diseases. 
With 36 approved mAb products and an unprecedented number of mAb-based therapeutics 
in clinical trials mAbs have become the fastest growing class of biological drug (Love et al., 
2013). Initial issues resulting from immunogenicity of murine mAbs have been reduced, or 
removed, by the development of methods to produce chimeric, humanised and fully human 
antibodies (Nissim & Chernajovsky, 2008). The global market for antibody drugs was worth 
nearly $63.4 billion in 2013. This market is expected to grow resulting in totals near $122.6 
billion globally in 2019, according to BCC Research (BCC Research, 2015a).  
1.2 A Brief History of Antibodies 
The beginning of antibody discovery dates back as far as the 18
th
 century when Edward 
Jenner essentially described vaccination when he showed that inoculating a boy with 
material from a cowpox pustule rendered him immune to the similar, but more serious, 
smallpox (Riedel, 2005). The earliest reference to antibodies was in 1890 when Emil von 
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Behring and Shibasabura Kitasato demonstrated that serum from animals immunised against 
diphtheria could cure infected animals. The potential of this work for therapy in humans was 
immediately recognisable and von Behring was awarded the Nobel Prize in 1901 (Kantha, 
1991).  
In 1900 Paul Ehrlich, regarded as one of the founders of modern immunology, proposed a 
model for an antibody molecule in which the antibody was branched and consisted of 
multiple sites for binding to foreign material, known as antigen, and for the activation of the 
complement pathway (Davies & Chacko, 1993).  In 1948 Astrid Fagraeus detailed the 
involvement of plasma B cells in the generation of antibodies in her doctoral thesis and later 
in 1957 Frank Burnet and David Talmage described their clonal selection theory, which 
stated that a lymphocyte produces a specific antibody molecule that is determined prior to 
any interaction with an antigen (Burnet, 1957). By 1959 the molecular structure of antibodies 
had been elucidated and independently published by Gerald Edelman and Rodney Porter; 
they were later jointly awarded the Nobel Prize in 1972 (Edelman, 1959; Porter, 1959).   
In 1975, Kohler and Milstein described the process of fusing a mouse myeloma cell with a B 
lymphocyte isolated from the spleen of a mouse that had been immunized with an antigen of 
interest, thereby allowing the in vitro synthesis of antigen-specific, monoclonal antibodies 
(Kohler & Milstein, 1975). Overcoming the limitations of their polyclonal counterparts, 
monoclonal antibodies allowed for an almost limitless and reproducible source of a specific 
antibody for use in research, diagnostics or therapeutics. This breakthrough essentially 
ushered in the modern era of antibody research and discovery. 
In 1976, only a year after Kohler and Milstein’s monoclonal antibody generation 
breakthrough, Susumu Tonegawa described the cloning of the first antibody gene 
(Tonegawa, 1976). In the 40 years since, the field of monoclonal antibody discovery and the 
tools which can be incorporated into the process have progressed to the point where the 
generation of monoclonal antibodies is a common practice, through a variety of methods, in 
laboratories worldwide.  
1.3 Antibody-producing cells 
Monoclonal antibody production typically begins with B lymphocytes. These can be 
obtained from varied sources, predominantly from lymphoid organs of immunised animals 
or from the peripheral blood of recently infected or immunised humans. B lymphocytes 
produce antibody to target and destroy invading foreign particles (e.g. bacteria, viruses) and 
protect the host.  
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The naïve B cell repertoire is thought to consist of  10
10
 potential antibody sequences (i.e. 
based on recombination of 51 potential V (variable) segments, 23 D (diversity) and 6 J 
(joining) segments in the VH and 360 different VL (lambda or kappa) sequences) (Dobson et 
al., 2015). Following V(D)J recombination in the bone marrow, the naïve B cells enter the 
peripheral B-cell pool. On encountering an antigen they produce low affinity IgM, but then 
become activated and undergo affinity maturation, through somatic hypermutation, in the 
germinal centres (i.e. spleen, lymph nodes, tonsils, and Peyer’s patches) prior to 
differentiation into memory or plasma cells (Dobson et al., 2015). The stages of B cell 
development and their location and antibody status are detailed below in Table 1.1. 
Table 1.1: Details for each of the stages of B cell development. 
Stage Principal Location Antibody Status 
Pre-B cell Bone Marrow V(D)J recombined 
IgM  
No mutation in V-regions 
Naïve B cell Peripheral Blood Selected for productively recombined antibodies 
IgM  
No mutations in V genes 
Antibody affinities 10
5
-10
6 
M 
-1
 
Memory B cell Peripheral Blood Selected for antigen binding 
10X higher Ig mRNA levels 
IgM/IgG/IgA/IgE  
Somatic mutation in the V-regions 
Antibody affinities 10
7
-10
10 
M 
-1
 
Plasma B cell Spleen/Bone Marrow Selected for antigen binding 
100X higher Ig mRNA levels 
IgM/IgG/IgA/IgE  
Somatic mutation in the V-regions 
Antibody affinities 10
7
-10
10 
M 
-1
 
 
There are three subsets of B lymphocyte of interest for antibody production. These are the 
memory B cells, plasmablasts and plasma cells all of which have high affinity, somatically-
mutated B cell antigen receptors (BCRs) (Tiller, 2011).  
1.3.1 Memory B cells 
Following the initial interaction with an antigen, naïve B cells produce antigen-specific IgM, 
followed by IgG and finally germinal centre (GC) formation. Memory B cells respond in a 
rapid and efficient manner when exposed to the same antigen, even at low levels, a 
subsequent time and quickly differentiate into antibody-secreting cells which produce 
protective, affinity matured Ig (Takemori, 2014).  
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Memory B cells persist for a lifetime and are consistently present in the peripheral blood of 
previously infected or immunised individuals at low levels (Lanzavecchia et al, 2007). Their 
frequency can be increased by repeated exposure to the antigen. Memory B cells can be 
stimulated to differentiate into antibody-secreting cells ex vivo by addition of mitogens or a 
cocktail of cytokines (Agematsu et al., 1998; Tarlinton, 2014).  
1.3.2 Antibody-secreting cells  
Derived from memory B cells upon activation there are two recognised subsets within the 
antibody-secreting cells (ASCs); these are plasmablasts and plasma cells (both long and 
short-lived). 
1.3.2.1 Plasmablasts 
Plasmablasts are proliferating, antibody-secreting B cells which have been activated by an 
antigen. They are short-lived cells which appear in the peripheral blood and lymphoid organs 
for a short window-of-time during secondary response (i.e. in response to an immunological 
boost). They appear in the peripheral blood approximately 7 days after injection (Tarlinton, 
2014).  
1.3.2.2 Plasma cells 
Plasma cells are terminally-differentiated B cells which secrete antibodies at a very high rate, 
but are short-lived (~1-3 days ex vivo) (Tarlinton, 2014). They are present in the blood in 
high numbers 6-10 days after immunisation and then migrate to the bone marrow where they 
remain as long-lived plasma cells (Lanzavecchia et al., 2007). Plasma cells represent <1% of 
lymphoid cells, but are responsible for the production of the vast majority of circulating IgG  
(Clargo et al., 2014).  
 
1.4 Production of monoclonal antibodies 
1.4.1 Hybridoma Technology 
The hybridoma method involves the immortalisation of antibody producing B cells from the 
spleens of immunised animals by fusion with a myeloma cell line, allowing for the 
continuous production of antibodies with the desired specificity (Kohler & Milstein, 1975).  
There are three basic fusion techniques used to generate hybridomas for the purpose of 
monoclonal antibody production. The first, and most commonly used method, involves the 
use of fusogenic chemical agents such as polyethylene glycol (PEG). While the exact 
mechanism has not been elucidated it is thought that adjacent cell membranes are driven 
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together by volume exclusion (Smith & Crowe, 2015). This approach is relatively cheap and 
simple but suffers from a very low fusion efficiency with efficiencies estimated at 
approximately 1 stable hybridoma from 100,000 starting B cells (Greenfield, 2014).  
The second involves the use of fusogenic viruses such as murine parainfluenza virus type 1, 
more commonly known as Sendai virus. The viral nucleocapsid is introduced into the 
cytoplasm of the host cell through insertion of the viral fusion protein (i.e. F protein) into the 
cell membrane (Smith & Crowe, 2015). There are commercially available kits, which 
provide Sendai virus for fusion purposes. One particular producer, Cosmo Bio,  has shown 
mouse hybridomas that obtain a fusion efficiency of 100% using specific medium additives 
and 96 % of cells go on to produce antibody compared with PEG fusion which gives results 
of 38 % and 9 %, respectively (http://www.cosmobio.co.jp/). This approach is only 
compatible with murine cells and as such would not be suitable for generation of a human 
hybridoma.  
The third and generally accepted as most efficient method of cell fusion, electrical 
cytofusion, is suitable for all cell types and has been optimized for the purpose of human 
hybridoma generation (Smith & Crowe, 2015) . It involves the application of high-intensity 
electric field pulses to cells.This causes transient membrane permeabilisation. This method 
requires optimization in a number of steps, such as means to bring cells into contact with 
each other (i.e. chemical or physical) and the pulsing conditions used.  
Hybridoma technology has several appealing features, including a relatively simple protocol, 
low costs with the principle being that the  authentic sequence and pairing of antibody DNA 
from a natural B cell is preserved and allows for the expression of a naturally occurring full-
length human mAb (Smith & Crowe, 2015). In terms of screening, hybridoma cells can be 
plated without  the need for feeder cells, even at one cell per well in 96-well plates. Although 
this can result in slightly lower cloning efficiency, the surviving hybrids are very stable and 
usually good producers of mAbs.   
The major disadvantage of the hybridoma method is low fusion efficiency, resulting in a 
limited number of mAbs produced per experiment. This principal limitation in hybridoma 
screening had, in the past, tended to be concerned with screening throughput and as such the 
low efficiency of fusion was not extremely pressing. However, as techniques become 
available to process far greater numbers of hybridomas, a means to increase efficiency is 
needed (Greenfield, 2014). Stimulation of B cells substantially increases the fusion 
efficiency and development of mAbs. The most commonly used method is the infection and 
transformation of B cells by Epstein Barr Virus (EBV), the details of which will be discussed 
in the subsequent section. 
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1.4.2 Immortalization of the human B cells by Epstein-Barr virus (EBV)  
The use of Epstein-Barr Virus (EBV) was invented by Steinitz et al. to generate a human 
monoclonal antibody specific to a synthetic hapten (NNP.20) (Steinitz et al., 1977). It 
utilises the supernatant of the B95-8 marmoset cell line which was established by Miller et 
al. The culture supernatant contains EBV which infects the B cells and transforms them in 
culture over a 1-2 week period (Miller et al., 1972).  
Similar to the hybridoma process, transformation with EBV is inefficient and the 
transformed cells frequently suffer from genomic instability and loss of antibody production 
that could hamper antibody discovery (Kwakkenbos et al., 2014). Additionally the EBV-
transformed cells are not cancerous cells and cannot continue to grow and produce 
antibodies indefinitely due to cell senescence. While this could be overcome by generating a 
large cell bank of the EBV-transformed cells early in the process, cells are often subjected to 
hybridoma fusion to produce the desired cell line for long-term culture and antibody 
production (Gorny, 2012).  
A subsequent finding has shown that the activation of B cells with an oligodeoxynucleotide 
containing the CpG motif, which acts as an agonist to Toll-like receptor 9, can greatly 
enhance the efficiency of EBV transformation (i.e. transformation is increased from 1%–2% 
to 30%–100% of B lymphocytes) (Traggiai et al., 2004). 
1.4.3 Combinatorial Libraries 
The challenge of circumventing the limitations of the hybridoma technique coupled with the 
requirement for large quantities of high quality antibodies led to the emergence of methods 
for their generation recombinantly. These antibody libraries consist of a large number (i.e. up 
to billions) of heavy and light chains which have been generated by PCR from the mRNA of 
B cells. They can generated from a wide array of animals (e.g. mouse, rat, rabbit, camelid, 
shark and human among others) once enough molecular information is available for the 
given species to allow amplification of antibody regions (Berry & Popkov, 2015).They can 
be designated as either immune, naïve or synthetic.  
1.4.3.1 Types of combinatorial library 
1.4.3.1.1  Immune libraries 
Immune libraries are generated from individuals who have mounted an antibody response 
following exposure to an immunogen of interest. Exposure may have occurred through 
active immunisation, as is the case with laboratory animals, or by natural means (e.g. 
exposure to an infectious agent, pathogen or toxin, as well as immune response to diseases 
such as cancer or those which affect the immune system). Immune libraries provide an 
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enriched source of antigen-specific, affinity-matured antibodies by harnessing the natural in 
vivo mechanisms of the host (Berry & Popkov, 2015). Immune libraries typically do, 
however, require the immunisation of animals ahead of time and with growing concerns into 
the ethics and procedures over extensive use of animals for experimentation the use of naïve 
and synthetic libraries, discussed below, are highly attractive (Festing et al., 1998; Leenaars 
& Hendriksen, 2005).   
1.4.3.1.2 Naïve libraries 
Naïve libraries are generated from B cells of individuals who have had no known prior 
exposure to a particular immunogen, which theoretically means an antibody to a vast range 
of targets could be isolated from a large (i.e. >10
10
 library size), diverse ‘single-pot’ library 
without the need for immunisation and library construction for each different antigen of 
interest (Persson, 2009). The most common source of B cells is peripheral blood of multiple 
human donors, often from blood banks (Pansri et al., 2009), but theoretically naïve libraries 
could be generated from any animal if required (Berry & Popkov, 2015). Due to the lack of 
natural affinity maturation processes in the host, the isolated antibodies often require 
improvement by employing available mutagenesis strategies, some of which are discussed 
later in this chapter. Nevertheless, the use of naïve libraries has been shown to identify 
numerous novel antibodies, against varied targets, and offers a very attractive alternative to 
the use of immune libraries (Edwards et al., 2003; Pershad et al., 2010).  
1.4.3.1.3 Synthetic libraries 
Synthetic antibody libraries are based on synthetic DNA sequences and involve introduction 
of diversity in the CDRs of germline V-gene segments (Pande et al.,  2010). While 
particularly promising in the fact that they offer the ability to strategically design very large 
antibody libraries with desired properties (e.g. low immunogenicity or high expression) their 
uptake has not been as great as their alternatives, most likely owing to the complexity 
involved in their design (Berry & Popkov, 2015). Several companies such as Medimmune, 
Genentech and Morphosys AG have generated very large synthetic libraries (i.e. up to 10
11
 
library size) and isolated antibodies in the nano- and picomolar range (Knappik et al., 2000; 
Ponsel et al., 2011). 
1.4.3.2 Methods for screening of combinatorial libraries 
Commonly described as display methods, an array of approaches for generation and 
screening of these combinatorial libraries have now become commonplace in modern 
laboratories. They offer an attractive approach as modifications are easily introduced in the 
primary antibody sequence leading to affinity maturations, often resulting in higher affinity 
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for binding to the antigen, generation of fusion proteins and addition of detection and 
purification tags. Additionally, the use of recombinant technology allows us to overcome 
what is termed the “affinity ceiling” of antibodies produced in vivo and provide libraries of 
higher diversity than those generated in the natural immune response (Hearty & O’Kennedy, 
2011).  Display methods afford us the ability to choose those ligands which have the desired 
biological properties and permits synthesis of “tailor-made” antibodies for use in diagnosis, 
immunotherapy or for immunoassay development. The predominant processes which include 
phage display, yeast display, bacterial display, ribosome display and mRNA display are 
discussed below. A comparison of methods for the production of monoclonal antibodies, 
mentioned in this chapter, is represented in Figure 1.1.  
 
Figure 1.1: Schematic representation of the different approaches for producing 
monoclonal antibodies. The traditional hybridoma technology for obtaining mouse 
antibodies is shown on the left. The right shows the main procedures for obtaining 
antibodies through display systems (phage, in vitro and cell display). With display 
technologies, antibodies can be developed from immune, naïve, or synthetic libraries and 
derived from different sources. There are also a number of different antibody fragments 
which can be produced. Image adapted  from (Aires da Silva et al., 2008). 
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1.4.3.2.1 Phage Display 
Phage display was first described, in 1985, when George Smith demonstrated that the 
linkage between phenotype and genotype could be established in filamentous bacteriophage, 
which is illustrated in Figure 1.2  (Barbas et al., 2001). Following on from this discovery, in 
the early 1990s several laboratories described phage display systems for antibody fragments 
(McCafferty et al., 1990) (Barbas et al., 1991). In terms of antibody generation, antibody 
genes are linked to the amino terminus of the phage minor coat protein pIII. When 
expressed, the encoded fusion product is incorporated into the mature phage particle during 
normal phage biogenesis. The resulting phage particle expresses antibody on its surface and 
contains the antibody encoding gene (Aires da Silva et al., 2008). 
 
Figure 1.2: Display of a scFv antibody on a filamentous bacteriophage particle. The 
location of the capsid proteins and the scFv antibody are clearly indicated by arrows. 
Filamentous phage particles are covered by approximately 3000 copies of the small major 
coat protein pVIII. Few copies of the minor coat proteins pIII and pVI are displayed at one 
extremity of the phage particle, while pVII and pIX proteins are located at the other 
extremity. The scFv is displayed as a fusion to g3p (pIII) protein at the tip of the phage. The 
phage particles may incorporate either pIII derived from the helper phage or from the scFv 
fusion protein and, therefore, in reality, the scFv is not fused to all pIII protein molecules, 
allowing the phage to retain its ability to infect bacteria. 
Large libraries containing millions of different antibodies can be obtained by force cloning in 
Escherichia coli. From these repertoires, phage carrying specific antibodies can be isolated 
by repeated cycles of selection on the antigen of interest, each of which involves binding, 
washing, elution and amplification (Hoogenboom, 2002). A more detailed description of 
considerations in selection processes is provided elsewhere by Conroy et al.,(2009). 
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1.4.3.2.2 Cell Display Methods 
Cell display methods employ various cell systems, either prokaryotic or eukaryotic, for 
expression and selection of antibody fragments demonstrating desirable characteristics.  
Prior to the introduction of phage display technologies, methods to display antibodies on 
bacterial cells had been demonstrated. The method was hindered by the lack of an efficient 
screening method but with the introduction of high-speed flow cytometry technologies, 
namely fluorescence-activated cell sorting (FACS) its use has grown (Aires da Silva et al., 
2008).  While Gram-positive bacteria (e.g. Bacillus brevis and Bacillus subtilus), which 
secrete proteins directly into the medium due to the lack of  cell wall, have been exploited to 
produce and purify different antibody fragments, Gram-negative bacteria (e.g. Escherichia 
coli ) are more commonly used (Schirrmann et al. 2008). Because the expression of 
recombinant antibodies in the cytoplasm principally results in non-functional aggregates, 
most are produced in the periplasm of the bacteria using N-terminal leader sequences 
(Schirrmann et al., 2008). This was enabled by the work of Skerra and Pluckthun, who 
described the first expression of a functional antibody fragment in E.coli, and observed that 
directing the fragment to the oxidizing environment of the periplasmic space allowed for the 
correct formation of disulfide bonds (Skerra & Plückthun, 1988). The expressed antibody 
fragment can then be isolated from the periplasmic fraction or in some cases from the culture 
supernatant (Schirrmann et al., 2008). Although bacterial display theoretically holds certain 
advantages over phage display (e.g. less technically demanding) a direct comparison of the 
methods, by Lunder et al., found that phage display tends to be more successful in 
identifying ligands of interest (Lunder et al., 2005). An additional disadvantage to 
prokaryotic expression is their inability to provide post-translational modifications such as 
glycosylation (Altshuler et al., 2011). 
Using eukaryotic hosts a more sophisticated protein secretion and folding apparatus is 
provided, as well as the capacity for post-translational modifications, when compared to 
prokaryotes.  While mammalian cells are still the system of choice for the production of 
antibodies the disadvantages associated with their use (which include a requirement for 
highly specialised dedicated facilities, high cost and lengthy production times) mean that 
other systems have been investigated. Yeast, filamentous fungi, insect cells along with 
transgenic plants and animals have all been used in the production of recombinant antibodies 
(Schirrmann et al., 2008). Perhaps the most widely used eukaryotic display technology is 
yeast display. Antibody fragments are displayed on the cell surface as part of a hybrid 
protein that is made up of the antibody or antibody fragment and the Aga2p agglutinin 
subunit, which is covalently linked by two disulfide bonds to Aga1 agglutinin in the yeast 
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cell wall (Altshuler et al., 2011). The use of yeast technology combines the ease of culture 
seen with prokaryotic systems with the capacity for folding and secretion of eukaryotic 
systems. Other benefits of the system include rapid and quantitative screening facilitated by 
FACS and convenient evaluation of characteristics such as affinity without the need for 
soluble expression and purification of each clone of interest (Gai & Wittrup, 2007). 
1.4.3.2.3 ‘In vitro’ display technologies 
The predominant technologies described as ‘In vitro’ display methods are ribosome display 
and mRNA display. These methods are outlined in Figure 1.3. 
During ribosome display, DNA encoding the library is transcribed in vitro. The resulting 
mRNA lacks a stop codon, giving rise to linked mRNA-ribosome-protein complexes during 
in vitro translation. These can be stabilised and directly used for selection against an antigen 
of interest.  The mRNA incorporated in bound complexes is eluted and purified. Reverse 
transcription polymerase chain reaction can introduce mutations and yields a DNA pool 
enriched for binders that can be used for the next iteration (Lipovsek & Plückthun, 2004). 
In the case of mRNA display, covalent mRNA-protein complexes are created by ligation of a 
DNA linker with a small adaptor molecule, puromycin, to create the in-vitro-transcribed 
mRNA, which lacks a stop codon. The mRNA is translated in vitro, and the ribosome stalls 
at the RNA-DNA junction. Puromycin then binds the ribosomal A-site and the nascent 
polypeptide is thereby transferred to puromycin, as if it were an aminoacyl-tRNA. The 
resulting covalently linked mRNA-protein complex is isolated, reverse-transcribed and used 
in selection procedures. The DNA strand is recovered from target-bound complexes by 
hydrolysing the complementary mRNA at high pH and then amplified by PCR (Lipovsek & 
Plückthun, 2004). 
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Figure 1.3: In vitro display methods. Ribosome display and mRNA display. Image amended 
from (Lipovsek & Plückthun, 2004). 
 
Because they are performed entirely ‘in vitro’ these methods hold two advantages over other 
competing technologies. The first depends on the fact that library size can be much larger 
(10
12
-10
14
, Aires da Silva et al., 2008) as it does not depend on the transformation efficiency 
of competent bacteria but rather on the amount of ribosomes and different mRNA molecules 
present. Secondly, there is the potential to introduce random mutations after each selection 
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round by introducing randomization steps, using non-proofreading enzymes, introduced after 
RT-PCR (Amstutz et al., 2007). 
1.5 Strategies for improving recombinant antibodies  
Conventional methods of antibody production such as polyclonal and hybridoma production 
are severely limited in their ability for improvement or modification. Recombinant antibody 
technology has a clear advantage over traditional antibody production in this respect. Not 
only can recombinant antibodies be “tailored” through genetic modification for a particular 
application, they can be “retailored” and improved to keep up with changing requirements. 
An excellent example of this is provided by Korpimäki and colleagues, at the University of 
Turku, where they converted an anti-sulfonamide mAb obtained from a hybridoma and 
modified its specificity to bind up to 15 sulfonamide derivatives, significantly improving the 
capabilities of the immunoassay (Bienenmann-Ploum et al., 2005; Korpimäki et al., 2003; 
Korpimäki et al., 2002). Altering the amino acid sequence of antibodies using gene 
engineering allows for an improvement in characteristics such as affinity, specificity, 
stability and immunogenicity (Altshuler et al., 2011). Mutagenesis strategies can be divided 
into the following categories, random mutagenesis, site-directed mutagenesis and DNA 
recombination. 
1.5.1 Random mutagenesis 
Random mutagenesis involves the random change of any amino acid in the antibody gene 
sequence.  Perhaps the most well-known method for random mutagenesis is error-prone 
PCR. Error-prone PCR employs low-fidelity polymerases and/or conditions which favour 
mis-incorporation of nucleotides (e.g. presence of Mn
+2
, limiting amounts of dATP and 
dCTP) to create libraries of random mutants (Sheedy et al., 2007; Maynard & Georgiou, 
2000). Alternatively a bacterial mutator strain, for example MutD5, can be used to introduce 
single base substitutions at high frequency compared to normal cells (Sheedy et al., 2007). 
These strains have an impaired mis-match repair system and can have mutation frequencies 
in the region of 0.2-1 substitutions per 1000 nucleotides per cycle of propagation (Maynard 
& Georgiou, 2000). The major advantage of random mutagenesis is that it does not require 
any information about the antibody structure or the interacting amino acids. However, the 
disadvantage lies in the fact that mutant libraries often have a large proportion of 
functionally inactive mutants (Altshuler et al., 2011). 
1.5.2 Site-directed mutagenesis 
Site-directed mutagenesis, in contrast to random mutagenesis, introduces mutations at 
chosen positions in the antibody gene sequence. Site-directed mutagenesis can be used 
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alongside crystallography studies to elucidate information about the active site and in this 
way perhaps provide an insight into antigen binding (Sheedy et al., 2007). The introduction 
of “in silico” techniques adds weight to this in that it could potentially allow the simulation 
of mutation and its consequences at specific points. This would allow for a more rational 
selection of those mutations, which seem to confer positive effects on antigen-antibody 
binding, for experimental manipulations (Altshuler et al., 2011). 
1.5.3 DNA recombination 
DNA recombination, also known as antibody shuffling, somewhat mimics somatic 
hypermutation and as a result is thought to be more efficient than random or directed 
mutagenesis approaches (Sheedy et al., 2007). Shuffling of antibody genes can be carried out 
in a number of ways. The first is chain shuffling whereby the heavy and light chains of 
antibodies, selected as positive binders, from an immune library, are recombined. Fitzgerald 
et al. describe a 185-fold increase in sensitivity of a halfuginone-specific scFv using chain 
shuffling and its subsequent incorporation into an immunoassay for detection in samples 
(Fitzgerald et al., 2011).  The second, deemed DNA shuffling, involves digestion of the 
antibody DNA with DNAse 1 and its subsequent reassembly and amplification by PCR. A 
third method called staggered extension process or StEP is also reliant on PCR and involves 
template switching caused by shortened extension times. This shuffles portions of the parent 
antibody genes (Sheedy et al., 2007).  
 
1.6 Strategies for reducing immunogenicity of monoclonal antibodies 
Even though the first monoclonal antibody-based human therapeutic was from a murine 
source (i.e. muronomab-CD3 under the trade name ORTHOCLONE OKT3) concerns over 
their potential to be highly immunogenic in patients led to the development of strategies to 
minimise the non-human portion of monoclonal antibodies for therapy (Kellermann & 
Green, 2002). The category from which a monoclonal antibody drug has been derived can be 
garnered from the suffix of their generic mAb name (i.e. –omab is of murine origin, -ximab 
is chimeric, -zumab is humanised and –umab fully human) (Lee & Owen, 2012).  
1.6.1 Chimerisation of monoclonal antibodies 
Chimerisation, first described in 1984,  involves the use of molecular biology to enable 
grafting of the antigen-specific variable domains of the selected murine antibody on to the 
human antibody constant domains (Ribatti, 2014). Chimeric antibodies are approximately 
70% human, making them considerably less immunogenic, and have a human Fc portion 
which means they can interact with human effector cells and can elicit activation of 
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complement (Chames et al., 2009). A number of marketed monoclonal antibody therapeutics 
generated by chimerisation include abciximab (REOPRO®), rituximab (RITUXAN® or 
MABTHERA®) and infliximab (REMICADE®) (Zhang, 2012).  
While this approach reduced the proportion of murine content in the antibody, chimeric 
antibodies can still be quite immunogenic (Kellermann & Green, 2002) and other strategies 
to further reduce the murine content of the monoclonal antibodies generated were soon 
developed.  
1.6.2 Humanisation of monoclonal antibodies 
Methods for humanisation of monoclonal antibodies, which are approximately 85-90% of 
human origin (Chames et al., 2009), can be generally divided into two approaches. The first 
are deemed the rational methods which employ a design cycle and aim to either minimise the 
non-human content or to simplify the design cycle. Examples of  rational methods for 
humanisation include complementarity determining region (CDR) grafting, specificity 
determining residue (SDR) grafting, superhumanisation, resurfacing or human string content 
(HSC) optimisation (Lu et al., 2012). While advantageous because they retain the full Ig 
format, which can help to maintain important characteristics of the antibody, these 
approaches require a detailed knowledge of the sequence and structure of the selected 
antibody in order to be made possible.  
The second are known as empirical methods, which involve the generation and screening of 
libraries for antibodies with desired properties, and include methods such as guided 
selection, humaneering, CDR repair and framework repair and shuffling. These approaches 
are often considered disadvantageous because the libraries generated are typically fragment 
libraries (i.e. scFv or Fab) and require conversion into a final Ig format (Lu et al., 2012).  
While these approaches have been widely used and have resulted in a number of drugs 
reaching the market, including omalizumab (XOLAIR®), trastuzumab (HERCEPTIN®) and 
bevacizumab (AVASTIN®) (Zhang, 2012), the potential to alter affinity by introducing a 
large degree of change in the CDR regions means that these antibodies still maintain a high 
proportion of non-human sequence (Bernett et al., 2010).  
1.6.3 Fully Human monoclonal antibody production 
Human monoclonal antibodies are desirable because they are indistinguishable from 
endogenous antibodies and as such are thought to have enhanced pharmacokinetic and 
pharmacodynamics properties when compared to chimeric and humanised antibodies (Beerli 
& Rader, 2010).  
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Monoclonal antibodies which are designated as “fully human” typically originate from one 
of two different sources, transgenic mice/rats or from recombinant libraries (Bernett et al., 
2010). Those antibodies selected from naïve recombinant libraries will often need to go 
through several iterations of improvement to reach the desired affinity (Lu et al., 2012). 
Nevertheless several human monoclonal drugs generated in this manner have been 
developed into therapeutics, e.g. adalimumab (HUMIRA®), belimumab (BENLYSTA®) 
(Zhang, 2012).  
Transgenic rodents have been also been used to generate fully human antibodies by 
effectively disabling the production of the animal’s own murine antibodies and replacing that 
function with human antibody genes (Ribatti, 2014). These mice have been shown to be 
capable of producing high-affinity antibodies with completely human sequences, by 
performing VDJ recombination and somatic hypermutation as they normally would 
(Maynard & Georgiou, 2000). The antibodies are generated by immunisation of these 
transgenic animals and subsequent generation of libraries, or by producing hybridomas.  
Initially a reduced immunogenic response seen in transgenic animals meant that more 
animals were required to generate the diversity required for any one screening campaign 
(Lee & Owen, 2012) but several companies (e.g. KyMab, OMT and Ablexis among others) 
have responded to this shortcoming and are now generating improved transgenic strains of 
rodents which incorporate improvements such as retaining a greater amount of murine cis 
elements to allow more efficient B cell receptor assembly and signalling, as well as including 
a more complete human Ig repertoire  so that responses seen are similar to those in wild-type 
mice (Lu et al., 2012).  Therapeutics on the market generated in this way include 
ofatumumab (ARZERRA®) and panitumumab (VECTIBIX®) among others.  
Of course the other potential source of fully human monoclonal antibodies would be to 
generate antibodies from human sources. While active immunisation of humans is obviously 
not possible, for ethical reasons, the use of B cells from patients recovering from a disease or 
those having been exposed to an infectious agent could be utilised (Aires da Silva et al., 
2008). Moreover, it is not possible to easily access the secondary lymphoid tissues (i.e. the 
spleen) as would be the case when generating antibodies using immunised animals and while 
tonsil tissue has been utilised (Duvall et al., 2011), it would not typically coincide with an 
immune response of interest. Accordingly the main source of human B cells is peripheral 
blood, ideally from recently vaccinated or infected patients so that the frequency of 
circulating B cells is sufficient to proceed.  
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1.7 Rationale for moving towards human B cells as source of monoclonal antibodies 
The advent of display technologies for the production of antibody fragments has greatly 
extended their field of application. In addition, gene engineering has allowed for the 
preparation of antibodies to non-immunogenic or toxic antigens which could not be 
generated using typical hybridoma technology. Coupled with this, the ability to evolve these 
antibodies by genetic means, to include more desirable traits (e.g. increased affinity, tags for 
detection and purification), makes recombinant antibody production an extremely powerful 
tool. There are several explanations given as to why antibodies generated by recombinant 
means have not superseded those produced by traditional hybridoma technology. These 
include the fact that the phage display platform was covered by a number of patents making 
it costly, the lack of knowledge about the technology and the apparent shortcomings in 
expertise and library availability and perceived issues with expression of the recombinant 
fragments (Bradbury et al., 2011). There is no universal method which can reliably provide 
high yields of recombinant antibody and this stems from the complexity and difference in 
each antibody-based molecule (Schirrmann et al., 2008). 
The use of immunised animals in combination with the advanced technologies, discussed 
earlier in this chapter, has led to the successful production and employment of numerous 
chimeric, humanised and human monoclonal antibodies. These techniques will continue to 
be utilised to generate antibodies and indeed there are hundreds of new antibody candidates 
at various stages in clinical trials, worldwide (Zhang, 2012). Despite these successes, the fact 
remains that experts in the field maintain the opinion that the ideal source for monoclonal 
therapeutic antibodies is human B cells (Duvall & Fiorini, 2014). The immunogenicity of 
human and humanised antibodies have been found to be less than that of  non-human and 
chimeric mAbs, which can elicit human anti-mouse antibody (HAMA), human anti-rat 
antibody (HARA) and human anti-chimeric antibody (HACA) responses. However human 
anti-human antibody (HAHA) responses have been observed in certain cases, mainly 
attributed to differences (e.g. in idiotype, allotype or glycosylation patterns) between the 
generated mAbs and those which would occur naturally in humans (Beerli & Rader, 2010). 
A number of advantages that exist when using human B cells as the source material for the 
production of monoclonal antibodies include the fact that the antibodies are fully human and 
have minimal chance of cross reacting with self-antigens as they have been selected in the 
human system. Furthermore, humans can mount a powerful immune response and can direct 
it against the components, of the invading pathogen, that confer infection and virulence 
which are often not seen by immune systems of other hosts (Lanzavecchia et al., 2006).  
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Methods which have been applied to the use of human B cells, both naïve and immune, for 
monoclonal antibody generation include human B cell library generation (i.e. EBV 
immortalisation or hybridoma generation from naïve B cells or B cells of individuals who 
have been naturally exposed or vaccinated against a particular agent or have recovered from 
a disease), use of display technologies (i.e. generation of a recombinant libraries using the 
isolated B cells, with naïve or immune, and subsequent screening using display approaches) 
and the isolation and screening of single cells (Duvall & Fiorini, 2014).  
The generation of human B cell libraries was initially hindered by the low efficiencies for 
both hybridoma fusion and EBV transformation, which have been discussed in sections 1.4.1 
and 1.4.2, respectively. This level of inefficiency may be considered acceptable when 
dealing with the splenocytes isolated from an immunised animal (i.e. typically around 10
8 
cells from personal experience) but because of the low frequency of B lymphocytes in blood 
(i.e. generally accepted levels in 10 mL of peripheral blood from a non-immunised donor are 
approximately 1 x 10
7
 peripheral blood mononuclear cells (PBMCs) of which B 
lymphocytes constitute roughly 15%) (Miyahira, 2012) the inefficiencies would likely result 
in failure and unacceptable loss of precious cells.  
Furthermore, until recently there were very few suitable fusion partners available to allow 
production of human hybridomas. Thankfully there are now several options available to 
allow successful fusion with human B cells (e.g. SHM-D3327 and HMMA 2.5 cell lines 
from ATCC) (Gorny, 2012). In addition, the simplest strategy for immortalisation of human 
B cells, EBV transformation, has recently seen the identification of methods to boost 
efficiency from 1-2% to 30-100%, as previously mentioned in Section 1.4.2. This will allow 
for B cells to be expanded in vitro prior to and after screening, facilitating cell banking and 
further characterisation (Smith & Crowe, 2015).  
Although the use of display methods has proven useful in this area, the ability to maintain 
the natural VHVL pairing is highly desirable and as such has led to the development of 
techniques which allow for investigations of cells on an individual basis. In the next section, 
traditional approaches will be discussed and compared with these rapidly developing single 
cell techniques.  
Single cell PCR, which could remove the need for generation of combinatorial libraries or 
long-lived cell lines, is an approach which holds a great degree of promise in the area of 
human mAb discovery. Issues that require attention relate to the technological issue of 
capturing enough genetic material from a single cell to allow amplification of both of the 
variable regions. Memory B cells, which persist in circulation for many years, contain very 
little RNA and, conversely, plasma cells which contain ample amounts of RNA appear in the 
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peripheral blood for a very narrow window of time (i.e. 6-10 days following exposure to a 
particular agent) (Clargo et al., 2014). The B cells can be enriched from peripheral blood by 
FACS or using bead-based isolation approaches, which are commercially available from 
numerous companies, to facilitate the process. Additionally, a number of elegant techniques 
which have been designed to identify antigen-specific single B cells have emerged in the 
field recently and they are discussed later in this chapter.  By coupling these technologies 
with single cell PCR there is the potential to overcome all of the limitations that are 
associated with other methods.  
1.8 Screening approaches for monoclonal antibody discovery 
The continued improvement of the efficiencies of hybridoma fusion and EBV transformation 
and the generation of large combinatorial libraries has now become commonplace. The need 
for screening approaches which can comprehensively screen such a large, heterogeneous 
population of cells has resulted in a surge in modifications to existing technologies and also 
in novel antibody screening platforms.  
While traditional approaches have tended to employ bulk measurements, incorporating 
multiple iterations of screening, before finally identifying the single cell producing the 
antibody of interest there has been a shift towards single cell analysis. This means that cells 
that may have been overgrown by fast-growing clones are now identified and not masked in 
the larger culture (Greenfield, 2014; Smith & Crowe, 2015).  
Some of the most common approaches (e.g. microtitre plate-based screening and FACS) 
alongside some of the new, emerging platforms for single cell antibody discovery are 
described below.  
1.8.1 Cloning by limiting dilution 
The screening of mammalian cells in typical antibody discovery approaches (e.g. hybridoma 
cells, non-fused B cells or EBV transformed B cells) relies on the employment of cloning by 
limiting dilution. Cloning by limiting dilution is a method based on the Poisson distribution. 
Dilution of cells to an appropriate number per well can maximize the proportion of wells that 
contain one single clone (Fuller et al., 2001). It involves the segregation of cells in the wells 
of microtitre plates (96 or 384 well) and screening of the supernatants for positive binding to 
the required antigen, as shown in Figure 1.4. Depending on the original seeding level, 
several rounds of cloning may be required to attain clonality of the cells. In order to address 
the entire population of cells they are often plated with numerous (5-5000) cells per well. 
There is a balance to be met between overloading wells and the number of plates that it is 
feasible to screen. By adding too many cells to a well an antigen-specific cell of interest may 
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be overlooked due to its presence being masked by fast-growing non-productive clones. 
Conversely some cells do not survive well on a single cell basis for an extended period of 
time and may require the presence of feeder cells, growth supplements, or conditioned 
medium and single cell plating will result in a higher number of plates to process. Ultimately 
the facilities available, within a particular laboratory, may become the limiting factor and 
numbers screened will depend on the levels of automation available.  
 
Figure 1.4: Antibody discovery process for mammalian cells. The process of cloning by 
limiting dilution, for both hybridomas and B cells. (A) Cells are fused with a myeloma cell 
line (hybridoma) or remain unmodified for screening (B cells) (B) Cells are divided into the 
wells of microtitre plates at a given frequency, typically 1-5000 depending on the level of 
automation available. Cells are allowed to incubate for up to two weeks and then the 
supernatants are screened for a desired response (e.g. binding) (C) Wells which exhibit a 
positive response in initial tests are then diluted and segregated further in the wells of a 
microtitre plate until single cell occupancy is achieved (D) A number of positives are taken 
forward for characterisation (e.g. kinetic analysis by Biacore, cross reactivity by ELISA and 
functional analysis by numerous bioassays (e.g. apoptosis, agonist, antagonist). 
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1.8.2 Fluorescence activated cell sorting (FACS) 
Fluorescence activated cell sorting (FACS) is a modified version of flow cytometry, 
developed, in Stanford University by Len Herzenberg and his research group, in the 1960’s  
(Lanier, 2014). Cells which have been stained with fluorescently-labelled antibodies, 
antigens or other reagents determining a property of interest are then held in suspension and 
the liquid broken into droplets by application of vibration. Prior to breaking into droplets the 
flow of liquid containing the cells passes through a measuring station where the fluorescent 
properties of each cell are analysed. An electrical charging ring is present at the point where 
the droplets are formed and a charge is assigned (i.e. positive, negative or neutral) to each 
droplet based on the previously determined fluorescent measurement. The droplets are then 
sorted and collected based on their charge as they pass through an electrostatic field, as 
shown in Figure 1.5 (Jahan-Tigh et al.,2012).  
 
Figure 1.5: Schematic of the principle of fluorescence activated cell sorting (FACS). (A) 
Hydrodynamic focusing and vibration by a transducer produces a stream that breaks into 
droplets, containing cells which have been stained with fluorescently-labelled antibodies (B) 
Droplets are interrogated by the laser and the signals are processed to give the “sort 
decision” (i.e. if the droplet contains a green fluorescent cell it will be charged and sorted 
accordingly) (C) A charge is applied, if appropriate, as the droplet breaks off. (D) The 
charged droplet containing the cell of interest is directed by the electrostatic field into the 
designated collection tube.  
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1.8.3 Next generation sequencing 
Next generation sequencing (NGS) or “deep sequencing” has been employed in the area of 
antibody discovery to complement, and indeed entirely eliminate, the need for traditional 
screening. It involves in depth sequence analysis of the variable region gene repertoires from 
a heterogeneous population of cells (e.g. B lymphocytes from an immunised animal or 
members of a combinatorial library) and the use of  bioinformatics to allow pairing of the 
appropriate VH and VL regions, based on their frequency in the population (Haessler & 
Reddy, 2014). The antibodies can then be synthesised, expressed and tested in terms of 
antigen binding or other required properties.  
The increase in throughput and the decrease in cost for this type of sequencing analysis that 
has occurred in the past number of years means that it is now possible to determine the 
sequence of millions of different variable regions in a short space of time (Dobson et al., 
2015). 
One drawback of this approach is that the natural VH/VL pairings are not definitively 
identified and are instead elucidated from the frequencies of each in the particular population 
(Mathonet & Ullman, 2013). Other limitations include the costs associated with processing 
of such a large number of samples and the fact that the error rate is higher than that observed 
in Sanger sequencing (Mathonet & Ullman, 2013).  
While NGS cannot yet address the entire potential human repertoire (i.e. theoretically 10
11
) 
its use in conjunction with other techniques can be used to provide a more streamlined and 
informed antibody discovery process. The use of NGS to perform quality control on 
combinatorial libraries could serve to provide a more accurate evaluation of diversity of a 
particular library in place of simply stating the  number of transformants as is currently the 
case (Fischer, 2011).  Furthermore its application to populations before and after each round 
of immunisation, or after natural infection, could lead to important insights into humoral 
immunity and aid in the development of more effective vaccines (Mathonet & Ullman, 
2013).  
As the technology is relatively new to the field, it can be expected that the limitations that 
currently exist for the method will be circumvented in coming years and that the utilisation 
of NGS as an antibody discovery process will improve the ability to identify new therapeutic 
candidates. A particularly interesting example of such an advancement is described by 
DeKosky et al. who demonstrate a means to maintain the VH/VL pairing in their screening of 
peripheral blood B cells of both healthy and recovering donors. By spatially addressing the 
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cells in microengraved microwells which contained poly(dT) magnetic beads the individual 
cells could be lysed and the mRNA captured on the beads and in situ. The variable regions 
were then linked by performing PCR on the cDNA generated and sequencing carried out 
(DeKosky et al., 2013).  
1.8.4 Microengraved microwells 
Microengraved microwells are produced using a soft-lithography approach, which results in 
a chip comprising up to 62,500 individual polydimethylsiloxane (PDMS) wells which can 
range in volume from 0.1-1.0 nL. A number of research groups, and companies, utilise this 
approach to analyse heterogeneous populations of cells. Detection of a secreted response can 
be achieved in a number of ways. The first is the so-called ISAAC (i.e. immunoassay array 
on a chip) method where specificity is detected as a halo of fluorescence around the well 
containing the cell of interest (Figure 1.6 A-C) (Jin et al., 2009).  
 
Figure 1.6: Examples of outputs from microwell-based antibody screening platforms. (A) 
Signals for antigen-specific antibodies secreted from individual cells were detected and 
visualised as a halo of fluorescence around the well containing the cell. (B) The cells are 
then stained using Oregon Green (C) Antibody signals and cell signals were merged to allow 
for accurate retrieval of the desired cell. (D) Phase contrast micrograph of cells in the 
microwells of the microarray. The arrowheads indicate the location of cells in the wells. 
Scale bar, 200 mm. (E) Fluorescence micrograph of the corresponding region of a 
microarray showing conjugation of captured antibody with fluorescently-labelled antigen. 
Images A-C were taken from Jin et al (Jin et al., 2009). Images D-E were taken from Love et 
al. (Love et al., 2006). 
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The second involves sealing a functionalised glass slide to the top of the array and generating 
a printed array of secreted proteins from each of the cells, which can then be probed with 
appropriate secondary reagents similar to commercial arrays of antibodies or proteins (Figure 
1.6  D-E) (Love et al., 2006). They are also amenable to performance of homogenous assays 
in the microwell itself. Following identification of those cells exhibiting desired properties, 
such as secretion of an antigen-specific antibody, the cells are subsequently recovered for 
clonal expansion/recombinant retrieval using a micropipette or the cell is lysed, RT-PCR 
carried out and the VH and VL sequences paired using next generation sequencing (DeKosky 
et al., 2013).  
1.8.5 Microfluidic microchambers 
This approach employs a microfluidic chip with 'lab in a trench' like chambers where cells 
are captured and cultured, as shown in Figure 1.7 (Diercks et al., 2009). For antibody 
discovery applications, secreted antibodies are captured on protein beads and later detected 
by washing out the chambers with medium prior to the addition of labelled antigen.  
 
Figure 1.7: Schematic of the layout for one recirculating microchamber. Control channels 
are shown in red (100 µm width), and flow channels are show in blue (13 µm height) or light 
blue (2.5 µm height). The three valves forming the recirculating peristaltic pump are 
labelled p1, p2, and p3. The total volume of the recirculating chamber is 4.7 nL. Sample is 
loaded into a 2.7 nL segment of this chamber. Image taken from Diercks et al. (Diercks et 
al., 2009). 
 
 
Positive antibody binders are visualised by automated microscopy of fluorescent beads in 
each well and cells removed by micromanipulation for further manipulations, similar to 
those mentioned above. Cells can be cultured and expanded in the chambers, before 
retrieval, if required.  
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 Lecault et al. describe the production of a PDMS chip using multi-layer photolithography, 
which contained 1,600 individual microchambers each of 4.1 nL volume, and whose 
environment can be precisely controlled by the integrated micro-valves (Lecault et al., 
2011). A researcher working in the same research group also demonstrated the use of a 
similar chip, with 200 pL chambers, to accurately determine the kinetic rate constants of 
antibodies secreted from single hybridoma cells by flushing each different concentration of 
antigen utilised from the chamber by way of microfluidic sieve valves (Singhal et al., 2010).  
1.8.6 Microdroplets 
The use of microdroplets as a single cell screening tool has also recently developed within 
the field. It involves the isolation of individual cells by capturing them in two-phase droplets 
which range in volume from picolitre to nanolitre (Mazutis et al., 2013). They can be used 
for single cell analysis in a range of applications from antibody and cytokine secretion to 
gene expression or enzyme activity (Love et al., 2013). Droplets are then sorted by FADS 
(Figure 1.8).  FADS (Fluorescence activated droplet sorting) works on the same principle as 
FACS but overcomes the limitation of detection of secreted product as secreted product is 
also contained within the droplet or using microfluidic chips to interrogate each individual 
droplet. Interestingly, passive droplet fusion, electro-coalescence, and pico-injection have all 
been utilised to allow addition of  reagents at a defined time point. This adds to the diversity 
of assays which can be carried out in droplets (Mazutis et al., 2013). 
These platforms utilising microdroplets are employed for a vast array of single cell studies 
which range from viability and cytotoxicity studies utilising libraries of drug candidates 
(Brouzes et al., 2009), heterogeneous immunoassay development using magnetic beads 
(Sista et al., 2008) and monoclonal antibody discovery (El Debs et al., 2012; Mazutis et al., 
2013)  all in highly reproducible nano- to femto-litre droplets.  
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Figure 1.8: Application of microdroplet screening, using a microfluidic sorting device, for 
antibody discovery. (A) The cells to be screened are encapsulated in a microdroplet with the 
assay reagents under laminar flow (i.e. In this case the cells are hybridoma cells secreting 
murine antibodies and the assay reagents comprise a goat anti-mouse-Fc capture antibody 
and a GFP-labelled anti-goat detection antibody). Droplets are collected and incubated off-
chip for a designated amount of time to allow secretion of antibody from the cells. (B) The 
droplets are then re-injected into a second microfluidic device to be sorted (C) Cells are 
sorted based on the presence of a bright green (GFP) colour. Droplets containing no bead, 
no cell, a cell which does not secrete antibody, or an antibody-producing cell but no bead 
are discarded, whereas droplets containing an antibody-producing cell and a bead (which 
becomes fluorescent due to specific interaction of the components of the droplet) are 
collected. Image taken from Mazutis et al. (Mazutis et al., 2013).  
1.9 Antibody Characterisation  
Following their successful generation, screening and selection the need to further 
characterise the chosen antibodies in a number of different ways, for a number of different 
reasons or applications will emerge. In typical screening approaches, the final number of 
candidates selected for characterisation are often reduced to a manageable number through 
iterative rounds of selection. The development of high-throughput, automated procedures 
which allow for a higher number of candidates to be characterised are becoming 
commonplace and the ability to carry out at least some of the characterisation on the entire 
population of antibodies in a particular library or cell population would be highly 
advantageous. The concept of screening more or all potential candidates, to help identify 
better monoclonal antibodies, is elaborated upon in experimental chapters 6 and 3, 
respectively.  
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Those methods predominantly used as standard, to determine key attributes of each 
candidate antibody, and which are most relevant to the work carried out in this thesis are the 
use of immunoassays, bioassays and determination of kinetic rate constants using surface 
plasmon resonance (SPR).   
1.9.1 Characterisation using Immunoassays 
Following selection, monoclonal antibodies will typically be tested for maintained 
recognition of the desired antigen, by employing an immunoassay. For recombinant systems, 
lysates of individual clones can be prepared and for mammalian systems, the supernatants 
are assessed. This can be a time-consuming process but is a necessary step to ensuring that 
only clones which exhibit true recognition of the antigen are brought forward to the next 
rounds of screening and characterisation. Typically this screening can represent a bottle-neck 
in the overall process and in many facilities automation is applied to reduce the labour and 
time involved. Other clever methods can serve to address this bottle-neck such as that of  
Guo et al., who describe an ‘on-plate’ method which negates the need for the preparation of 
lysates for each bacterial clone. Instead, the method detects secreted antibody directly in the 
growth medium (Guo et al., 2010).  
Following identification of the clones which exhibit maintained binding to the antigen, it is 
customary to then define certain characteristics of each of the antibody candidates. Criteria 
such as specificity for the target antigen, cross-reactivity with similar antigens, sensitivity 
(limits of detection (LOD) and quantitation (LOQ)) and detection range can all be 
determined utilising various immunoassays.  
Within Chapter 6 the characterisation of a recombinant scFv fragment against C-Reactive 
protein, and its subsequent employment in a sandwich assay for the detection of CRP in 
patient serum samples is described.  
1.9.2 Characterisation using Bioassays 
In the development of therapeutic monoclonal antibodies, it is not sufficient that they merely 
bind to the target antigen for which they have selected but that they elicit the desired 
response in the patient.  The response may include neutralisation of a particular agent or 
inhibition, interruption or induction of a particular cellular process as well as triggering cell 
death. There are three main modes of action for therapeutic antibodies which, along with 
examples of assays used to identify them, are briefly described below.  
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1.9.2.1 Binding to cell bound antigen involving Fc effector function 
This first class of antibody operates by binding to their antigen, on the cell surface, which 
results in cell death through Fc-mediated effector functions. These include (i) antibody-
dependent cell-mediated cytotoxicity (ADCC) which occurs when Fc-receptors on effector 
cells recognise the antibody bound to the cell and the cells are killed by cell-mediated lysis 
or phagocytosis, (ii) complement-dependent cytotoxicity (CDC) occurs when complement 
binds to Fc of the cell bound antibody, and (iii) Fc-dependent apoptosis (Harris, 2004) 
Therapeutic monoclonal antibodies in this class include RITUXAN® (i.e. Rituximab induces 
apoptosis, ADCC and CDC and renders cells more sensitive to chemotherapy) and 
HERCEPTIN® (i.e. Trastuzumab induces ADCC and causes cell sensitivity to 
chemotherapy) (Jiang et al., 2011). Detection of these effects can be carried out  using 
several commercial assays which measure release of certain compounds (e.g. Lactate 
dehydrogenase or LDH cytotoxicity assays such as CytoTox-ONE from Promega), monitor 
cell viability (e.g. Tetrazolium or Resazurin reduction cell viability assays available from 
multiple suppliers such as Roche and Sigma) or apoptosis (e.g. Annexin V assays or 
detection of caspases such as Apo-ONE from Promega) (Riss, 2005).  
1.9.2.2 Binding to cell bound antigen not involving Fc effector function 
The second class of antibody also involves the binding of a cell surface antigen but its effects 
are not mediated by the Fc region. Instead it effectively neutralises, blocks, inhibits or 
induces a particular process within that cell. Antibody drugs which proceed through this 
mechanism include REMICADE® (i.e. Infliximab neutralises the activity of TNF-α) and 
VECTIBIX® (i.e. Panitumumab inhibits EGRF signalling and induces apoptosis) (Jiang et 
al., 2011). Assays typically monitor effects on cell proliferation (e.g. CyQUANT from 
Invitrogen or WST-1 assay from Roche) or cell viability and death, as mentioned above.  
1.9.2.3 Binding of soluble antigens  
The final class of therapeutic class of antibodies work by binding a particular soluble ligand, 
thus preventing it from binding to its receptor and inducing a particular cellular pathway. 
They include AVASTIN® (i.e. Bevacizuab which neutralises VEGFA activity) and 
XOLAIR® (i.e. Omalizumab which inhibits the binding of IgE to FcεRI) (Jiang et al., 2011). 
These are again monitored as mentioned in previous sections or can be measured in serum to 
determine their efficacy (Sato et al., 2012).  
Due to the complexity of the assays utilised for assessment of therapeutic effect, they are 
predominantly carried out at the very end of the screening and characterisation process. The 
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ability to apply these types of assays earlier in the overall process is becoming more and 
more desirable as selecting candidates on functional effect, and not merely on binding, may 
help to  improve the rate of failure in the final stages of antibody characterisation (Smith et 
al., 2012). Within chapter 5 a proof-of-concept experiment to employ a purified anti-Fas 
antibody to induce apoptosis in mammalian cells (i.e. Jurkat cells which have a Fas receptor) 
in an ultra-high throughput manner is demonstrated.  
1.9.3 Characterisation using surface plasmon resonance (SPR) 
Characterisation by SPR allows a label-free real time approach to elucidate a number of 
different qualities of each of the antibodies to be screened. These include measurement of 
quality of binding, affinity and rate constant determinations as well as the ability to study 
aspects such as thermodynamics of the antibodies. These SPR instruments, all with slightly 
different specifications, are available from a number of different vendors including Reichert 
Technologies (e.g. SR7000DC and SR7500DC SPR systems), BioRad (e.g. Proteon XPR36), 
ICx Nomadics (e.g. sensiQ) and GE Healthcare (e.g. Biacore instruments 3000, T100, T200, 
4000).  
1.9.3.1 Principle of SPR 
SPR is commonly used for the study of molecular binding interactions between free analyte 
in solution and probe molecules which are immobilised to the sensor surface. Instruments 
which employ surface plasmon resonance for the study of biomolecular interaction typically 
use a standard Kretschmann configuration  (Kretschmann, 1971) and utilise sensor chips 
which consist of a glass slide coated in a thin layer of metal, usually gold. In this setup light 
passes through a prism, reflects off the back side of the sensor chip surface and into the 
detector (Figure 1.9A). At a certain incident angle, known as the resonance angle, light is 
absorbed by the electrons in the metal film of the sensor chip causing them to resonate. 
These resonating electrons, known as surface plasmons, are highly sensitive to changes in 
their environment. The result of the reflection on the sensor chip is an intensity loss in the 
reflected beam which appears as a dark band and can be seen as a dip in the SPR reflection 
intensity curve. When a binding event takes place the angular position of the dark band shifts 
and shift in the reflection curve is detected and can be converted into response units (RU) to 
allow assessment of the interaction between the two binding partners in a time-dependent 
manner (Figure 1.9B).  
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Figure 1.9: Basis of the detection principle in an SPR instrument. (A) Monochromatic and 
p-polarised light is focused onto a gold chip surface immobilised with an antibody, by means 
of a prism under conditions of total internal reflection. (B) As antigen is injected over the 
immobilised surface, a change in refractive index near the sensor chip surface, results in a 
shift in the resonant angle of reflected light which is measured and recorded. The shift in 
reflected light is measured constantly and the results presented as a sensorgram of the 
change in measured response over time.  
1.9.3.2 Application of SPR to antibody screening 
In a typical setup one binding partner, known as the ligand, is immobilised to the sensor 
surface and the other binding partner, known as the analyte, free in solution is injected over 
the sensor surface. In the case of a specific antibody the kinetics of the binding event can be 
studied by monitoring the change in the SPR response over time, which is displayed as a 
sensogram (Figure 1.10).  
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Figure 1.10: Typical sensogram output monitoring a binding interaction using SPR. 
Initially there are many binding sites available resulting in rapid increase in the SPR 
response as the analyte binds to the ligand. The analyte continues to be delivered to the 
surface, it continues to bind and the number of binding sites decreases corresponding to a 
decrease in binding rate. As the system reaches equilibrium (i.e. the number of binding and 
unbinding events becomes equal) the SPR response levels off. When no more analyte is 
introduced the molecules will continue to unbind resulting in a decrease in SPR response. 
The association constant (ka) can be extracted from the behaviour of the binding response 
and likewise the dissociation constant (kd) is generated based on the unbinding response. 
The ratio of the two rate constants yields the affinity (KD) of the system.  
Other setups can be employed to increase the efficiency of the system. In a capture format, 
for example, an anti-species or anti-tag antibody is immobilised on the sensor surface, 
followed by the antibody and sample and then the antigen of interest. 
In terms of antibody screening, the employment of this type of screening provides several 
important traits of each of the antibody candidates. As well as confirming binding to the 
antigen in solution under flow conditions the ability to elucidate the rate constants (i.e. 
association constant or “on-rate” ka and the dissociation constant or “off-rate” kd) as well as 
the affinity (i.e. KD) means that antibodies best suited to their final application can be 
identified easily.  
For instance, in selecting antibodies for diagnostic point-of care applications a high affinity 
as well a fast association rate (i.e. binds to the antigen quickly) and a slow dissociation rate 
(i.e. remains bound to the antigen in a stable manner to allow accurate reading of the result) 
are all important features. In addition the study of the effect of ambient temperature and the 
thermodynamics of the interaction become of paramount importance in this type of analysis, 
as testing environments will vary and antibodies will need to maintain stable kinetics over a 
range of temperatures (Leonard et al., 2011).  
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Furthermore, when screening therapeutic antibodies the rate constants are particularly 
important in the effectiveness of that drug in vivo. A particularly striking example is that of 
anti-viral mAb, pavlivizumab (SYNAGIS®), which targets Respiratory syncytial 
virus (RSV). It was succeeded by a second generation variant, motavizumab, which had a 70 
times greater affinity, a six-fold faster association rate and eleven-fold slower dissociation 
rate (Marasco & Sui, 2007). The increased potency of  motavizumab, which shows a 83% 
reduction in RSV hospitalisations and 71% reduction in the number of patients needing 
outpatient management, is thought to be attributed to its superior association rate (Marasco 
& Sui, 2007).  
A specific and detailed example of the application of SPR screening to a particular antibody 
population is discussed in Chapter 6. Using a capture format assay on a Biacore 4000, 960 
scFv clones are screened, ranked and the top binders subjected to kinetic analysis in a high-
throughput manner.  
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1.10  Thesis description and summary 
This thesis will describe the development of a novel microcapillary-based microtool for the 
discovery of monoclonal antibodies and its application to both recombinant and mammalian 
antibody sources, as outlined in Figure 1.11.  To demonstrate the flexibility of the new 
microcapillary tool, throughout the thesis the sources of monoclonal antibodies vary greatly, 
from commercial and custom-built recombinant libraries to native B cells from immunised 
animals. These antibodies are directed towards both diagnostic (e.g. cardiac biomarkers such 
as Troponin I, C-reactive protein, Myoglobin and Myeloperoxidase) and therapeutic targets 
(e.g. Intact cancer cells) covering a wide range of potential applications. Furthermore there 
are numerous antigens used in the screens carried out and, unlike many studies, the aim of 
this body of research is to demonstrate the utility of the newly developed technology rather 
than to identify antibodies to any one designated target.  
 
Figure 1.11: Experimental chapter designation. Each of the experimental chapters (3-6) 
addresses a specific application in high-throughput antibody screening. Chapter 3 involves 
the development of a new microcapillary-based microtool to facilitate single cell screening. 
Chapter 4 and Chapter 5 describe the application of the newly developed technology to 
bacterial libraries and mammalian cells, respectively.  Chapter 6 details the use of ancillary 
high-throughput techniques (i.e. SPR screening and automated immunoassay platforms) to 
enhance the overall screening procedure.  
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The initial experimental chapter, Chapter 3, investigates the potential to utilise arrays of 
fused silica capillaries to spatially address millions of individual cells and to detect antibody 
secreted from any one cell in the population in a reliable manner. The thorough 
investigations carried out in this body of work detail the development of the technology from 
a radical idea to an actual realised entity. Areas of investigation include the ability to grow 
and detect secreted products from individual cells, the ability to carry out an antibody 
detection assay on a removable surface to identify cells of interest, the development of a 
procedure to allow relation of the physical array to the assay image generated as well as 
demonstration of a number of homogenous assay solutions as well as several additional 
multiplexing offerings.  
The second experimental chapter, Chapter 4, describes the application of this newly 
developed microtool to a number of different recombinant libraries to assess its performance 
against the traditional approach of phage display. The first challenge involves the use of the 
technology in screening an anti-CRP library, which was previously developed and screened 
in-house, and comparison of the resultant antibodies with those obtained in the earlier 
campaigns. The next challenge involves the use of a commercially available naïve library to 
screen for antibody fragments against multiple targets. The final challenge was to undertake 
the screening and comparison of outputs from an externally sourced library.  
The third experimental chapter, Chapter 5, details the feasibility studies carried out to 
determine the possibility of screening of mammalian cells using the technology. It involves 
the use of a mammalian cell line to optimise the process for cells of this type and then the 
application of these optimised protocols to allow for screening of native B cells using the 
developed technology. In addition to these screening campaigns, methods to capture the 
genetic information from cells of interest through single cell PCR and the development and 
demonstration of a functional bioassay (i.e. detection of apoptosis) on the microcapillary 
array platform are described.  
The final experimental chapter, Chapter 6, details approaches which can be used to 
complement the type of high throughput screening approach that has been developed. By 
screening more cells, one may ultimately end up with more positive hits and high-throughput 
methods for ranking and characterisation become important. In order to address this need, a 
series of protocols were developed for high-throughput SPR-based ranking of antibody 
fragments in crude lysates. In addition, a set of procedures to utilise automated liquid 
handling stations to carry out ELISA-based screening and characterisation of selected 
antibodies were also optimised.  
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Chapter 2 
Materials and Methods 
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2.1 Materials 
2.1.1 Purchased Reagents 
All general reagents were purchased from Sigma Chemical Co. (St. Louis, MO, USA), 
unless otherwise stated. 
Item Source 
Series S sensor chips CM5 
Amine coupling reagents  
10X Stock HBS-EP+ buffer 
GE Healthcare, Uppsala, Sweden. 
Polyclonal (goat) anti- HA epitope tag  
PageRuler pre-stained protein ladder 
Thermo Scientific, Waltham, MA, 
USA. 
Monoclonal (mouse) anti-cTnI antibodies Hytest Ltd, Turku, Finland. 
HRP-labelled monoclonal (rat) anti-HA Roche Diagnostics, Switzerland. 
Overnight express auto-induction medium 
pET28b plasmid vector 
Rosetta 2 competent cells  
Polyclonal (rabbit) anti-C-Reactive Protein  
Cy5-labelled streptavidin 
Cy5-labelled monoclonal (goat) anti-mouse  
Monoclonal (mouse) anti-Fas, human activating clone CH11 
Merck Millipore, Cork, Ireland. 
 
1KB plus DNA ladder 
SybrSafe DNA stain  
PCR reagents 
CO2 Independent Medium 
Superscript® III reverse transcriptase 
Trizol 
Invitrogen, Dublin, Ireland. 
Restriction enzymes 
Antarctic phosphatase  
T4 ligase 
New England Biolabs (NEB), MA, 
USA. 
Nickel-NTA purification resin Qiagen, Hilden, Germany. 
NucleoSpin® plasmid purification kit  
NucleoSpin® Extract II Purification System 
Macherey Nagel, Dueren, Germany. 
Vivaspin concentration columns Sartorius Ltd., Goettingen, Germany. 
XL1-Blue electro-competent cells Agilent technologies, CA, USA. 
NUNC maxisorb ninety-six well plates Fisher Ireland, Dublin, Ireland.  
Sterile ninety-six well plates Cruinn Diagnostics, Dublin, Ireland. 
(3-Aminopropyl) triethoxysilane (APTES) 
Bovine Serum Albumin (BSA) 
Sigma Aldrich, St. Louis, MO, USA.  
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Foetal Bovine Serum (FBS) 
RPMI 1640 medium 
Monoclonal (mouse)  anti-cMYC 
HRP-labelled polyclonal (goat) anti-HIS tag 
HRP-labelled polyclonal (goat) anti-Mouse 
Polyclonal (goat) anti-mouse 
C4-HSL 
3,3’, 5, 5’-Tetramethylbenzidine (TMB) 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
Chloroform  
Isopropanol 
Ethanol 
DEPC Water 
Polydimethylsiloxane (PDMS) Stockwell Elastomerics, PA, USA.  
Cardiac Troponin I (cTnI) 
Cardiac Troponin T (cTnT) 
Life Diagnostics, Westchester, PA, 
USA. 
C-Reactive protein (CRP)  
Myeloperoxidase (MPO) 
Transferrin (TRA) 
CRP-depleted serum 
BBI solutions, Cardiff, UK.   
 
Monoclonal (mouse) anti-human IgE 107 
Biotinylated monoclonal (mouse) anti-human IgE 182 
mAbTech AB, Sweden.  
Monoclonal (mouse) anti-CK18 M5 
Monoclonal (mouse) anti-CK18 M6 
Monoclonal (mouse) anti-CK18 M30 
BioAxxess, Tewkesbury, UK.  
Human Domain Library Source Bioscience, Nottingham, UK.  
Cy5-labelled monoclonal (mouse) anti-HA Tebu Bio, Le-Perray-en-Yvelines, 
France. 
Human IgG 
Cy5-labelled polyclonal (goat) anti-human IgG  
Biomeda Corp., CA, USA.  
Labelling Kits (Cy3/Cy5) Thermo Fisher Scientific, IL, USA.  
Polyclonal (goat) anti-HA Bethyl Laboratories Inc., UK.  
Monoclonal (mouse) anti-EpCAM 
Cy5-labelled monoclonal (mouse) anti-EpCAM 
Biolegend Inc., CA, USA.  
Briclone National Institute of Cellular Biology, 
DCU, Dublin 9, Ireland. 
HSL conjugates and unconjugated compounds Supplied, for evaluation, by 
independent UK laboratory. 
Jurkat T lymphoblastoid cell line 
 (ATCC TIB-152) 
Multiple myeloma B lymphocyte cell line (ATCC TIB-196) 
Kindly donated by ABG, DCU, 
Dublin.  
FRET DNA probes TIB MOLBIOL, Berlin, Germany 
GFP reassembly vectors [pET11a-Z-NGFP (NZ), pMRBAD-
Z-CGFP (CZ)] 
Obtained under MTA from Yale 
University 
pQE30-GFP vector Kindly donated by Dr. Paul Clarke, 
Dublin City University, Dublin, 
Ireland. 
Clinical samples (CRP) Obtained from the Mater Misericordiae 
University Hospital, Dublin, Ireland.  
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2.1.2 Buffer and Media Formulations 
2.1.2.1 Phosphate buffered saline (PBS) 
One Dulbecco’s A tablet (DA, Oxoid) was dissolved per 100 mL of distilled water according 
to the manufacturer’s instructions. When dissolved, prepared PBS contained 0.15 M NaCl, 
2.5 mM potassium chloride, 10 mM disodium hydrogen phosphate and 18 mM sodium 
dihydrogen phosphate, pH 7.4. This buffer will be referred to throughout as PBS. 
2.1.2.2 PBS-Tween (PBST) 
Tween 20 surfactant was added to PBS (described in 2.1.2.1 above) to a final concentration 
of 0.05% (v/v) and mixed. 
2.1.2.3 Tris-acetic acid-EDTA buffer (TAE) 
A 50 X stock solution of TAE buffer was prepared in a final volume of 1 litre by dissolving 
242 g Tris, and addition of 57.1 mL glacial acetic acid followed by 100 mL of 0.5 M EDTA. 
pH 8.0. All agarose gels were run in 1 X TAE by diluting the stock solution 1/50 with ultra-
pure water. 
2.1.2.4 Luria Bertani broth (LB)  
Medium was prepared by dissolving 10g Tryptone, 5g Yeast Extract and 5g NaCl, in 1L 
distilled water. Medium was then autoclaved for 15 minutes at 121ºC, for sterilisation. Solid 
medium was made by adding 15 g/L bacteriological agar. 
2.1.2.5 SOC broth 
Medium was prepared by dissolving 20g Tryptone, 5g Yeast Extract and 0.5g NaCl, in 1L 
distilled water. Medium was then autoclaved for 15 minutes at 121ºC, for sterilisation. Once 
cooled additional components (2.5mM KCl, 20mM MgCl2, 20mM glucose) were added, by 
sterile means to the medium. 
2.1.2.6 ZYP-5052 broth  
ZYP-5052, the auto-induction medium prepared in-house and described in Studier et al., is a rich 
medium for growth with little or no induction during log phase and auto-induction of expression 
as the culture approaches saturation (Studier, 2005). It is prepared by adding 1 mL 1M MgSO4, 
20 mL 50X 5052 and 50 mL 20X NPS to approximately 928 mL of ZY medium. Medium was 
then autoclaved for 15 minutes at 121ºC, for sterilisation. 
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ZY medium was prepared by dissolving 10 g tryptone and 5 g yeast extract in 1 L of distilled 
water. 5052 (50X) was prepared by dissolving 25 g glycerol, 2.5 g glucose and 10 g α-
lactose in 100 mL distilled H2O.  (5052 = 0.5% (v/v) glycerol, 0.05% (w/v) glucose, 0.2% 
(w/v) α-lactose). NPS (20X) was prepared by dissolving 6.6 g (NH4)2SO4, 13.6 g KH2PO4 
and 14.2 g Na2HPO4 in 100 mL of distilled H2O.  
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2.2 Methods-General 
2.2.1 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)  
The gel casting apparatus was prepared, as per manufacturer’s instructions. The mixture for 
the 12.5% separation gel and 4.5% stacking gel were prepared as outlined in Table 2.1, 
without adding the TEMED as this would accelerate the polymerisation. 
 
Table 2.1: Composition of separation and stacking gels for SDS-PAGE analysis of 
proteins. 
Reagent Separating Gel 
(12.5%) 
Reagent Stacking Gel 
(4.5%) 
1M TrisHCl, pH 8.8 1.5 mL 1M TrisHCl, pH 6.8 300 µL 
30% (v/v) Acrylagel 2.5 mL 30% (v/v) Acrylagel 375 µL 
2% (v/v) Bis-Acrylagel 1.0 mL 2% (v/v) Bis-Acrylagel 150 µL 
Water Deionized 934 µL Water Deionized 1.74 mL 
10% (w/v) SDS 30 µL 10% (w/v) SDS 24 µL 
10%  (w/v) APS 30 µL 10% (w/v) APS  24 µL 
TEMED 6 µL TEMED 2.5 µL 
  
On addition of the TEMED to the separation gel only, the mixture was mixed thoroughly and 
pipetted into the space between the two glass plates of the Biorad electrophoresis apparatus. 
The mixture was allowed to reach approximately 2-3 cm from the top of the smaller plate. 
The mixture was then immediately covered gently with isopropanol to promote more rapid 
polymerisation of the gel. Once the gel had polymerised, the isopropanol layer was removed 
by inverting the apparatus. The gel was then rinsed with distilled water and blotted dry with 
filter paper. The TEMED was then added to the stacking gel mixture and mixed thoroughly. 
The stacking gel mixture was then pipetted on the surface of the separating gel.  The plastic 
comb was gently inserted into the gap between the two glass plates and the gel was allowed 
to set.  
Samples, at the required dilution, were prepared for loading by adding 4X loading dye (60 
mM Tris-HCl (pH 6.8), 25% (w/v) glycerol, 2% (w/v) SDS, 14.4 mM 2-mercaptoethanol 
and 0.1% (w/v) bromophenol blue) to a final concentration of 1X and heated for 10 minutes 
at 98ºC. Gel apparatus was assembled according to manufacturer’s instructions and 1X 
electrophoresis buffer (25 mM Tris, 250 mM Glycine (electrophoresis grade), pH 8.3 and 
0.1% (w/v) SDS) was poured into the inner chamber until it reached the top of the plates.  
More of the running buffer was then gently poured into the outer chamber until it covered at 
least the bottom centimetre of the gel. Approximately 20 L of sample and 6 L of 
molecular weight marker (PageRuler pre-stained protein marker) were loaded onto the gel 
and it was run at 200 V until the tracker dye (bromophenol blue) had almost reached the 
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bottom of the gel. The gel was stained in Instant Blue stain for 1 hour and subsequently 
documented, using a BioRad GelDoc
TM
 EZ system. 
2.2.2 Small-scale antibody production 
Cultures were grown in 50 mL tubes containing 10 mL of auto-induction medium, to allow 
for expression of desired protein, overnight at 37 ºC /200 rpm. For the pCOMB vector LB 
medium containing 100 µg/mL carbenicillin was utilised, while for the pET vectors LB 
medium containing 70 µg/mL kanamycin was used. The cultures were then centrifuged at 
4,500 x g for 20 minutes, the cell pellets were re-suspended in one-tenth the original culture 
volume of PBS and subjected to three freeze-thaw cycles (-80ºC until frozen/37 ºC until 
thawed). Cell debris was removed by centrifugation at 4,500 x g for 10 minutes. Supernatant 
was stored at 4 ºC for immediate use or at -20 ºC for future use.  
2.2.3 Large-scale antibody production 
On the first day, a 10 mL culture of XL1 Blue E.coli expressing the desired protein were 
incubated overnight at 37ºC/200 rpm. For the pCOMB vector and the HSL clones, LB 
medium containing 100 µg/mL carbenicillin was utilised, while for the pET vectors LB 
medium containing 70 µg/mL kanamycin was used. On the following day a 250 mL culture, 
of overnight express auto-induction medium containing 100 µg/mL carbenicillin, was 
inoculated with 250 µL of the overnight culture. The culture was incubated at 37ºC/200 rpm 
overnight. Following expression of the desired protein the culture was centrifuged at  4,500 x 
g for 20 minutes to pellet the cells. The pellet was then re-suspended in one-tenth the original 
culture volume of 1X PBS and subjected to three rounds of freeze-thawing (-80ºC/37ºC) to 
completely lyse the cells. The cell debris was pelleted by centrifugation at 14,500 x g for 20 
minutes. The supernatant was filtered through a 20 µm filter and the scFv purified by IMAC, 
as described in Section 2.2.4. 
 
2.2.4 IMAC purification  
The Ni-NTA mixture (2 mL) was loaded into a column (2mLs slurry gives 1 mL column) 
and allowed to settle. The column was equilibrated using 10mLs of lysis buffer (50 mM 
NaH2PO4, 300 mM NaCl, 10 mM Imidazole, pH 7.5).  The filtered lysate was passed 
through the column. The flow through was collected and passed through the column once 
more.  The resin was then washed once with 8mLs of wash buffer A (50 mM NaH2PO4, 1M 
NaCl, 10% (v/v) glycerol, 20mM imidazole, 1% (v/v) triton X100, pH 7.5) and twice with 8 
mL of wash buffer B (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 7.5. The 
desired proteins were eluted with 5 mL elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 
mM imidazole, pH 7.5). A 100 µL sample of each fraction was kept for analysis on SDS-
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PAGE gel. The elution fraction was buffer exchanged and concentrated into PBS by passage 
through a vivaspin (10 kDa MWCO) column.  
2.2.5 Recombinant library information 
The anti-Troponin scFv antibody library was constructed from mRNA extracted from the 
spleen and bone marrow of two chickens immunised with purified cardiac Troponin I, 
cardiac Troponin T and myoglobin. The antibody variable domain genes were cloned into 
the pComb3XSS phagemid vector according to protocols described by Barbas and co-
workers (Barbas et al., 2001). The library size was 2.2 x 10
9
. The clones analysed throughout 
the Biacore study were monoclonal scFvs from the final output (Round 4) of phage display 
screening against cTnI. 
The anti-CRP and anti-MPO scFv antibody library was constructed from mRNA extracted 
from the spleen and bone marrow of two chickens immunised with purified CRP, MPO and 
FABP. The antibody variable domain genes were cloned into the pComb3XSS phagemid 
vector according to protocols described by Barbas and co-workers (Barbas et al., 2001). The 
library size was 3 × 10
7
.  
2.2.6 Purification of plasmid vectors 
An E. coli colony was taken from a LB agar plate and grown overnight in 5 mL LB broth, 
containing appropriate antibiotic, at 37
o
C and 200 rpm. The plasmid was then purified using 
the Macherey Nagel NucleoSpin® plasmid purification kit, according to the manufacturer’s 
instructions. Briefly, the bacteria were pelleted by centrifugation at 4,500 x g. for 5 minutes 
and the supernatant discarded.  The cell pellet was completely resuspended in 250 μL buffer 
A1. Following this 250 μL lysis buffer A2 was added to the cells, mixed gently by inverting 
the tube 6–8 times, and incubated at room temperature for up to 5 min or until lysate appears 
clear. Neutralisation buffer A3 (300 μL) was then added and mixed as previously described. 
Lysate was then transferred to a clean 2 mL micro-centrifuge tube and clarified by 
centrifugation for 5 min at 11,000 x g. The supernatant was decanted into a NucleoSpin® 
plasmid column and centrifuged for 1 min at 11,000 x g. The flow-through was discarded 
and the column was placed back into the collection tube. The silica membrane was then 
washed by addition of 600 μL ethanol-supplemented buffer A4 and centrifuged for 1 min at 
11,000 x g. The flow-through was once again discarded and the column centrifuged as 
previously to dry the silica membrane. Pure DNA was finally eluted, into a fresh collection 
tube, under low ionic strength conditions with 50 µL slightly alkaline buffer AE (5 mM, 
Tris-HCl, pH8.5) or DEPC water.  
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2.2.7 PCR amplification of specific gene products.  
A polymerase chain reaction (PCR) was carried out using various templates. The PCR 
reaction was prepared as detailed in Table 2.2. The reactions were then subjected to cycling 
conditions as outlined in Table 2.3. Primers used for each different PCR are listed in Table 
2.4.  
Table 2.2: Reaction volumes for polymerase chain reaction (PCR). The reactions were then 
subjected to cycling conditions as outlined in Table 2.3. Products were then analysed on a 
1% (w/v) agarose gel by electrophoresis. 
Reagent Volume ( µL) 
Template  2 
5X Reaction Buffer 10 
25 mM MgCl2 4 
10 mM dNTPs 1 
Primer 1  1 
Primer 2  1 
Taq Polymerase 1 
DEPC Water 30 (to give 50 µL total volume) 
 
Table 2.3: PCR cycling conditions. 
Temperature Step Time  
95°C         Initial Denaturation 5 min  
95°C Denaturation 30 sec 
30 Cycles 56°C Annealing  30 sec 
72°C Extension 1 min 
72°C Final Extension 10 min  
 
Table 2.4 DNA primers used for amplification 
PCR Section Primer Sequence 
Human IgE CH1 region 5.2.3 ConE-IgE  
CCA CAC AGA GCC CAC CCG TC 
CE1-IgE    
GCT GAA ACT AGT GTT GTC GAC 
Avian VH 5.4.4 CSCVHo-FL (Long Linker) 
GGT CAG TCC TCT AGA TCT TCC GGC GGT GGT 
GGC AGC TCC GGT GGT GGC GGT TCC GCC GTG 
ACG TTG GAC GAG  
CSCG-B  
CTG GCC GGC CTG GCC ACT AGT GGA GGA GAC 
GAT GAC TTC GGT CC 
Avian Vλ 5.4.4 CSCVK  
GTG GCC CAG GCG GCC CTG ACT CAG CCG TCC 
TCG GTG TC  
CKJo-B  
GGA AGA TCT AGA GGA CTG ACC TAG GAC GGT 
CAG G 
Avian SOE 5.4.4 CSC-F  
GAG GAG GAG GAG GAG GAG GTG GCC CAG GCG 
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GCC CTG ACT CAG 
CSC-B  
GAG GAG GAG GAG GAG GAG GAG CTG GCC GGC 
CTG GCC ACT AGT GGA GG  
cTnI peptides 6.2.4 GFP-pep1-For   
ACG TGG ATC CGA AAA TTA GCG CGA GCC GTA 
AAC TGC AGC TGA AAA CCG AGG GTG GTG GCA 
TGA GTA AAG GAG AAG AAC  
 
GFP-pep2-For   
ACG TGG ATC CGA ACT ATC GTG CGT ATG CGA 
CCG AAC CGC ATG CGA AGA AGA AAA GCA AAA 
TTG AGG GTG GTG GCA TGA GTA AAG GAG AAG 
AAC  
 
GFP-pep3-For   
ACG TGG ATC CGC AGC CGC TGG AAC TGA CCG 
GCC TGG GCT TTG CGG AAC TGC AGG AGG GTG 
GTG GCA TGA GTA AAG GAG AAG AAC 
 
GFP-pET-Back  
ACG TAA GCT TTT TGT ATA GTT CAT CCA TGC  
 
2.2.8 Agarose gel electrophoresis for DNA characterisation 
DNA was analysed by running on agarose gels (containing 1X SybrSafe for staining of 
DNA) in a horizontal gel apparatus. Gels were prepared by dissolving agarose (typically 1% 
(w/v)) in 1X TAE buffer by heating and SybrSafe added to the cooled gel prior to setting. 
The gels were placed in the gel apparatus and 1X TAE used as the running buffer. A tracker 
dye was incorporated into the sample (1 µL dye + 5 µL sample) to facilitate loading of 
samples. Gels were run at 100 Volts for 1 hour or until the tracker dye reached the end of the 
gel. Gels were then visualised on a blue light transilluminator and photographed using using 
a BioRad GelDoc
TM
 EZ system. 
2.2.9 Gel purification of PCR products from agarose gel 
DNA was purified from the agarose gel using a Macherey Nagel NucleoSpin® Extract II 
Purification System as per the manufacturer’s instructions. Briefly, the DNA band of interest 
was excised using a clean, sterile scalpel blade and the agarose slice transferred to a sterile 
1.5 mL microcentrifuge tube and weighed. The fragment was then dissolved in NT1 buffer 
(200 μL buffer NTI 100 mg of agarose gel) at 50ºC for 5-10 minutes or until the agarose had 
completely dissolved. Once dissolved, the mixture was applied onto the silica membrane of 
the NucleoSpin® Extract II columns provided, and centrifuged for 30 seconds at 11,000 x g. 
The flow-through was discarded the column placed back into the collection tube. 
Contaminations were removed by washing with 700 µL ethanolic buffer NT3 and 
centrifuging as previously.  Pure DNA was finally eluted, into a fresh collection tube, under 
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low ionic strength conditions with slightly alkaline buffer NE (5 mM, Tris-HCl, pH8.5) or 
DEPC water.  
2.2.10 Dephosphorylation of digested plasmid vector using Antarctic phosphatase.  
The purified vector was de-phosphorylated using Antarctic phosphatase, which catalyses the 
removal of 5´ phosphate groups from DNA and RNA, according to manufacturer’s 
instructions. Briefly, 1/10 volume of 10X Antarctic phosphatase reaction buffer was added to 
1-5 µg of DNA cut with restriction endonuclease. 1 µL of Antarctic phosphatase (5 units) 
was added, mixed and incubated at 37°C for approximately 30 minutes, The enzyme was 
then heat inactivated  for 5 minutes at 65°C. Since phosphatase-treated fragments lack the 5´ 
phosphoryl termini required by ligases, they cannot self-ligate and this property is used to 
decrease the vector background in cloning strategies. The DNA present in both the digested 
insert and the digested and de-phosphorylated vector were then quantified at 260 nm, using a 
Nanodrop instrument, before proceeding to ligation.  
2.2.11 Transformation of ligation mixes into electro-competent cells by electroporation 
A 2 L fraction of the ligation mix was added to 50 L of electro-competent cells (on ice) 
and stirred gently with a pipette tip.  The mixture was added to an ice-cold electroporation 
cuvette which was placed in the gene pulser chamber and pulsed at 2.5 kV. The cuvette was 
removed from the apparatus, transferred to a sterile 20 mL tube and 3 mL of SOC medium 
(pre-warmed to 37C) added. The transformation was then incubated at 250 rpm and 37C 
for 1 hour. Serial dilutions were then carried out and 100 L spread on LB agar plates, 
containing appropriate antibiotic, and incubated overnight at 37ºC to select for positive 
transformants. 
 
2.2.12 Colony pick PCR for confirmation of inserts in transformants.  
Single colonies were picked from transformation plates and resuspended in 10 µL sterile 
DEPC water.  A 2 µL volume of this was used as template in a PCR reaction, carried out as 
described in 2.2.7, varying the primers used depending on the peptide concerned. The 
remaining solution was used for expression testing or streaked on an LB agar plate 
containing appropriate antibiotic and incubated overnight at 37ºC to provide a stock of each 
transformant for future use.  
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2.3 Methods- Chapter 3 
2.3.1 Assessment of auto-induction versus standard induction.  
Each of the media was prepared as outlined in section 2.1.2. An overnight stock of GFP 
expressing E.coli was then added to a 10mL culture of each and incubated at 37°C/200rpm. 
The auto-induction samples were kept under these conditions overnight while the IPTG 
induced culture had 1 mM IPTG added once it had reached the log phase of growth 
(approximately 0.6 OD600nm). It was then incubated at 30°C/200 rpm overnight. On the 
following day the cultures were centrifuged at 4,500 x g and the pellets observed. A lysate 
was subsequently produced from each of the cultures and analysed by SDS-PAGE, as 
described in section 2.2.1. All media are detailed in section 2.1.2 
2.3.2 Assessment of expression of protein and viability of cells in the microcapillary 
array.  
A stock of GFP-expressing E. coli, at a concentration of 4.6 x 10
9
 cells/mL, were centrifuged 
at 4,500 x g for 10 minutes and re-suspended in overnight express medium. A 100 µL was 
then added to an array, using a micropipette. The array was then sealed with a thin layer of 
PDMS, imaged using a fluorescent microscope (Olympus IX81 fitted with a FITC filter; 10X 
magnification) and subsequently incubated at 37°C overnight. The area was then imaged, on 
the following day, as described previously. A nitrogen gas flow was then applied to the top 
of the array and any contents removed were then captured on an agar plate beneath. The 
plate was then incubated at 37°C overnight.  
2.3.3 Analysis of GFP-expressing Escherichia coli in the microcapillary array 
A stock of GFP expressing E.coli, at a concentration of 4.6 x 10
9
 cells/mL, was diluted in 
series (1/10) in overnight express medium. A 5 µL aliquot of each dilution was then added to 
an array. The array was then sealed with a thin layer of PDMS and incubated at 37°C 
overnight. After incubation, the array was imaged using a fluorescent microscope (Olympus 
IX81 fitted with a FITC filter; 10X magnification). In order to identify a cell number which 
results in single cell occupancy of the array, a cell enumeration was carried out on agar 
plates simultaneously.  
2.3.4 Performance of a direct assay through the microcapillary array onto a PDMS 
surface.  
The surface of the PDMS was coated with 10 µg/mL human IgG (hIgG) in PBS and 
incubated for 1 hour at room temperature. The hIgG was carefully removed with a pipette 
and the surface blocked with 3% (w/v) BSA in PBS, and incubated as before. The BSA was 
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removed, the surface was rinsed gently with PBS and allowed to dry. The PDMS was then 
degassed for 30 minutes, in a standard dessicator. A 2.5 µg/mL dilution of Cy5-labelled anti-
hIgG, in 3% (w/v) BSA, was then added to the array and the array sealed to the prepared 
PDMS surface. The array was then incubated for 1 hour at room temperature. Following 
incubation the PDMS was gently rinsed with PBS, allowed to dry and imaged using either 
the Perkin Elmer Gx ScanArray or an Olympus IX81 fluorescent microscope.  
2.3.5 Chemical modification strategies tested on polydimethylsiloxane (PDMS) surfaces. 
The first two modification strategies were taken from the work of Yu et al. (2007) and the 
final three were suggested by Vladimir Gubala of the surface science group within the 
Biomedical Diagnostics institute. The carboxy modification strategies (1 and 2) were carried 
out by Dr. Gubala and are described in Coyle et al. (2012).  
2.3.5.1 Preparation of PDMS-EDC surface 
A layer of PDMS was immersed in 10% (v/v) (3-Aminopropyl)triethoxysilane (APTES) in 
absolute ethanol for 10 min at room temperature. The APTES-treated PDMS were rinsed by 
96% (v/v) ethanol, air-dried and then heated at 80°C in a vacuum oven for 2 hours. The 
resulting PDMS-APTES was then modified for producing carboxyl groups by addition of 
succinic anhydride (SAA), at 50 µg/mL in pure water for 2 hours at room temperature. The 
surface was then rinsed and air-dried under nitrogen before addition of 20 µg/mL EDC (1-
Ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride) mixed with coating protein (5 
µg/mL human IgG) for one hour at room temperature. The surface was then rinsed with Tris-
HCl buffer to stop the crosslinking reaction and the surface was blocked with 1% (w/v) BSA 
for 2 hours at 37°C.  
 
2.3.5.2 Preparation of PDMS-GA surface 
A layer of PDMS was immersed in 10% (v/v) APTES in absolute ethanol for 10 min at room 
temperature. The APTES-treated PDMS were rinsed by 96% (v/v) ethanol, air-dried and 
then heated at 80°C in a vacuum oven for 2 hours. The surface was then modified by 2.5 % 
(v/v) glutaraldehyde (GA) for 1 hour at room temperature. The surface was then rinsed with 
Tris-HCl and dried under nitrogen flow. Coating protein (5 µg/mL human IgG) was then 
added in Tris-HCl at room temperature for 2 hours and subsequently blocked with 1% (w/v) 
BSA for 2 hours at 37°C.  
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2.3.5.3 Preparation of PDMS-Carboxy (1) surface 
Coatings were kindly carried out by Dr. Vladimir Gubala using a computer-controlled 
PECVD reactor Europlasma, model CD300 (Oudenaarde, Ghent, Belgium). Surfaces were 
prepared as described in Coyle et al. (2012) with this Carboxy 1 surface representing the 
tetraethyl orthosilicate (TEOS) only surface. 
2.3.5.4 Preparation of PDMS-Carboxy (2) surface 
Coatings were kindly carried out by Dr. Vladimir Gubala using a computer controlled 
PECVD reactor Europlasma, model CD300 (Oudenaarde, Ghent, Belgium). Surfaces were 
prepared as described in Coyle et al. with this Carboxy 2 surface representing the tetraethyl 
orthosilicate (TEOS) and acrylic acid (AA) surface.  
2.3.5.5 Preparation of PDMS-APTES surface 
A layer of PDMS was subjected to oxygen plasma treatment for 10 minutes and then 
submerged in 3% (v/v) APTES in 98% (v/v) ethanol for 1 hour at room temperature. The 
surface was then rinsed with 98% (v/v) ethanol and baked at 60°C overnight. 
2.3.6 Determine feasibility of performing immunoassay in the array and comparison 
with microtitre plates. 
A DiCAST screen was carried out using a sandwich FLISA on array. A thin-layer of 
APTES-modified PDMS was coated with 5 µg/mL anti-hIgG (un-labelled) in PBS and 
incubated for one hour at room temperature. The PDMS was then blocked by addition of 3% 
(w/v) BSA and incubated for one hour at room temperature. The PDMS was then degassed 
for 30 minutes, in a standard dessicator. Dilutions (1/10 series) of hIgG were prepared in 
1.5% (w/v) BSA and added to distinct areas of a 40 µm array starting at a dilution of 250 
µg/mL and the array was sealed to the prepared PDMS. The array was then incubated for 
one hour at room temperature.  After incubation the array was carefully removed and the 
PDMS surface was washed gently with PBS. A 2.5 µg/mL dilution of Cy5-labelled anti-
hIgG was then added to the surface and incubated for one hour at room temperature. Plates 
were then washed, as previously described. The thin layer of PDMS was then air-dried and 
scanned using a Perkin Elmer GxArray scanner with a 633 nm laser.  A microtitre plate was 
simultaneously prepared using the same solutions so that a direct comparison could be 
carried out.  
2.3.7 Shaking versus static investigation assay 
Wells of a microtitre plate (standard or with a layer of cured PDMS) were coated with 2 
µg/mL CRP and incubated for one hour at 37°C. The wells were then blocked by addition of 
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3% (w/v) BSA and incubated for one hour at room temperature. A culture of avian anti-CRP 
scFv (F8) was diluted in auto-induction medium, added to the wells and incubated at 37°C 
overnight, either static or shaking (200rpm).  After incubation, the plates were washed three 
times with PBST followed by three times with PBS. A 2.5 µg/mL dilution of Cy5-labelled 
anti-HA was added to the plates and incubated for one hour at 37°C. The plates were then 
washed as previously described, and the fluorescence read using a Tecan Safire II plate 
reader.  
2.3.8 Expression of recombinant system and detection of expressed antibodies on array. 
A thin-layer of APTES-modified PDMS was coated with 5 µg/mL C-reactive protein (CRP) 
in PBS and incubated for one hour at room temperature. The PDMS was then blocked by 
addition of 3% (w/v) BSA and incubated for one hour at room temperature. The PDMS was 
then degassed for 30 minutes, in a standard dessicator. A stock (approx. 2 x 10
9
 cfu/mL) of 
anti-CRP avian scFv (Clone F8) previously selected using phage display was diluted in 
series (1 in 10) in overnight express medium and added to distinct areas of a 40 µm 
microcapillary array. The array was then incubated at 37°C overnight.  After incubation the 
array was carefully removed and the PDMS surface was washed gently with PBS. A 
2.5µg/mL dilution of Cy5-labelled anti-HA was then added to the surface and incubated for 
one hour at room temperature. The surface was then washed as previously described. The 
thin layer of PDMS was then air-dried and scanned using a Perkin Elmer GxArray scanner 
with a 633 nm laser.   
2.3.9 Multi-analyte assay development 
2.3.9.1 Analysis of potential cross-talk between available fluorophores.  
Initially a test to ensure that no interference from the different fluorescent proteins was 
trialled on the scanner used. To do this Cy3-labelled BSA and Cy5-labelled BSA were added 
to and array singly and mixed, sealed to PDMS and incubated for 1 hour at RT. The array 
was then removed and the PDMS scanned using a Perkin Elmer GxArray scanner using both 
the 633 nm laser and the 543 nm laser. An average fluorescence was taken from each area on 
the scan. There is no non-specific signal observed when analysing the proteins in a mixture. 
This means that it is possible to use the dyes in the same DiCAST assay without interference. 
Solutions prepared were also analysed in the wells of a microtitre plate using a Tecan Safire 
II plate reader at wavelengths for Cy3 (Excitation 550 nm/ Emission 570 nm) and Cy5 
(Excitation 650 nm/ Emission 670 nm).  
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2.3.9.2 Assessment of the performance of a capture format assay 
A thin-layer of APTES-modified PDMS was coated with 4 µg/mL anti-HA in PBS and 
incubated for 1 hour at room temperature. The PDMS was then blocked by addition of 3% 
(w/v) BSA and incubated for 1 hour at room temperature. The PDMS was degassed for 30 
minutes, in a standard dessicator. A 10
-6
 dilution of anti-CRP scFv expressed in E.coli was 
prepared in auto-induction medium and added to a 40 µm array. The array was sealed to the 
prepared PDMS and incubated at 37°C overnight.  After incubation, the array was carefully 
removed and the PDMS surface was washed gently with PBS. A 2.5 µg/mL dilution of Cy5-
labelled CRP was added to the surface and incubated for 1 hour at room temperature. The 
surface was then washed as previously described. The thin layer of PDMS was then air-dried 
and scanned using a Perkin Elmer GxArray scanner using a 633 nm laser.   
2.3.9.3 Multi-analyte proof-of-concept assay 
A thin-layer of APTES-modified PDMS was coated with 4 µg/mL anti-HA in PBS and 
incubated for 1 hour at room temperature. The PDMS was then blocked by addition of 3% 
(w/v) BSA and incubated for 1 hour at room temperature. The PDMS was then degassed for 
30 minutes, in a standard dessicator. A 10
-6
 dilution of anti-CRP scFv expressed in E.coli 
was prepared in auto-induction medium and added to 3 distinct areas of a 40 µm array and 
the array was sealed to the prepared PDMS. The array was then incubated at 37°C overnight.  
After incubation the array was carefully removed and the PDMS surface was washed gently 
with PBS. A 2.5 µg/mL dilution of Cy5-labelled CRP alone, Cy5-labelled CRP mixed with 
Cy3-labelled CRP and Cy3-labelled CRP alone was added to the surface and incubated for 1 
hour at room temperature. The surface was then washed as previously described. The thin 
layer of PDMS was then air-dried and scanned using a Perkin Elmer GxArray scanner using 
both the 543 nm and 633nm lasers.   
2.3.10 Double sided analysis 
Two pieces of APTES-modified PDMS were coated with 5 µg/mL CRP and 5µg/mL human 
IgG (hIgG) and incubated for 1h at room temperature. The PDMS was then blocked by 
addition of 3% (w/v) BSA and incubated for 1h at room temperature. The PDMS was 
degassed for 30 minutes, in a standard dessicator. A 10
-6
 dilution of anti-CRP scFv expressed 
in E.coli was prepared in auto-induction medium and added a 40 µm array and the array was 
sealed to the prepared PDMS, sequentially. The array was then incubated, in a vertical 
orientation, at 37°C overnight.  After incubation the arrays were carefully removed and the 
PDMS surfaces washed gently with PBS. A 2.5 µg/mL dilution of Cy5-labelled anti-HA was 
added to the surface and incubated for 1h at room temperature. The surface was then washed 
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as previously described. The thin layers of PDMS were then air-dried and scanned using a 
Perkin Elmer GxArray scanner using a 633 nm laser. 
2.3.11 Multi-lift analysis 
APTES-modified PDMS were coated with 5 µg/mL CRP and 5 µg/mL human IgG (hIgG) 
and incubated for 1h at room temperature. The PDMS was then blocked by addition of 3% 
(w/v) BSA and incubated for 1h at room temperature. The PDMS was degassed for 30 
minutes, in a standard dessicator. A 10
-6
 dilution of anti-CRP scFv expressed in E.coli was 
prepared in auto-induction medium and added a 40 µm array which was sealed to the 
prepared PDMS. The array was then incubated at 37°C for eight hours.  After incubation the 
arrays were carefully removed and the PDMS surfaces washed gently with PBS and a 2.5 
µg/mL dilution of Cy5-labelled anti-HA was added to the surface and incubated for 1h at 
room temperature. The surface was then washed as previously described. The thin layers of 
PDMS were then air-dried and scanned using a Perkin Elmer GxArray scanner using a 633 
nm laser. The array was sealed to a new, identically prepared surface and allowed to incubate 
overnight at 37°C. The assay was then completed, as described previously.  
2.3.12 Diffusion  
PDMS-APTES was coated with 5 µg/mL human IgG and incubated for 1 hour at room 
temperature. The surface was then blocked using 3% (w/v) BSA for 1 hour at room 
temperature. Following removal of the blocking solution the surface was rinsed with PBS, 
air-dried and degassed for 30 minutes, in a standard dessicator. Dilutions of Cy5-labelled 
anti-human IgG were then added to a microcapillary array in one of three ways, prior to 
sealing to the prepared PDMS surface: 
1. Standard - A solution of 2.5 µg/mL of Cy5-labelled anti-human IgG was loaded 
directly into the array as per standard procedures.  
2. Diffusion proof-of-concept- PBS was loaded into the array and the 2.5 µg/mL 
solution of Cy5-labelled anti-human IgG were added on top of the array.  
3. Diffusion Control- The 2.5 µg/mL solution of Cy5-labelled anti-human IgG was 
added on top in a dry area of the array. 
The array was allowed to incubate for three hours at room temperature then washed with 
PBS and imaged using a Perkin Elmer ScanArray GX microarray scanner.  
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2.3.13 Determination of feasibility of in-solution analysis/FRET analysis on array 
The DNA probes were as follows: 
DNA probe 1: 5′- Cy5-TTA CGG TTG GTG GCG TCT CTG 
DNA probe 2: 3′- AAT GCC AAC CAC CGC AGA GAC-Cy5.5 
In order to measure the energy transfer between the donor and acceptor in solution, 1 x 10
-8 
M solutions of the donor labelled oligonucleotide was mixed 1:1 (v/v) with hybridisation 
buffer alone, or with hybridisation buffer containing 1 x 10
-8 
M acceptor-labelled 
complementary oligonucleotide. Acceptor-labelled oligonucleotide was also mixed 1:1 (v/v) 
with buffer resulting in three final solutions containing donor alone, donor and acceptor 
mixed and acceptor alone. 100 µL of each solution was immediately added to wells of a 
black NUNC 96 well plate and 2 µL of each solution added to different regions of a 40 µm 
diameter microcapillary array. Both array and the micotitre plate were incubated at 37
o
C for 
30 min before analysis. The micotitre plate was analysed using a Tecan Sapphire II (Ex 610 
nm and Em 650-750 scan) fluorescent plate reader and the array analysed using a fluorescent 
microscope with a filter for use with Cy5.  
2.3.14 Determination of feasibility of in-solution analysis/GFP-reassembly on array 
These experiments were carried out using the control vector set supplied. The first vector, 
pET11a-Z-NGFP (NZ), contained the N-terminal region of GFP fused to a leucine zipper 
peptide (anti-parallel to that on Vector 2). It was ampicillin resistant and expression was 
induced by IPTG addition (Lac I operon). The second vector, pMRBAD-Z-CGFP (CZ), 
encoded the C-terminal of GFP fused to a different leucine zipper peptide (anti-parallel to 
that on Vector 1).  It was kanamycin resistant and expression was induced by arabinose 
addition (AraC operon). 
Plasmids were transformed into BL21 (DE3) E. coli separately. A sequential transformation 
was then carried out, meaning that the cells transformed with one plasmid were made 
competent and then transformed with the second plasmid. This meant that both plasmids 
were contained within the same cell, denoted in this report as “in vivo”. Positive 
transformants were identified by growth on screening medium which contains 1µM IPTG, 
0.2% (w/v) arabinose, 35µg/mL kanamycin, 100µg/mL carbenicillin. This was carried out on 
solid medium and also in solution (in plate and on array). Cultures were grown at 37°C 
overnight, followed by 2-3 days at 15-25°C.  
In addition to ‘in vivo’ screening, cells containing single plasmids were mixed and co-
expressed, denoted in this report as ‘in vitro’. This was done in the absence of antibiotics, as 
growth would have been inhibited.  A 10 µL aliquot of each culture [CZ only, NZ only, 
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CZ+NZ ‘in vivo’ (i.e. in the same cell), CZ+NZ ‘in vitro’ (i.e. mixed culture) in appropriate 
expression medium, was added to the array and incubated for 5 days at 25°C. 
2.3.15 Removal of contents of a microcapillary array using high pressure nitrogen.  
A laser hole was burned through an acetate sheet using a CO2 laser. The ablation was kindly 
carried out by Jose Garcia in the BDI. The size of the laser hole was observed and measured 
using a light microscope. The acetate was placed over a microcapillary array containing a 
solution of food dye and a flow of high pressure nitrogen applied to the area on the acetate 
which contained the ablated hole. The clearance zone in the array was then observed and 
measured using a light microscope using 10X magnification.  
2.3.16 Investigation into volume retrieved and viability of cells following removal from 
the microcapillary array using the removal prototype.  
The contents of a single capillary were then removed from the array and captured in the well 
of a microtitre plate (containing 85 µL of medium) below, six times. The contents of three of 
the wells were serially diluted and plated overnight at 37°C. The remaining three wells were 
incubated overnight at 37°C/200 rpm and plated, as before, on the subsequent day. A control 
was included for each condition (immediate enumeration or post 18 hour incubation 
enumeration) by pipetting 1.2 µL of the starting culture into 85 µL in the microtitre plate. 
This control would represent a 1000X greater number of cells than the standard retrieval. 
Bacteria were enumerated on each of the plates and the average for each condition 
calculated.  
2.3.17 Development of a system for alignment of the array to the scanned image.  
Alignment marks were introduced, by engineer Brian O’Reilly, into the array using SU8 
photoresist polymer. To test the feasibility of their use a control assay was carried out. 
Briefly a thin-layer of APTES-modified PDMS was coated with 5 µg/mL of hIgG (un-
labelled) in PBS and incubated for 1 hour at room temperature. The PDMS was then blocked 
by addition of 3% (w/v) BSA and incubated for 1 hour at room temperature. The PDMS was 
then degassed for 30 minute, in a standard dessicator.. A 2.5 µg/mL solution of Cy5-labelled 
anti-hIgG was added to the array in the area of the alignment mark and was sealed to the 
prepared PDMS. The thin layer of PDMS was then air-dried and scanned using a Perkin 
Elmer GxArray scanner using a 633 nm laser.   
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2.3.18 Dual coating for alignment 
APTES-modified PDMS was coated with either dual or single coating.  Single coating 
involves coating with 5 µg/mL CRP in the assay area and 5 µg/mL human IgG (hIgG) in the 
alignment area. Dual coating involves 5µg/mL CRP mixed with 5 µg/mL hIgG in PBS.  
Both surfaces were incubated for 1h at room temperature. The PDMS was then blocked by 
addition of 3% (w/v) BSA and incubated for 1h at room temperature. The PDMS was 
degassed for 30 minutes, in a standard dessicator. The control avian anti-CRP scFv (F8) was 
diluted in series (1 in 5) in auto-induction medium and added to two 40 µm arrays and the 
arrays were sealed to the prepared PDMS surfaces (Dual and singly coated). The arrays were 
then incubated at 37°C overnight.  After incubation the arrays were carefully removed and 
the PDMS surfaces washed gently with PBS. A 2.5 µg/mL dilution of Cy5-labelled anti-HA 
was added to the surface and incubated for 1h at room temperature. The surface was then 
washed as previously described. The thin layer of PDMS was then air-dried and scanned 
using a Perkin Elmer GxArray scanner using a 633 nm laser. 
2.4 Methods-Chapter 4 
2.4.1 Microcapillary array assay  
APTES-modified PDMS was coated with 5 µg/mL antigen (various, detailed in Table 2.5) 
and 5 µg/mL human IgG (alignment assay) in PBS and incubated for 1h at room 
temperature. The PDMS was then blocked by addition of 3% (w/v) BSA and incubated for 
1h at room temperature. The PDMS was degassed for 30 minutes, in a standard dessicator. 
The cells to be screened were diluted to the required level, in appropriate medium, loaded on 
to a 40µm array and the array was sealed to the prepared PDMS. Cell number loaded to the 
array is on the basis of limiting dilution. A solution of Cy5-labelled anti-human IgG (1 
µg/mL) was also added in the designated alignment areas, prior to sealing. The array was 
then incubated at 37°C overnight for bacteria and 2-3 days for mammalian cells.  After 
incubation the array was carefully removed and the PDMS surface was washed gently with 
PBS. A secondary detection agent (various, detailed in Table 2.5) was added to the surface 
and incubated for 1h at room temperature. The surface was washed, as previously described, 
air-dried and scanned using a Perkin Elmer GxArray scanner with a 533nm (Cy3) or 633nm 
laser (Cy5). 
Details for microcapillary array assays, coating and detection reagents, are detailed in Table 
2.5. Each of the coating reagents also had 5 µg/mL human IgG included, to allow for 
alignment. For bacterial assays, cells were diluted in auto-induction medium. Mammalian 
cells were diluted in CO2 independent medium with 10% (v/v) FCS and 5% (v/v) Briclone.   
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Table 2.5: Array assay reagent details. 
Assay Section Coating Reagent Detection Reagent 
CRP Library 4.1.2 anti-HA (4 µg/mL) Cy5-labelled CRP (2.5 µg/mL) 
Multi-Analyte 4.1.4 anti-HA (4 µg/mL) Cy5-labelled CRP (2.5 µg/mL) 
Cy3-labelled MPO (2.5 µg/mL) 
Double-sided 4.1.4 Side 1:MPO (5 µg/mL) 
Side 2:CRP  (5 µg/mL) 
Cy5-labelled anti-HA (5 
µg/mL) 
dAb Library 
(Protein) 
4.2.3 Transferrin, cTnI or cTnT (5 µg/mL) Anti-cMYC (5 µg/mL) 
Cy5-labelled anti-Mouse  (2 
µg/mL) 
dAb Library 
(Cells) 
4.2.3 Anti-cMYC (5 µg/mL) 
 
Jurkat cells (1 x 10
6
 cells/mL) 
stained with anti-EpCAM (5 
µg/mL) 
HSL (Antigen) 4.3.2 
4.3.3 
 HSL-BSA conjugate (16 µg/mL) Anti-cMYC (5 µg/mL) 
Cy5-labelled anti-Mouse (2 
µg/mL) 
HSL (Capture) 4.3.2 Anti-cMYC (5 µg/mL) 
 
Cy5-labelled HSL-BSA 
conjugate (16 µg/mL) 
 
2.4.2 Bacterial ELISA confirmation (On-plate assay) 
From the positive clones identified, those retrieved from the microcapillary array were 
grown overnight in LB medium at 37°C/200rpm. Cultures were plated out twice and single 
colonies selected for each retrieval, to ensure monoclonality. A confirmatory ELISA was 
then carried out on these clones, using an on-plate method previously described in Guo et al., 
(2010). Briefly, plates were coated with 2 µg/mL of the selected antigen (Table 2.6) for 1 
hour at 37°C. Wells were then blocked with 3% (w/v) BSA for 1 hour at 37°C. Clones were 
then expressed (1 per well) in the prepared wells in auto-induction medium overnight at 
37°C/200 rpm. After incubation wells were washed three times with PBST and three times 
with PBS. Secondary detection was carried out using the appropriate secondary antibody, as 
detailed in Table 2.6, and incubated at 37°C for 1 hour. Plates were then washed as 
previously described and TMB added to the wells and incubated for 20 minutes at room 
temperature. Colour development was stopped using 10% (v/v) HCl and plates were read at 
450 nm using a Tecan Safire II plate reader. 
Assay details, coating and detection reagents, are given in Table 2.6. Cells were added to the 
plate in auto-induction medium.  
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Table 2.6: On-plate assay reagent details. 
Assay Section Coating Reagent Detection Reagent 
CRP Library 4.1.2 CRP (2 µg/mL) HRP-labelled anti-HA (50 ng/mL) 
Multi-Analyte 4.1.4 CRP (2 µg/mL) 
MPO (1 µg/mL) 
HRP-labelled anti-HA (50 ng/mL) 
Double-sided 4.1.4 CRP (2 µg/mL) 
MPO (1 µg/mL) 
HRP-labelled anti-HA (50 ng/mL) 
dAb Library 
(Protein) 
4.2.3 Transferrin, cTnI or cTnT (2 µg/mL) Anti-cMYC (5 µg/mL) 
HRP-labelled anti-Mouse (1 µg/mL) 
dAb Library 
(Cells) 
4.2.3 Jurkat cells (1 x 10
6
 cells/mL)  
 
Anti-cMYC (5 µg/mL) 
HRP-labelled anti-Mouse (1 µg/mL) 
HSL 
(Antigen) 
4.3.2 
4.3.3 
 HSL-BSA conjugate (8 µg/mL) Anti-cMYC (5 µg/mL) 
HRP-labelled anti-Mouse (1 µg/mL) 
HSL 
(Capture) 
4.3.2 
 
Anti-cMYC (5 µg/mL) 
 
HSL-BSA conjugate  (8µg/mL) 
HRP-labelled anti-BSA (2.0µg/mL) 
 
2.4.3 Non-competitive ELISA for determination of antibody lysate titer.  
Microtitre plates were coated with 2 µg/mL antigen, detailed in Table 2.7, for 1 hour at 
37°C. The plates were then blocked with 200 µL of a 3% (w/v) BSA and incubated at 37°C 
for 1 hour. Dilutions (1in 5 series) of lysate were prepared in 1% (w/v) BSA and each 
dilution added to the plates in triplicate. The plates were then incubated at 37°C for 1 hour, 
followed by 3 washes with PBS-Tween and 3 washes with PBS. The secondary detection 
reagent (Table 2.7) was prepared in 1% (w/v) BSA, added to the plates and incubated at 
37°C for 1 hour. Wells were then washed, as before and TMB was added and incubated for 
20 minutes at room temperature. Colour development was stopped using 10% (v/v) HCl and 
plates were read using a Tecan Safire II plate reader at 450 nm.  
Table 2.7: Titer ELISA Reagent details 
Assay Section Coating reagent Dilution Series Detection reagent 
CRP 4.1.3 2 µg/mL CRP 1 in 5 HRP-labelled anti-HA  
(50 ng/mL) 
MPO 4.1.4 1 µg/mL MPO 1 in 5 HRP-labelled anti-HA  
(50 ng/mL) 
HSL (All) 4.3.4 4 µg/mL HSL-BSA 1 in 5 HRP-labelled anti-HA  
(50 ng/mL) 
 
2.4.4 Competitive ELISA for determination of antibody performance.  
The ELISA plates were coated with antigen, detailed in Table 2.8, and blocked with 3% 
(w/v) BSA. Dilutions of antigen, as shown in Table 2.8, were prepared in 1% (w/v) BSA and 
mixed with an equal volume of each antibody. The dilution of each individual scFv lysate 
was determined from the titer determined as described in section 2.4.3.  This mixture was 
added to the coated and blocked plates and incubated at 37°C for 1 hour. Plates were washed 
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three times with PBS-Tween and 3 times with PBS. Secondary detection was again carried 
out using selected detection reagent (Table 2.8) in 1% (w/v) BSA, incubated at 37°C for 1 
hour. Wells were then washed, as before and TMB was added and incubated for 20 minutes 
at room temperature. Colour development was stopped using 10% (v/v) HCl and 
absorbances were read using a Tecan Safire II plate reader at 450 nm.  
Table 2.8: Competitive ELISA Reagent details 
Assay Section Coating reagent Antigen Conc.   
Dilution series 
Detection reagent 
CRP 4.1.3 2 µg/mL CRP 100 µg/mL  
1 in 5 series 
HRP-labelled anti-HA  
(50 ng/mL) 
MPO 4.1.4 1 µg/mL MPO 100 µg/mL  
1 in 5 series 
HRP-labelled anti-HA  
(50 ng/mL) 
HSL (3OXO) 4.3.4 4 µg/mL 3OXO-BSA 250 µM 
1 in 5 series 
HRP-labelled anti-HA  
(50 ng/mL) 
HSL (3OH) 4.3.4 4 µg/mL 3OH-BSA 250 µM 
1 in 5 series 
HRP-labelled anti-HA  
(50 ng/mL) 
HSL (NAC) 4.3.4 4 µg/mL NAC-BSA 250 µM 
1 in 5 series 
HRP-labelled anti-HIS  
(1 µg/mL) 
HSL (C4) 4.3.4 4 µg/mL NAC-BSA 25 mM  
1 in 5 series 
HRP-labelled anti-HIS  
(1 µg/mL) 
 
2.4.5 ELISA testing of purification fractions for final anti-HSL scFv clones.   
Microtitre plates were coated with 4 µg/mL 3OXO-BSA for 1 hour at 37°C. The plates were 
then blocked with 200 µL of a 3% (w/v) BSA and incubated at 37°C for 1 hour. Each of the 
purification fractions were added to the plates for each of the clones. The plates were then 
incubated at 37°C for 1 hour, followed by 3 washes with PBS-Tween and 3 washes with 
PBS. The secondary detection reagent, HRP-labelled anti-HIS (1 µg/mL) was prepared in 
1% (w/v) BSA, added to the plates and incubated at 37°C for 1 hour. Wells were then 
washed, as before and TMB was added and incubated for 20 minutes at room temperature. 
Colour development was stopped using 10% (v/v) HCl and plates were read using a Tecan 
Safire II plate reader at 450 nm.  
2.5 Methods-Chapter 5 
2.5.1 Sandwich ELISA for the detection of human IgE (hIgE). 
A 96 well microtitre plate was coated with 2 µg/mL anti-hIgE mAb 107 in PBS and 
incubated for 1 hour at 37°C. The wells were emptied and blocked by addition of 3% (w/v) 
BSA and incubated for 1 hour at 37°C. Supernatant from hIgE secreting multiple myeloma 
cells was added to the plates which were then incubated at 37°C for 1 hour. Wells were 
washed 3 times with PBST and 3 times with PBS. A 0.33 µg/mL dilution of anti-hIgE mAb 
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182-biotin was added to the wells and incubated for 1 hour at 37°C. Plates were washed as 
before and 2 µg/mL of HRP-labelled streptavidin was added to each well and incubated for 1 
hour at 37°C. Plates were then washed as previously described and absorbance was read 
using a Tecan Safire plate-reader at 450 nm. 
2.5.2 Detection of human IgE secreted from multiple myeloma cells which have been 
incubated on the microcapillary array. 
Cells were pelleted by centrifugation at 4,500 x g for 3 minutes and re-suspended in fresh 
RPMI 1640 medium supplemented with 10% (v/v) FBS. The cells were enumerated and a 
dilution of 7.2 x 10
4
 cells/mL was added to a 40 µm array and incubated for 2 days at 37°C 
and 5% CO2.  Following incubation, the cells were removed from the array using nitrogen 
gas and collected. The cells were the pelleted as previously described and the supernatant 
analysed by ELISA for hIgE, as detailed in section 2.5.1.  
2.5.3 Establishment of appropriate incubation time for immortalised B-cells (U266 
multiple myeloma cell line) to detect secreted antibody. 
A time course was carried out on hIgE-secreting U266 cells to determine the optimum 
incubation time to allow detectable levels of hIgE to accumulate. The medium used for all 
cell manipulations was RPMI 1640 with 10% (v/v) foetal bovine serum (FBS). A sandwich 
FLISA was carried out on each day of the time course as described in section 2.5.1, with the 
HRP-labelled streptavidin replaced with 2.5 µg/mL of Cy5-labelled streptavidin. 
Fluorescence was read using a Tecan Safire plate-reader at 650 nm excitation/670 nm 
emission with a bandwidth of 10 nm. 
2.5.4 Growth of multiple myeloma cells in the array and subsequent detection of 
secreted human IgE. 
A DiCAST screen was carried out using a sandwich FLISA on array. A thin-layer of 
APTES-modified PDMS was coated with 2 µg/mL anti-hIgE mAb 107 in PBS and incubated 
for 1 hour at room temperature. The PDMS was then blocked by addition of 3% (w/v) BSA 
and incubated for 1 hour at room temperature. The PDMS was then degassed for 30 minutes, 
in a standard dessicator.  Cell dilutions were added to distinct areas of a 40 µm array starting 
at a dilution of 5 x 10
5 
cells/mL and diluted in series (1/10) and the array was sealed to the 
prepared PDMS. The array was then incubated at 37°C and 5% CO2 for 4 days.  After 
incubation cell the array was carefully removed and the PDMS surface was washed gently 
with PBS. A 0.33 µg/mL dilution of anti-hIgE mAb 182-biotin was added to the PDMS and 
incubated for 1 hour at room temperature. The PDMS was then washed as before and 2.5 
µg/mL of Cy5-labelled streptavidin was added to the surface and incubated for 1 hour at 
59 
 
37°C. Plates were then washed as previously described. The thin layer of PDMS was then 
air-dried and scanned using a Perkin Elmer GxArray scanner using a 633 nm laser.  
2.5.5 Determination of possibility of passing mammalian cells through the capillaries of 
an array.  
Newly passaged U266 multiple myeloma cells were enumerated and added to an area of a 40 
µm microcapillary array at a cell number of 7.2 x 10
4
 cells/mL. They were then removed 
from the array using high pressure nitrogen gas and collected in a microtitre plate. The cells 
were subsequently enumerated to estimate the loss of cells on passage through the capillaries 
of the array. In addition the size of the cells was determined using a Millipore Sceptor 
device.  
 
2.5.6 Removal of mammalian cells from the capillaries of an array using the DiCAST 
prototypes laser removal approach. 
Multiple myeloma cells were added to a 40 µm array at a concentration of approximately 2 x 
10
6
 cells/mL. The array was then loaded on to the prototype and a standard retrieval was 
carried out. Cells were captured in 384 well plates containing 50 µL/well of RPMI 1640 
medium supplemented with 10 % (v/v) FBS. Intact cells, in target wells, were observed 
using a light microscope at 4X and 10X magnifications. For subsequent retrievals, following 
observations made using HRP into TMB the volume per well was increased to 85 µL/well. 
2.5.7 Detection of mouse IgG from naïve B cells isolated from a murine spleen.  
In order to determine the feasibility of screening murine splenic cells directly after sacrifice a 
sandwich FLISA, against mouse IgG, was carried out using DiCAST.  A thin-layer of 
APTES-modified PDMS was coated with 2 µg/mL anti-hIgE mAb 107 in PBS and incubated 
for 1 hour at room temperature. The PDMS was then blocked by addition of 3% (w/v) BSA 
and incubated for 1 hour at room temperature. The PDMS was then degassed for 30 minutes, 
in a standard dessicator. A mouse was sacrificed and the spleen removed. The spleen was 
then added to 1mL RPI 1640 medium with 10% (v/v) FBS. The B cells were collected by 
rinsing the medium through the spleen. Cells were centrifuged for 5 minutes at 4,500 x g. 
The pelleted cells were then re-suspended in fresh medium and enumerated. The cell count 
was 3 x 10
7
 cells/mL. Cells were diluted in series (1/10) and loaded onto a 40 µm array in 
distinct areas. The array was then incubated for 4 days at 37°C and 5% CO2. Following 
incubation the array was removed from the PDMS and washed gently with PBS. A 2.5 
µg/mL of Cy5-labelled anti-mouse IgG was prepared, added to the PDMS and incubated for 
1 hour at 37°C. The PDMS was then washed gently with PBS, air-dried and scanned using a 
Perkin Elmer GxArray scanner using a 633 nm laser. 
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2.5.8 Multiplexed screening of murine B cells from a mouse immunised with three 
different proteins.  
Two pieces of thin-layer APTES-modified PDMS were coated, with either 5 µg/mL 
Myoglobin or 5 µg/mL anti-mouse IgG in PBS, and incubated for 1 hour at room 
temperature. The PDMS was then blocked by addition of 3% (w/v) BSA and incubated for 1 
hour at room temperature. The PDMS was degassed for 30 minutes, in a standard dessicator. 
A mouse previously immunised with CRP, Transferrin and Myoglobin was sacrificed and 
the spleen removed. The spleen was then added to 1 mL CO2 independent medium with 10% 
(v/v) FBS and 5% (v/v) Briclone. The B cells were collected by rinsing the medium through 
the spleen. Cells were centrifuged for 5 minutes at 4,500 x g. The pelleted cells were then re-
suspended in fresh medium, enumerated and diluted to a suitable loading density, in this case 
1 x 10
6 
cells/mL. The array was then sealed to each surface, sequentially, and incubated for 3 
days at 37°C and 5% CO2. Following incubation the array was removed from the PDMS and 
stored and the PDMS surfaces were washed gently with PBS. A 2.5 µg/mL dilution of Cy5-
labelled anti-mouse IgG was prepared, added to the PDMS surface for Side 1 (Myoglobin 
coated).  A 2.5 µg/mL dilution of Cy3-labelled CRP and Cy5-labelled Transferrin was 
prepared and added to the surface for Side 2 (anti-mouse IgG coated). Both were incubated 
for 1 hour at room temperature. The PDMS was then washed gently with PBS, air-dried and 
scanned using a Perkin Elmer GxArray scanner with a 633nm laser (Cy5) and a 533nm laser 
(Cy3). 
2.5.9 B cell confirmatory ELISA   
The contents of capillaries of interest were captured in the wells of 384-well plates 
containing DMEM with 10% (v/v) FCS and 5% (v/v) Briclone and incubated at 37°C and 
5% CO2.   Subsequent to appropriate incubation supernatants were analysed by direct binding 
ELISA. Briefly, ELISA plates were coated with 2 µg/mL of the selected antigen for 1 hour at 
37°C. Wells were blocked with 3% (w/v) BSA for 1 hour at 37°C. Supernatants from B cells 
were then added to the wells of the plate and incubated for 1 hour at 37°C.  After incubation 
wells were washed three times with PBST and three times with PBS. A solution of HRP-
labelled anti-mouse IgG was added to the wells and incubated at 37°C for 1 hour. Plates 
were then washed as previously described and TMB added to the wells and incubated for 20 
minutes at room temperature. Colour development was stopped using 10% (v/v) HCl and 
absorbances were read at 450 nm using a Tecan Safire II plate reader.  
2.5.10 Labelling of Jurkat cells as antigen 
Jurkat cells were centrifuged for 3 minutes at 4,500 x g and resuspended in 3 % (w/v) BSA 
containing 5 µg/mL Cy5-labelled anti-EpCAM and incubated at 37°C for 1 hour. The cells 
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were washed three times by centrifuging as described previously and resuspending in PBS. 
Cells were finally resuspended in 3 % (w/v) BSA and used for screening.  
2.5.11 Isolation of mRNA from cells  
Multiple myeloma cells were enumerated, diluted in series (1/10) and pelleted by 
centrifugation at 4,500 x g for 3 minutes. The pellet was then resuspended in 1 mL Trizol 
and incubated at room temperature for 5 minutes. Following incubation 250 µL of 
Chloroform was added, the tube was shaken vigorously for 15 seconds and then centrifuged 
at 12,000 x g for 5 minutes. At this point there were three layers visible in the tube (Top 
Layer-Aqueous; Middle Layer/Interphase-White precipitated DNA; Bottom Layer-Pink 
Organic phase). The aqueous layer was carefully pipetted into a fresh 1.5 mL Eppendorf and 
550 µL of isopropanol was added to the aqueous phase, mixed gently and incubated at room 
temperature for 5 minutes. The sample was then centrifuged at maximal speed (~14,500 x g) 
for 20 minutes. The isopropanol was carefully removed from the pellet and 1 mL of 75% 
(v/v) ethanol (in DEPC-treated water) added to the tube, mixed gently and centrifuged as 
before. The ethanol was then poured off and the pellets allowed to air dry. The pellet was 
then resuspended in 20 µL of DEPC-treated water, quantified using a Nanodrop 2000 and 
stored at -80°C until further use.  
2.5.12 Reverse transcription of mRNA from cells to cDNA using Superscript® III 
reverse transcriptase 
The mRNA was reverse-transcribed to produce cDNA using Superscript® III reverse 
transcriptase, as per the manufacturer’s instructions, which are outlined below in Table 2.9.  
Table 2.9: Procedure and reagent preparation for reverse transcription of mRNA using 
Superscript® III reverse transcriptase. 
Reagent Volume (µL) 
MIX 1  
RNA  5 
Oligo dT Primer 1 
10mM dNTPs 1 
DEPC Water 3  (to give 10 µL total volume) 
Mix thoroughly and incubate at 65°C for 5 minutes. Place on ice for > 1 minute. 
 
MIX 2  
10X RT Buffer 2 
25 mM  MgCl2 4 
0.1mM DTT 2 
RNAOut 1 
Superscript RT 1 
Add 10 µL of Mix 2 to Mix 1. Mix thoroughly. Incubate at 50°C for 50 minutes, followed by 85°C 
for 5 minutes. Place on ice. Add 1 µL of RNase H and incubate at 37°C for 20 minutes.  Store at -
20°C for further analysis. 
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2.5.13 Amplification of variable regions for single cell cloning 
The cDNA generated from RNA obtained from single cells (avian splenic cells producing 
anti-Jurkat antibodies) was used as a template to amplify the variable regions of the 
antibodies using PCR, as described in section 2.2.7. Splicing by overlap extension (SOE) 
was generated from the variable regions to generate a scFv fragment. All primers are listed 
in Table 2.4. The scFv fragment for each cell was then cloned into a phagemid vector as 
described in section 2.5.14.  
2.5.14 Restriction digestion of cloning fragments for single cell cloning  
Digestion of 10 µg of both the purified PCR product and vector backbone (pCOMB3XSS) 
was carried out using NEB restriction enzyme Sfi I (36 U/µg DNA for insert and 6 U/µg 
DNA for vector) for 5 hours at 50°C, as per the Cold Spring Harbour, Phage display 
laboratory manual (Barbas et al., 2001). Digested fragments were then run on a 1% (w/v) 
agarose gel (section 2.2.8) and purified as described in section 2.2.9. The digested and 
purified vector was then dephosphorylated using antarctic phosphatase as detailed in section 
2.2.10 and used in a ligation reaction, as described in section 2.5.15.  
2.5.15 Ligation of cloning fragments for single cell cloning 
The ligation reaction was set up as follows and incubated at room temperature overnight 
 
Sfi I digested pCOMB 3XSS    (700 ng/rxn) 17     µL 
Sfi I digested scFv insert                     (350 ng/rxn) 23.6  µL 
Ligase         2     µL 
Ligase Buffer (10X)    10     µL 
DEPC sterile water     47.4  µL (to give 100 µL reaction 
volume) 
Following the incubation, the ligation mix was transformed into XL1-Blue electro-competent 
cells as described in section 2.2.11. A colony pick PCR was carried out on single colonies 
from transformations plates to confirm presence of the scFv insert was carried out, as 
described in section 2.2.12.  Colonies positive for insert were then expressed and lysates 
tested for maintained binding as detailed in section 2.5.16.  
2.5.16 Assessment of binding of cloned scFv fragments to intact Jurkat cells 
Freshly passaged Jurkat cells were washed in PBS, resuspended in lysate of each different 
clone to be tested and incubated for 1 hour at 37°C. The cells were washed three times by 
centrifuging for 3 minutes at 4,500 x g and resuspending in PBS. Following the final wash, 
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the cells were transferred to a fresh tube containing 2.5 µg/mL biotinylated anti-HA and 
incubated for 1 hour at 37°C. The cells were then washed as previously described and 
resuspended in 5 µg/mL Cy5-labelled streptavidin in a fresh tube. Following the incubation 
cells were washed as previously described and visualised using a fluorescent microscope 
with a Cy5 filter at 10X and 20X magnifications.  
2.5.17 Functional Bioassay proof of concept 
PDMS was coated with 1 µg/mL M6 (anti-CK18) antibody for 1 hour at room temperature. 
The PDMS was then blocked by addition of 3% (w/v) BSA and incubated at room 
temperature for 1 hour. Jurkat cells (ATCC) diluted to 10
5
 cells/mL were treated with a final 
volume of 20 µg/mL anti-Fas antibody, added to the array and incubated at 37°C/5% CO2 for 
24 hours. Following incubation, the array was removed carefully and the PDMS surface was 
washed gently with PBS. Secondary detection was carried out using a mixture of 1 µg/mL 
Cy3-labelled M5 (anti-CK18) and 1 µg/mL Cy5-labelled M30 (anti-caspase cleaved CK18), 
which was  labelled in-house, and incubated for 1 hour at room temperature.  The surface 
was then washed as previously described, air-dried and scanned using a Perkin Elmer 
GxArray scanner with a 533nm (Cy3) and a 633nm laser (Cy5). 
2.6 Methods-Chapter 6 
2.6.1 Biomek Usage 
Use of the Beckman Coulter Biomek 2000 laboratory automation workstation was carried 
out as per the manufacturer’s instructions. Programmes written were designed for use in 
coating, blocking, filling, carrying out dilution series and washing plates for all assay work.  
2.6.2 Checkerboard Sandwich ELISA for determination of optimal coating 
concentration 
Plates were coated with a range of dilutions of the polyclonal anti-CRP antibody 
(20/4/0.8/0.16/0 µg/mL) for 1 hour at 37°C. Wells were then blocked with 3% (w/v) BSA for 
1 hour at 37°C. Dilutions of CRP (15 µg/mL; diluted in series 1/5) were prepared, added to 
the wells of the plate and incubated at 37°C for 1 hour. After incubation wells were washed 
three times with PBST and three times with PBS. The anti-CRP scFv A6 was then added to 
the wells at a 1 in 500 dilution (~1 µg/mL). Plates were washed as previously described and 
a 50 ng/mL dilution of HRP-labelled anti-HA was then added to the wells and incubated at 
37°C for 1 hour. Plates were then washed as previously described and TMB added to the 
wells and incubated for 20 minutes at room temperature. Colour development was stopped 
using 10% (v/v) HCl and plates were read at 450nm using a Tecan Safire II plate reader.  
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2.6.3 Checkerboard Sandwich ELISA for determination of primary antibody (A6) 
concentration. 
Plates were coated with a 4 µg/mL polyclonal anti-CRP antibody for 1 hour at 37°C. Wells 
were then blocked with 3% (w/v) BSA for 1 hour at 37°C. Dilutions of CRP (15 µg/mL; 
diluted in series 1/5) were added to the well of the plate, in triplicate, and incubated at 37°C 
for 1 hour. After incubation wells were washed three times with PBST and three times with 
PBS. The anti-CRP scFv A6 was then added to the wells at 1 in 100 (~5 µg/mL), 1 in 250 
(~2 µg/mL) or 1 in 500 (~1 µg/mL) dilution. Plates were washed as previously described and 
a 50 ng/mL dilution of HRP-labelled anti-HA was then added to the wells and incubated at 
37°C for 1 hour. Plates were then washed as previously described and TMB added to the 
wells and incubated for 20 minutes at room temperature. Colour development was stopped 
using 10% (v/v) HCl and absorbances were read at 450 nm using a Tecan Safire II plate 
reader.  
2.6.4 Optimised anti-CRP sandwich ELISA 
Plates were coated with 4 µg/mL, as determined to be optimal in section 2.6.2, of the 
polyclonal anti-CRP antibody for 1 hour at 37°C. Wells were then blocked with 3% (w/v) 
BSA for 1 hour at 37°C. Dilutions of CRP (1 µg/mL; diluted in series 1/2.5) were added to 
the well of the plate, in triplicate, and incubated at 37°C for 1 hour. After incubation wells 
were washed three times with PBST and three times with PBS. The anti-CRP scFv A6 was 
then added to the wells at a 1 in 500 dilution (~1 µg/mL). Plates were washed as previously 
described and a 50 ng/mL dilution of HRP-labelled anti-HA was then added to the wells and 
incubated at 37°C for 1 hour. Plates were then washed as previously described and TMB 
added to the wells and incubated for 20 minutes at room temperature. Colour development 
was stopped using 10% (v/v) HCl and absorbances were read at 450 nm using a Tecan Safire 
II plate reader.  
2.6.5 Determination of CRP levels in spiked samples using anti-CRP sandwich ELISA 
A standard curve was generated as described in section 2.6.4, with each standard 
determination carried out in triplicate. The spiked samples were obtained by preparing ten 
separate samples containing 0.001 µg/mL CRP. For samples designated buffer both standard 
curve and “unknown” samples were prepared in PBS containing 1.5% (w/v) BSA. For 
samples labelled serum, both standard curve and “unknown” samples were prepared in CRP 
depleted serum. The standard curve was generated using the BIAevaluation software and a 
four parameter equation fitted to the data. Sample concentrations were then calculated based 
on the standard curve obtained.  
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2.6.6 Application of anti-CRP sandwich ELISA to clinical samples  
Plates were coated with 4 µg/mL, as determined to be optimal in section 2.6.2, of the 
polyclonal anti-CRP antibody for 1 hour at 37°C. Wells were then blocked with 3% (w/v) 
BSA for 1 hour at 37°C. Dilutions of CRP in serum (1 µg/mL; diluted in series 1/2.5) were 
added to the well of the plate, in triplicate, and incubated at 37°C for 1 hour. Each of the 
clinical samples was diluted 1 in 2 and then 1 in 5 series and added to the plate.  After 
incubation wells were washed three times with PBST and three times with PBS. The anti-
CRP scFv A6 was then added to the wells at a 1 in 500 dilution (~1 µg/mL). Plates were 
washed as previously described and a 50 ng/mL dilution of HRP-labelled anti-HA was then 
added to the wells and incubated at 37°C for 1 hour. Plates were washed as previously 
described and TMB added to the wells and incubated for 20 minutes at room temperature. 
Colour development was stopped using 10% (v/v) HCl and absorbances were read at 450nm 
using a Tecan Safire II plate reader. The standard curve was generated using the 
BIAevaluation software and a four parameter equation fitted to the data. Sample 
concentrations were then calculated based on the standard curve obtained.  
2.6.7 Determination of CRP levels in clinical serum samples using anti-CRP sandwich 
ELISA 
Assays were carried out, as per section 2.6.6. In place of a dilution series for each of the 
clinical samples, ten samples at a 1 in 2000 dilution were assayed for each of the samples. 
The standard curve was generated using the BIAevaluation software and a four parameter 
equation fitted to the data. Sample concentrations were then calculated based on the standard 
curve obtained.  
2.6.8 Antibody lysate preparation for Biacore 4000 analysis 
Cultures were grown in sterile 96-well plates in auto-induction medium, to allow for 
expression of scFvs, overnight at 37 ºC /200 rpm. The plates were then centrifuged at 4,500 
x g for 20 minutes, the cell pellets were re-suspended in one-tenth the original culture 
volume of HBS-EP+ running buffer and subjected to three freeze-thaw cycles (-80ºC/37 ºC). 
Cell debris was removed by centrifugation at 4,500 x g for 10 minutes. Supernatant was 
diluted 1 in 4 in HBS-EP+ running buffer and used for analysis. 
2.6.9 Antibody immobilisation and antigen screening for high-throughput screen  
The anti-HA tag antibody was immobilised onto spots 1, 2, 4 and 5 of each flow cell, 
through amine coupling to a series S CM5 chip, by a 10 minute injection of 15 µg/mL 
antibody in 10 mM sodium acetate buffer, pH 4.2. Crude antibody-containing bacterial 
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lysates, diluted one in four in HBS-EP+ running buffer, were subsequently injected over 
spots 1 and 5 of each flow cell resulting in 8 different  antibodies captured  in every analysis 
cycle.  The analyte (cTnI), at a concentration of 50nM, was passed over all five analysis 
spots simultaneously at a flow rate of 30 µL/minute. Association and dissociation times were 
1 and 5 minutes, respectively, and the regeneration consisted of a 60 second injection of 20 
mM NaOH.  A total of 960 avian antibodies were analysed in this high-throughput screen, at 
an analysis temperature of 25ºC. 
Data analysis was performed using the dedicated Biacore 4000 software and the 
antibody/antigen interaction was analysed by calculating the complex stability (% left) by 
expressing ‘stability late’ (calculated from the average response from 295 to 300 s after 
antigen injection) as a percentage of ‘stability early’ (calculated from the average response 
from 5 s after antigen injection).  
2.6.10 Antibody immobilisation and antigen screening for ‘2 over 2’ Kinetics 
The anti-HA antibody was immobilised onto spots 1, 2, 4 and 5 of each flow cell, through 
amine coupling to a series S CM5 chip, by a 10 minute injection of 7.5 µg/mL antibody in 
10mM sodium acetate buffer, pH 4.2. The immobilisation was carried out using separate 
injections for each spot on the flow cell, meaning that different quantities of ligand were 
immobilised on each of the spots. This allowed for the two ligand densities required for the 
‘2 over 2’ screen.  The ligand was also immobilised on spot 3 to provide an appropriate 
reference and to negate the effect of non-specific binding of cTnI to the dextran surface of 
the chip. Each antibody-containing bacterial lysate, diluted one in four in HBS-EP+ running 
buffer, was injected over a pair of spots (1&2 or 4&5) of each flow cell. This resulted in 8 
different antibodies being captured, on two different density surfaces, in every analysis 
cycle. Two separate injections of analyte, at concentrations of 100 nM and 25 nM, were 
passed over all five analysis spots at a flow rate of 30 µL/min. A zero injection was also 
included to allow for adequate referencing.  Association and dissociation times were 1 and 
10 minutes, respectively, and the surface was regenerated with a 60 second injection of 20 
mM NaOH.  Ninety-six antibody fragments, the top 10% chosen based on their complex 
stability, were analysed in total. Analysis temperatures of 25ºC and 37ºC were compared. 
The response data was fitted globally to a 1:1 interaction model using the Biacore 4000 
evaluation software. 
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2.6.11 Full Kinetics 
The anti-HA tag antibody was immobilised onto spots 1, 2, 4 and 5 of each flow cell, 
through amine coupling to a series S CM5 chip, by a 10 minute injection of 7.5 µg/mL 
antibody in 10mM sodium acetate buffer pH 4.2. Crude antibody-containing bacterial 
lysates, diluted one in four in HBS-EP+ running buffer, were subsequently injected over 
spots 1 and 5 of each flow cell.  The analyte (cTnI), at a range of concentrations (100 nM to 
6.25 nM; diluted in series (1/2)) was passed over all five analysis spots simultaneously at a 
flow rate of 30 µl/min. Association and dissociation times were 1 and 10 minutes, 
respectively, and the regeneration consisted of a 60 second injection of 20mM NaOH.  The 
analysis temperature was 25 ºC. The response data was fitted globally to a 1:1 interaction 
model using the Biacore 4000 evaluation software. 
2.6.12 Cloning of cTnI peptides as GFP fusion into pET28b vector 
All conceptual and design elements of this cloning section were carried out by Dr. Paul 
Leonard. The cloning strategy involved the cloning of the gene encoding green fluorescence 
protein (GFP) into pET28b using BamHI and HindIII. A plasmid prep of pQE30 with eGFP 
insert was used as template DNA for the reaction, detailed in section 2.2.7. The cTnI 
peptides (1, 2 and 3) were incorporated into the 5’ primer to yield 6xHis-T7 tag-Peptide-
GFP-6xHis-STOP. The same back primer was used for all peptides with the forward primer 
(encoding peptide) changing for each peptide. Primers sequences are listed in Table 2.4.  
2.6.12.1 Restriction digestion of cloning fragments 
Digestion of 10 µg of both the purified PCR product and vector backbone (pET 28b) was 
carried out using NEB restriction enzymes BamHІ and HindIII (1 U enzyme/µg DNA). 
Compatibility of the enzymes was assessed by using NEB guidelines and it was determined 
that a sequential digest was required with the two enzymes concerned. The restriction 
digestion with HindIII was carried out first for 1 hour at 37ºC, after which the enzyme was 
inactivated by treatment at 80ºC for 20 minutes. This was followed by digestion with BamHІ 
for 1 hour at 37ºC. Digested fragments were then run on a 1% (w/v) agarose gel (section 
2.2.8) and purified as described in section 2.2.9. The purified vector (pET28b) was then de-
phosphorylated using Antarctic phosphatase as detailed in section 2.2.10 before proceeding 
to ligation as described in section 2.6.12.2.  
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2.6.12.2 Ligation of cloning fragments 
The ligation reaction was set up as follows and incubated at room temperature overnight 
Hind III /BamHI digested pET28b     (300 ng/rxn) 12   µL 
Hind III/BamHI digested gene insert (300 ng/rxn) 7     µL 
Ligase       1     µL 
Ligase Buffer (10X)    3     µL 
DEPC sterile water     7     µL (to give 30 µL reaction 
volume) 
Following the incubation, the ligation mix was transformed into Rosetta 2 electro-competent 
cells as described in section 2.2.11. A colony pick PCR was carried out as detailed in section 
2.2.12. A small scale expression culture was produced for each of the GFP-peptides to 
ensure correct expression. Following confirmation of expression, large-scale cultures were 
prepared as detailed in 2.2.3 and purified by IMAC (section 2.2.4) for use in Biacore epitope 
mapping experiments (section 2.6.13). 
2.6.13 Epitope mapping of recombinant scFv fragments on Biacore 4000.  
Each of the purified peptides was immobilised on a spot of each of the four flow cells 
through amine coupling to a series S CM5 chip, by a 10 minute injection of 7.5 µg/mL 
antibody in 10mM sodium acetate buffer, pH 4.2. Peptide 1 was immobilised to Spot 1, 
peptide 2 was immobilised to Spot 2, peptide 3 was immobilised to Spot 4 and peptide 4 was 
immobilised to Spot 5. Spot 3 remained unmodified to serve as a reference.  Crude antibody-
containing bacterial lysates, diluted one in four in HBS-EP+ running buffer, were 
subsequently injected over all spots of each flow cell.  Association and dissociation times 
were 1 and 5 minutes, respectively, and the regeneration consisted of a 60 second injection 
of 20 mM NaOH.  The analysis temperature was 25ºC. The binding response for each clone 
was then obtained, for each different analyte, using the Biacore 4000 evaluation software.  
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Chapter 3 
Development of a novel microcapillary array-based, 
single cell analysis platform.  
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Hypothesis 
Currently antibody screening approaches make use of successive rounds of screening, with 
each round containing fewer candidate antibodies, until a manageable number of potential 
clones has been achieved for further characterisation. By spatially addressing antibody-
secreting cells (ASCs) in the capillaries of a microcapillary array, all cells could be subjected 
to screening. In analysing the entire population on a single cell basis, with no bias towards 
fast-growing clones, the chance of finding rare and unique clones could hopefully be 
improved. This approach would provide a high-throughput, non-biased and streamlined 
antibody screening process for novel antibody discovery.  
Rationale 
The intrinsic specificities of monoclonal antibodies for their target antigen are fundamental 
for their application as research tools, in the field of diagnostics and for therapy. By 
exploiting the capabilities of the immune system to generate billions of potential antibodies 
that can specifically target practically any molecules they encounter, it is possible to  
generate mAbs for therapy from large combinatorial libraries expressed in bacteria (Sblattero 
& Bradbury, 2000), yeast (Gai & Wittrup, 2007) and mammalian cells (Wurm, 2004) and 
even by in vitro amplification techniques such as mRNA/ribosome display (Lipovsek & 
Plückthun, 2004).  
The ability to generate these libraries brings with it the problem of interrogating them 
efficiently, leaving researchers with the task of finding the one or few particular antibodies 
with desired characteristics from a highly diverse population of candidates. Depending on 
the starting source of antibodies current solutions involve selection by displaying the 
antibody on the surface of a phage particle (Bradbury et al., 2011) or cell (Bowers et al., 
2014) and selection by affinity-based biopanning (Ehrlich et al.,2000) or FACS (de Kruif et 
al., 1995). This is followed by further testing on a single cell basis in microtitre plate-type 
assays (Barbas et al., 2001; Guo et al., 2010; Lee et al., 2007). Searching for antigen-specific 
ASCs from large populations of hybridomas or native B cells normally involves spatially 
addressing cell populations into microtitre plates for analysis. This is followed by cloning by 
limiting dilution of positive wells to obtain monoclonality (Staszewski, 1984).  
This chapter investigates the feasibility of utilising porous, glass filters (Figure 3.1) as an 
ultra-high throughput screening tool for antibody discovery. The glass filters are 
manufactured commercially by fusing bundles of capillaries, of a certain diameter (5-100 
µm), and cutting them into slices (1mm thick or less). By spatially addressing antibody-
secreting cells (ASCs) in the capillaries, it was hoped that a powerful new tool to interrogate 
cells on a single cell basis could be achieved. 
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Figure 3.1: Microcaplliary array consisting of bundled, fused capillaries. The array used 
was composed of capillaries with a 10 µm diameter and the total number of capillaries 
present, for this particular array, was approximately 4.5 million.  
 
The envisioned procedure, illustrated in Figure 3.2, would begin by filling the capillaries 
with culture medium containing antibody-secreting cells. The cells would grow and express 
antibodies into the medium which could bind to antigen immobilised onto a PDMS surface 
reversibly sealed to the array. The PDMS was degassed prior to sealing to provide a means 
of pulling the medium, in the capillaries, into contact with the assay surface and also to 
obtain a tighter seal. Upon removal of the porous glass array, the bound antibody would be 
detected by the addition of secondary fluorescent reagents (e.g. fluorescently-labelled 
antibodies or antigens). Positive signals, represented by a fluorescent spot, would correspond 
to capillaries containing cells with antigen-specific antibody that could be recovered from 
the porous glass array for further analysis.  
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Figure 3.2: Proposed steps to allow for single cell analysis in the capillaries of a 
manufactured microcapillary array. (A) The microcapillary array is sealed to the antigen-
coated PDMS surface. (B) The antigen secreting cells are loaded into the array and begin to 
grow and express protein which, if specific to the antigen, will bind to the PDMS surface. 
(C) The array is removed and the PDMS surface subjected to several washing steps and 
fluorescence detection carried out. (D) The surface is visualised under a fluorescent 
microscope to identify any positive spots corresponding to antigen-specific antibodies. (E) 
The capillary containing the cell secreting the antibody of interest is located in the array and 
the contents removed.  
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The proposed technology would need to meet several demanding criteria prior to being 
declared fit for purpose. These include: 
 The ability to grow and observe detectable levels of expressed protein from the cells 
in the capillaries of the array.  
 The ability to carry out an assay, determining one or more characteristics of the 
cell/antibody expressed, within the capillary or on a removable surface.  
 The ability to retrieve the cell of interest, once identified, from the capillary for 
further analysis and cell banking.  
Each of these challenges, illustrated in Figure 3.3, were investigated initially in terms of their 
feasibility and then further developed and modified to allow for integration into a functional 
screening system.   
 
Figure 3.3: Schematic overview of thesis layout. Chapter 3 demonstrates the development 
of the single cell analysis technology from a concept into a fully integrated system. 
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Key Challenges 
Key Challenge 3.1 Assessment of the possibility of growing bacterial cells in the array  
3.1.1 Experimental Approach 
The ability of the bacterial cells to grow, remain viable and express protein which can 
subsequently be detected on an assay surface in the proposed process is investigated in this 
section. Initially a method to express the desired protein, without the need for addition of an 
induction agent at a later stage, was assessed. Following the identification of an appropriate 
method to auto-induce protein expression, the ability of cells to grow and express protein in 
the nanolitre volume capillaries was investigated.  
3.1.2 Comparison of auto-induction media with standard expression procedures.  
Typically, using recombinant systems, the induction of antibody production would be 
initiated using the compound Isopropyl β-D-1-thiogalactopyranoside (IPTG). IPTG 
inactivates the lac repressor and induces synthesis of beta-galactosidase, an enzyme that 
promotes lactose utilization. It is used to induce expression of cloned genes under control of 
the lac operon (Sambrook & Russell, 2001).  
As the bacteria will be loaded into the microcapillary array and sealed at the beginning of 
each experiment the use of an auto-induction system would be advantageous and would 
remove the need, and the uncertainty associated, with the addition of a reagent to the array. 
Auto-induction systems are based on the findings of Studier, who described the development 
of auto-induction medium, based on the fact that lactose can be responsible for target protein 
production but is hindered by certain compounds which become depleted during growth 
(Studier, 2005). On this basis, detailed medium formulations include components (e.g. 
glucose, amino acids and glycerol) which are differentially metabolised and allow for high 
density growth and auto-induction (Grabski et al., 2005).  
 
The performance of two different auto-induction systems, one prepared ‘in-house’ and one 
commercial, were compared with a standard IPTG-induced culture, as described in section 
2.3.1. The cultures were expressed overnight and then centrifuged to collect the cells at the 
base of the tube. The amount of cell material was observed as well as the amount of protein 
(GFP) expressed upon visualisation of the pelleted cells (Figure 3.4). In direct comparison 
the ZY and IPTG induced culture are similar in terms of cell density with overnight express 
medium producing slightly less. When the level of fluorescence is compared, as a means of 
assessing protein expression, the auto-induction media appear to outperform the traditional 
approach. Both of them produced pellets with uniform and high fluorescence, while the 
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IPTG-induced culture was not particularly uniform and was lower overall than the other 
cultures.  
 
Figure 3.4: Comparison of growth and expression in various media types. The cultures 
were grown in identical culture volumes overnight and the expressed cultures centrifuged 
and compared for each of the media types. ZY and ONX are auto-induction media systems 
and they were compared with the standard procedure, which involves the addition of IPTG 
once the culture has reached the logarithmic growth phase.  
In addition to visualisation of the cells the level of protein present in the lysate was analysed 
by SDS-PAGE as described in section 2.2.1. The result, shown in Figure 3.5, demonstrates 
that the methods all produce the specific protein, with the ZY producing the largest amount. 
Overnight express seems to have the least amount of non-target protein present in the lysate, 
with a strong band present for the target protein (Figure 3.5).  
 
Figure 3.5: SDS-PAGE analysis of target protein produced using various media types. 
Lysate was prepared for each of the expression cultures and analysed on SDS-PAGE to 
compare the levels of target protein expressed in each of the different media. A neat and a 1 
in 5 dilution were analysed, for each sample, to allow for accurate visualisation of the 
samples. The expected size is approximately 27 kDa for the target protein. 
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Based on the results obtained it appeared that the use of auto-induction media for array 
assays was a viable and desirable option. It allows  each cell to analysed without introducing 
any bias based on their growth rate.  
3.1.3 Investigation into protein expression and survival of bacteria in the 
microcapillary array.  
In order to determine whether cells can reproduce, express protein and survive in the 
microcapillary array E. coli expressing GFP were added to the array in auto-induction 
medium and allowed to incubate overnight at 37°C, as described in section 2.3.2. 
 
Figure 3.6: Expression of GFP by E. coli in the capillaries of the microcapillary array. 
The area of the array which contained cells was imaged, using a fluorescent microscope 
with FITC filter, at (A) 0 hours and (B) 18 hours. Scale bar is 100 µm. 
The ability of the cells to replicate and express protein in the array was then confirmed by 
direct visualisation of expressed GFP after 18 hours (Figure 3.6B). When compared with an 
image taken at 0 hours (Figure 3.6A) a distinct green colour can be seen in the capillaries 
indicating the expression of the protein by E. coli.   
In addition to visualisation of protein expression in the cells, a nitrogen flow was applied to a 
discrete portion of the array and the contents of several capillaries captured on an agar plate 
beneath. The plate was then incubated overnight to assess the viability of the cells following 
incubation in and removal from the microcapillary array. Bacterial growth was evident, 
following overnight incubation at 37 °C, as shown below in Figure 3.7.  
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Figure 3.7: Growth of bacterial cells following removal from the microcapillary array. 
Cells were removed from the array under a stream of nitrogen and captured on the agar 
plate beneath. Subsequent to incubation, bacterial growth was evident, indicating that the 
cells can remain viable throughout the process.  
 
3.1.4 Determine feasibility of single capillary analysis 
A key consideration when developing the microcapillary assay system proposed is the ability 
to address cells on a single cell basis, thus allowing for a non-biased screening approach.  To 
determine the ability to screen recombinant systems at single cell level, E. coli which express 
a GFP protein were diluted in series (1in 10) and loaded into the array in discrete areas, as 
detailed in section 2.3.3.  After overnight incubation, each area of the array was observed 
and recorded, as shown in Figure 3.8.  On visualisation of the array, a decrease in 
fluorescence could be seen down to the point where single capillaries were clearly visible. 
Based on a Poisson distribution, this indicates that by diluting the cells added to a suitable 
level, single cell occupancy of capillaries can be obtained and detected.  
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Figure 3.8: Visualisation of GFP-expressing E. coli in the capillaries of the array. 
Dilutions of the culture were observed until single capillaries could be identified. The cell 
count from plates was 4.6 x 10
9
 cfu/mL. Scale bar is 100 µm. 
 
Approximately 1 x 10
6
 cfu/mL should theoretically equate to 1 cell per capillary, based on 
the 40 µm capillary diameter (1.2 nL volume). Based on Figure 3.8, this appears to be 
accurate with the 10
-3
 dilution representing 1 cell per capillary, 10
-4
 representing 1 cell in 
every ten capillaries and 10
-5
 showing 1 cell in every hundred capillaries.  The ability to 
carry out single-cell analysis has been shown by observing expression of varying dilutions of 
a GFP-expressing E. coli bacteria. The dilution and cell number is largely important to 
achieving this, and will need to be determined for each recombinant system analysed.  
 
Summary for key challenge 3.1 
The ultimate aim for this particular section was to determine the possibility of growing cells, 
in addition to expressing and detecting target protein, in the capillaries of a microcapillary 
array. On investigation, the cells were proven to grow, express and remain viable in the array 
throughout incubation and retrieval. Furthermore, an auto-induction system was found to be 
comparable with traditional expression approaches.  
Key Challenge 3.2 Investigation into performance of assays on a polydimethylsiloxane 
(PDMS) surface. 
3.2.1 Experimental approach 
Following confirmation of cell growth in the capillaries of the array, the ability to detect the 
proteins expressed was investigated. Initial investigations into performing a direct assay on 
the PDMS surface and observing the resultant pattern were completed, as described in 2.3.4. 
The introduction of required washing and secondary detection steps identified instability in 
the coated surface and meant that assay performance was negatively affected (e.g. loss of 
coated protein resulted in loss of detectable reagent and an increase in non-specific binding 
as the blocking solution was removed). The discovery of this instability then required the 
development of a method to modify the PDMS to provide a more stable, reliable and 
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uniform surface. The surface was then compared with standard microtitre plates, under a 
number of conditions to verify its performance and suitability for future use. Assay 
development was then undertaken to enhance the offering in terms of information garnered 
about each single cell analysed.  
3.2.2 Feasibility of carrying out an assay on a PDMS surface.  
PDMS was identified as the ideal assay surface as it could reversibly seal to the array 
surface. In order to determine if protein could be patterned through the array and detected on 
the surface, human IgG was coated on the PDMS and fluorescently-labelled anti-IgG was 
loaded into the array. The array was sealed to the PDMS, as described in section 2.3.4, and 
following incubation the surface was imaged using a microarray scanner and a fluorescent 
microscope.  
Based on the images obtained (Figure 3.9), it was concluded that not only could protein be 
passed through the array and detected on PDMS surface but that the bonding between the 
PDMS and the array was sufficient to allow each capillary to remain sealed (i.e. no bleeding 
of protein between capillaries) throughout the process. This is evidenced by the clear black 
rings surrounding each capillary which corresponds to the capillary wall, as shown in Figure 
3.9B.  
 
Figure 3.9: Detection of fluorescent protein on the PDMS surface. The PDMS surface was 
coated with 10 µg/mL of human IgG. Fluorescently labelled anti-human IgG was then added 
to the capillaries of a microcapillary array with capillaries of 10 µm diameter, sealed to the 
PDMS and allowed to incubate. Following incubation, the array was removed and the 
surface imaged using (A) a Perkin Elmer Gx ScanArray microarray scanner (5 µm 
resolution) and (B) an Olympus IX81 fluorescent microscope (20X magnification). Scale bar 
is 100 µm.  
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The resolution limit (5 µm) of the microarray scanner meant that individual capillary 
patterns were not visible using the capillaries with a 10 µm diameter, as the distance between 
capillaries was only 1 µm. The use of the microarray scanner was the desired approach as it 
would remove several of the limitations of using the standard fluorescent microscope which 
included the need for image stitching, extended imaging times and low sensitivity. In 
response to this, the process was tested with a microcapillary array with 40 µm diameter 
capillaries (10 µm distance between capillaries) and the patterning process repeated, as 
above. The resulting image (Figure 3.10) showed clear definition between capillaries when 
scanned in the microarray scanner at a 5 µm resolution. While the increase in capillary 
diameter would represent a loss in overall throughput (approximately 10-fold reduction), the 
benefits of using the microarray scanner were considered more important during 
development stages of the technology. As a result, the remaining development was 
predominantly carried out using arrays with 40 µm diameter capillaries and imaged using the 
microarray scanner.  
 
Figure 3.10: Pattern of fluorescent protein on a PDMS surface using a microcapillary 
array with 40 µm diameter capillaries. The fluorescently labelled protein was added to the 
capillaries of an array, sealed to the PDMS and then allowed to incubate. Following 
incubation, the array was removed and the surface imaged using a Perkin Elmer Gx 
ScanArray microarray scanner at a 5 µm resolution. Scale bar is 100 µm.  
 
 
81 
 
3.2.3 Identification of an appropriate functionalisation approach to allow for assays to 
be reliably performed on PDMS surface.  
The assay surface, PDMS, was selected for use in the process as it allowed for complete but 
reversible seal to the microcapillary array. PDMS is naturally hydrophobic and chemically 
inert which lowers the possibility of immobilising biomolecules on its surface. It often has a 
tendency towards bio-fouling, which causes non-specific binding to the surface (Heyries, 
Marquette, & Blum, 2007). While straightforward assays (e.g. direct human IgG assays) 
performed well on non-treated or “native” PDMS, shown in section 3.2.2, problems became 
evident when performing expression assays and including washing and secondary detection 
steps. Based on these observations, and because of the importance of having a reproducible 
and uniform surface which remained stable during extended incubation of bacterial cultures, 
surface modification was undertaken. Several different methods to chemically modify the 
surface of the PDMS were tested, using a number of important criteria, with a view to 
enhancing the reliability of the assay performance.  
Each of the modification approaches, detailed in section 2.3.5, were subjected to numerous 
different challenges which would determine if they were compatible for use with the process 
(Table 3.1). In order to simplify the initial testing process, PDMS was cast and cured in the 
wells of microtitre places and the modifications and assays performed in the wells. In assays 
utilising purified antibodies in buffer all surfaces performed in a satisfactory manner, even 
surfaces which were untreated. In addition, none of the modifications inhibited sealing 
between the assay surface and array. However, several of the surface modifications 
performed poorly when they were tested in an expression on-plate assay. It appeared that 
they were not stable in extended incubations with culture as the background fluorescence 
was very high, indicating that the blocking carried out did not remain intact and secondary 
antibody bound non-specifically to the exposed surface. 
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Table 3.1: Summary of performance for each of the chemical modification strategies 
tested.  EDC is a (1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride) surface; 
GA is a glutaraldehyde surface; The Carboxy A surface is a tetraethyl orthosilicate (TEOS) 
surface; Carboxy B surface is a tetraethyl orthosilicate (TEOS) and acrylic acid (AA) 
surface and APTES is a (3-Aminopropyl)triethoxysilane surface. 
 
The three modification strategies which performed satisfactorily in the ‘on-plate’ expression 
tests were then taken forward for further investigation. A thin layer of PDMS was modified 
with each of the different strategies and the quality of the surface provided visualised by 
adding 2.5 µg/mL of Cy5-labelled anti-human IgG to the surface for one hour. The surface 
was then washed, air-dried and scanned using the Perkin Elmer microarray scanner (Figure 
3.11). 
 
Figure 3.11: Visualisation of surface quality obtained with several surface modification 
strategies. A square of PDMS, modified by each of the different methods, was incubated with 
a 2.5 µg/mL dilution of Cy5 labelled anti-hIgG for 1 hour. The surface was subsequently 
washed, air-dried and imaged in a microarray scanner to allow visualisation of the level and 
quality of protein binding on each of the surfaces.  
Based on the outcome of this investigation, shown in Figure 3.11, it was evident that the 
APTES approach gave the best and most uniform coverage. The uniformity is hugely 
important when comparing fluorescent signals, representing different antibody candidates, 
across the entire surface. It was selected as the most appropriate method to modify the 
PDMS surfaces used in the process. Previous studies had shown that modifications of this 
nature, carried out on PDMS surfaces were often time-limited due to hydrophobic recovery 
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caused by migration of buried PDMS (Heyries et al., 2007).  In light of this fact, APTES 
surfaces used in assays were as fresh as possible throughout all development phases.  
 
3.2.4 Direct comparison between an immunoassay performed in a microcapillary array 
and in a microtitre plate.  
This particular experiment was carried out to ascertain whether it was possible to carry out 
an immunoassay, with comparable sensitivity to those obtained using a microtitre plate, on 
the array. A direct comparison of a sandwich assay, using the same reagent preparations and 
conditions, was carried out on a microtitre plate and on a 40µm array, as described in section 
2.3.6. The results obtained were plotted and compared, as shown in Figure 3.12. The result 
obtained shows that detection levels and background values are comparable. This means that 
it is possible to carry out an immunoassay through the array, onto the coated and blocked 
PDMS surface. 
 
Figure 3.12: Comparison of immunoassay performance carried out on a plate and on 
array. The immunoassay carried out was an anti-human IgG sandwich FLISA. Human IgG 
concentration was varied to assess detection range. Readings obtained from the array 
analysis were based on the grey value obtained from a 1mm circular area for each of the 
assay dilutions.  F.U. denotes fluorescent units. Fluorescence was read at Cy5 wavelengths 
(Excitation 650 nm; emission 670 nm) on the plate reader and using the 633 nm laser on the 
microarray scanner. 
The assay response obtained is comparable with that from an assay carried out on a standard 
microtitre plate. The detection range is almost identical and background levels are also 
similar. The slight differences in curve shape between methods may be attributed to the 
variations in machines used for fluorescence detection. In addition, the 1mm
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(roughly 20 capillaries) on the array image encompasses the small dark area surrounding 
every capillary, which will alter the grey value reading and hence the smoothness of the 
graph generated.  
3.2.5 Shaking Vs Static expression 
The development of the on-plate expression method, described in Guo et al. (2012) 
demonstrated that it was possible to grow, express and detect antibodies in culture 
simultaneously. This is key in the development of the proposed microcapillary array assays, 
as antibody-producing cells would be incubated in the array and the antibody detected on a 
removable surface sealed to the array. The use of array assays in place of standard practices 
(microtitre plates) would require for antibody expression and detection to occur on a surface 
PDMS surface without shaking. As such, the levels of antibody expressed in both shaking 
and static experiments, on PDMS and a standard microtitre plate were compared, as detailed 
in section 2.3.7 and shown in Figure 3.13.  
 
Figure 3.13: Comparison of antibody production in static and agitated systems on-plate. 
The level of specific antibody was determined in shaking and static embodiments on both a 
standard microtitre plate format and also on a PDMS surface. The assay was performed at 
two time-points [6 hours and overnight (ON)]. F.U. denotes fluorescent units. Fluorescence 
was read at Cy5 wavelengths (Excitation 650 nm; emission 670 nm).  
The absorbance levels were higher in all cases for the overnight time point, which was 
expected. Additionally, as expected, the cultures which were shaken at 200rpm showed 
higher levels of antibody than the static equivalents. Overall the absorbance values on the 
PDMS surface, while sufficient, were lower than those observed on the microtitre plate. This 
was most likely due to inefficient modification of PDMS surface in the microtitre plate (i.e. 
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oxygen plasma treatment may not have efficiently accessed the surface. This problem should 
not arise when carrying out the proposed assays on flat PDMS pieces. When comparing the 
overnight, static data it could be observed that the PDMS surface and microtitre plate 
performed very similarly.  
3.2.6 Expression of recombinant antibodies in the microcapillary array and subsequent 
detection on a PDMS surface. 
Ultimately, the aim of this section was to develop a method whereby the antibodies secreted 
from growing cells could be reliably detected on a removable PDMS surface. Following 
identification of appropriate medium, conditions and substantial investigations into the 
modification of the PDMS surface this was deemed possible. The experiment used an anti-
CRP scFv, developed in the BDI, to demonstrate the principle. The direct format assay used 
is described in section 2.3.8 and illustrated in Figure 3.14. A range of cell dilutions was 
added to the array and analysed, and the resulting images are shown in Figure 3.15.  
 
 
Figure 3.14: Schematic of the format used for typical array assay. (A) Bacterial cells grow 
and express scFv fragments which, if antigen-specific, will bind to the antigen-coated PDMS 
surface. (B) Following incubation the array is removed and stored and secondary detection 
is carried out using a fluorescently labelled anti-tag antibody, before washing and scanning 
during image analysis.  
 
To successfully use the proposed technology to screen large antibody libraries, cells must be 
able to survive and express protein as previously investigated in this chapter. In addition, an 
assay on the PDMS surface must be carried out on the modified PDMS surface to allow for 
accurate identification of capillaries which contain a cell expressing an antibody of interest 
(e.g. antigen-specific).  
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Figure 3.15: Detection of anti-CRP avian scFv released from cells in the capillaries of a 
microcapillary array. Dilutions (1 in 10 series) of the scFv-expressing E. coli were added to 
the array and allowed to incubate overnight. Capillaries containing a cell producing an 
antigen-specific scFv were detected through the use of a fluorescently-labelled secondary 
anti-HA antibody. All steps are described in section 2.3.8. Scale bar is 100 µm.  
 
Here it was demonstrated that it is possible to detect the presence of an antigen-specific, 
recombinantly-expressed antibody on a modified PDMS surface. Each fluorescent spot on 
the image relates to a capillary which contains a cell secreting an antigen-specific scFv. The 
use of the microcapillary array in combination with this surface allows for the 
compartmentalisation of each cell and thus allows for the high-density, low volume, single 
cell analysis that was required. 
 
3.2.7 Assay format investigations  
Following on from the development of a successful recombinant assay in the microcapillary 
array (Section 3.2.6), a number of assay format changes that would allow for an increased 
functionality in the employment of the proposed technology for high-throughput single cell 
screening were identified. Each of these format changes are discussed, developed and the 
final optimised system demonstrated within this section.  
3.2.7.1 Multi-Analyte analysis 
The proposed multi-analyte assay would utilise a common coating element on the surface 
and probe the captured antibodies with two (or more) differentially labelled secondary 
reagents. This could allow for easier comparison between the antibodies, in terms of 
expression level or affinity, by enabling ranking based on the fluorescent intensity of the spot 
representing each antibody.  
In order to facilitate this approach the assay is required to use a “capture format” where all 
antibodies are captured (in this case by recombinant tag anti-HA) and, following incubation 
and expression, are probed with fluorescently labelled antigens, of interest. In this section the 
ability to use a capture format, as well as the ability to probe with two alternately labelled 
antigens simultaneously, illustrated in Figure 3.16, was investigated as detailed in section 
2.3.9.  
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Figure 3.16: Schematic of the format used for a multi-analyte array assay. (A) Bacterial 
cells grow and express scFv fragments which will all bind to the anti-tag antibody-coated on 
the PDMS surface. (B) Following incubation the array is removed and stored and secondary 
detection is carried out using a mixture of two different antigens labelled with alternate 
fluorescent dyes (Cy3/Cy5) before washing and scanning during image analysis. Outputs for 
each fluorophore can be overlaid and cells which bind one or both of the antigens in same 
screen can be identified.   
 
An anti-HA “capture” approach was tested to confirm that the alternative assay format would 
not negatively affect the performance of the system. The result obtained is shown in Figure 
3.17. The assay performed very well using the new format and could be implemented for use 
in multi-analyte detection assays as planned. 
 
Figure 3.17: Demonstration of assay using an alternative capture approach. All antibodies 
are captured and are detected with fluorescently labelled antigen. Single capillaries (40µm 
spots) are clearly evident at the designated dilution. Scale bar is 100 µm.  
Following confirmation of the proposed capture format, a series of experiments to ascertain 
whether it was feasible to read Cy3 and Cy5 simultaneously were carried out.  Using both 
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the Tecan Safire plate reader and the Perkin Elmer scanner, tests to identify any interference 
between dyes, were carried out using control proteins. Both dyes were analysed separately 
and then mixed and analysed, to determine any cross-talk that may be evident, as detailed in 
section 2.3.9.1. For each analysis type, average fluorescence was recorded and the results 
obtained are shown in Figure 3.18 and Figure 3.19.  
 
Figure 3.18:  Testing of any interference obtained between Cy3 and Cy5 samples using 
microtitre plate reader. No non-specific fluorescence is seen in the case of either protein. 
The Cy3 and Cy5 samples  are diluted  1 in 2,000 in PBS while the mix samples is a 1:1 mix 
of each protein diluted 1 in 1,000 in PBS. Cy 3 has an excitation at 550nm and emission at 
570nm, while Cy5 has an excitation at 650nm and emission at 670nm.  
 
Figure 3.19: Fluorescence pattern obtained from dyes passed through the array, singly 
and mixed. No non-specific fluorescence or cross over between fluorophores was seen in the 
case of either protein. The Cy3 and Cy5 samples  are diluted  1 in 2,000 in PBS while the 
mix sample is a 1:1 mix of each protein diluted 1 in 1,000 in PBS.  
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No level of cross-talk or non-specific fluorescence is seen between the samples (Cy3 and 
Cy5) using either a plate reader or scanner. Once the format and scanning conditions were 
confirmed to be compatible with a multiplex approach, an assay (described in section 
2.3.9.3) was carried out on array to test the performance. The result obtained is shown in 
Figure 3.20.  
 
Figure 3.20: Multi-analyte analysis feasibility assay. The same clone (anti-CRP scFv F8) 
was captured on an anti-HA tag-coated surface and probed with (A) CRP labelled with Cy3, 
(C) CRP labelled with Cy5 or (B) a mixture of the two. Each was scanned with the Cy3 laser 
(543nm) and the Cy5 laser (633nm).  
From the results obtained in this study it can be seen that there is no non-specific 
fluorescence in the single analyte samples. It can also be concluded that it is possible to use 
several fluorophores, depending on their excitation and emission profiles, on the same 
surface simultaneously to garner additional cross-reactivity information from an assay. This 
will be of particular interest when carrying out library screens. The ability to probe a library 
for antibodies against several different antigens (labelled with different fluorophores) 
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simultaneously allows for a great deal more information about potential candidates to be 
identified from a single assay, saving time and reagents and streamlining the discovery 
process. While the present analysis was limited to two fluorophores (Cy 3 and Cy 5) based 
on the lasers available in the instrument, the analysis methodology could be greatly enhanced 
by the introduction of additional lasers to the detection instrument.  
3.2.7.2 Double-sided analysis 
The straw-like nature of the microcapillary array means that there are two open surfaces 
available for analysis. While the multi-analyte approach, demonstrated in section 3.2.6.1, 
relies on a common coating element a double-sided approach would not; this point is 
explained in Figure 3.21. It offers the benefit of carrying out two very different assays on the 
same population of cells simultaneously, ultimately increasing overall throughout and the 
amount of information obtained in each screen.  
 
Figure 3.21: Schematic of the format used for a double sided array assay. (A) Bacterial 
cells grow and express scFv fragments which, if specific to either antigen/antibody on either 
of the surfaces, will bind to the prepared PDMS surface. (B) Following incubation the array 
is removed and stored and secondary detection is carried out using an appropriate detection 
element for each separate assay surface. Following this the surfaces were washed and 
scanned and detailed image analysis carried out to relate the two images to each other.  
 
Development of double-sided analysis, detailed in section 2.3.10, went through several 
iterations before performing successfully. The optimisation involved numerous sealing and 
incubation procedures. Sealing that was found to be optimal was sequential, with one side 
being sealed at a time. Typically the assay components would be incubated in a horizontal 
orientation, with the array on top of the PDMS. This means that the degas power pulls the 
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liquid to the assay surface, which is normally advantageous.  Due to the fact that horizontal 
incubation could introduce a bias towards the lower assay surface, either through the degas 
power or through natural sedimentation, vertical incubation was found to provide the best 
coverage on both sides of the assay.  A sample of a successful double-sided assay carried out 
using these optimised conditions is shown in Figure 3.22.  
 
Figure 3.22: Double sided assay feasibility. The cell portion of the assay, depicted in the top 
of the image, shows single cells expressing and detected on each side. The alignment marks 
obtained on each side of the assay are shown and compared in the bottom part of the image. 
The first side of the assay (A) provides a mirror image of the second side of the assay (B). A 
specific area of the total image was selected for illustration purposes. Scale bar is 100 µm.  
The double-sided analysis provides two scanned assay surfaces which are in fact mirror 
images of each other. Specialised software, developed by Brian Manning, can relate the 
images to each other and allows for each of the screening criteria to be combined for each 
individual clone. It offers a very powerful method to ask distinct questions of each clone, in 
each screen.  
3.2.7.3 Multi-lift analysis 
An additional approach, to increase the throughput of the process, is deemed ‘Multi-lift’. 
This approach involves removing the array from its original PDMS surface and sealing it to a 
subsequently prepared assay surface, as illustrated in Figure 3.23.  Much like the multi-
analyte and the double-sided assay approaches this expands the level and quantity of 
information that can be obtained simultaneously, for each individual antibody-secreting cell 
analysed. 
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Figure 3.23: Schematic of the format used for a multi-lift array assay. (A) Bacterial cells 
grow and express scFv fragments which, if specific to either antigen/antibody on the surface, 
will bind to the prepared PDMS surface. (B) Following the initial incubation (8h) the array 
is removed, sealed to another freshly prepared assay and incubated again (18h). Post-
incubation, both surfaces have secondary detection carried out using an appropriate 
detection element. Following this the surfaces were washed and scanned and detailed image 
analysis carried out to relate the two images to each other.  
 
 The multi-lift assay, described in section 2.3.11 and demonstrated in Figure 3.24, shows two 
identical assay images which represent two separate incubations on different assay surfaces.  
 
Figure 3.24: Feasibility for multi-lift approach using microcapillary array assay. A 
standard assay was carried out, as described in section 2.3.11. The first assay (A) was 
allowed to incubate for 8 hours before removal and completion of the assay. The array was 
then sealed to a second surface and incubated overnight and completed on the following day 
(B). A specific area of the total image was selected for illustration purposes. Scale bar is 100 
µm. 
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In developing this approach two very important factors for success became evident. The first 
was the requirement for each assay surface to be as fresh as possible prior to sealing. If a 
prepared surface was not required for a substantial amount of time (e.g. overnight) it would 
be best to either leave it in blocking solution or prepare it just before it was required. The 
second observation was that additional alignment solution should be added prior to each 
sealing. If this is not carried out the quality of alignment marks is poor in assays which are 
subsequent to the initial assay. This is most likely due to the evaporation of the solution 
during incubation.  
3.2.7.4 Assessment of diffusion through the capillaries.  
The purpose of this investigation was to determine whether diffusion through the array 
occurs. This would be advantageous in the development of functional bioassays which may 
require a secondary reagent added later on in the process. The ability to add an additional 
reagent to a microcapillary array which has already been incubating for a defined length of 
time could add a higher level of functionality to the assays carried out using the technology 
(e.g. Roche Diagnostics WST-1 assay for analysis of cell proliferation requires addition of a 
secondary reagent to growing cells after 24-48 hours incubation). The ability to have these 
secondary agents efficiently diffuse through the medium or buffer present means that 
reagents which would hinder the interaction to be studied, if present from the beginning of 
assay, can be added at a later point.  The experiment was carried out, as described in section 
2.3.12 and illustrated in Figure 3.25.  
 
Figure 3.25: Schematic demonstrating the principle of diffusion of reagents through a 
buffering solution in the capillaries of the array. The secondary reagent is added to the top 
of the array, allowed to diffuse through the buffer and bind to the prepared surface sealing 
the opposite side of the array.  
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The result obtained, shown in Figure 3.26, confirmed that diffusion through the array is 
possible. This is indicated by the presence of fluorescence bound to the human IgG-coated 
surface which was sealed to the opposite side of the array. The fluorescence seen in the 
diffusion sample is lower than the standard sealing (values are present in the image) but this 
can most likely be attributed to the dilution effect from the PBS, in the array, which the 
secondary antibody diffused through. The diffusion control lacked the PBS in the array and 
there was very little binding seen on the PDMS in these areas. While an outline can be seen, 
this can be explained as a drying effect artefact.  
 
Figure 3.26: Demonstration of diffusion through a microcapillary array. Varying dilutions 
of Cy5-labelled anti-human IgG were added through the array in either a standard or 
diffusion format. The resulting image showed that there was diffusion of the secondary 
antibody through the PBS loaded in the array, indicated by its binding to the human IgG 
coated surface sealed to the opposite side of the array. F.U. denotes ‘Fluorescent Units’ 
obtained from the microarray scanner software. ND denotes ‘Not Determined’.  
 
Based on these proof-of-concept investigations, it has been shown that diffusion through 
another liquid, in the capillaries of the array, is entirely possible. If this were to be used in a 
working assay format, a consideration should be made to the concentration of secondary 
agent that is added to the top of the array, as the liquid in the array will dilute that actual 
concentration by a certain factor.  
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3.2.8 Determine feasibility of in-solution analysis 
Homogeneous or in-solution assays hold the promise of delivering simplicity to end users by 
including fewer addition or reagent-transfer steps (Walters & Namchuk, 2003). It makes 
them highly amenable to automation and miniaturisation. The advantages for their 
application on the platform are obvious. They would reduce the need for additional assay 
steps and could possibly remove the need for a surface entirely. This would mean that 
retrieval of the desired cell from a capillary would be greatly simplified. This proof-of-
concept data was also included in the patent filing for the proposed technology, 
demonstrating that surface independent analysis was possible (Leonard et al., 2012).  
 
3.2.8.1 Determination of feasibility of in-solution analysis/FRET analysis on array 
The first in solution approach that was tested in the array was based on the detection of 
Förster or Fluorescence Resonance Energy Transfer (FRET), as detailed in section 2.3.13. 
FRET occurs based on the binding of two complementary DNA probes labelled with Cy5 
and Cy5.5. Once DNA hybridisation occurs, the Cy5 and Cy5.5 dyes are brought into close 
proximity of each other so that FRET can occur between the Cy5 donor and Cy5.5 acceptor. 
Due to the transfer of energy, the intensity of emitted light from Cy5 is reduced in the 
presence of Cy5.5 held in close proximity by the bound DNA.  In that way specific binding 
interactions could potentially be monitored on-array by measuring a shift in the level of 
fluorescence at a particular wavelength.  
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Figure 3.27: Demonstration of FRET between two complementary DNA probes. Analysis 
was carried out in a 96-well microtitre plate and read using a Tecan Sapphire II (A) as well 
as in the microcapillary array, using a fluorescent microscope (B).   
DNA-FRET was successfully demonstrated using fluorescence intensity measurements from 
spectral analysis in a microtitre plate (Figure 3.27A) and in a 40 µm diameter microcapillary 
array (Figure 3.27B). Binding of the two complementary DNA probes is detected by a clear 
decrease in Cy5 emission due to fluorescent energy transfer with the Cy5.5 acceptor. While 
it is possible to carry out FRET analysis on the array, the ability to use a time-lapse option or 
to have an automated scanner would greatly improve the feasibility of using this as a method 
for detection of binding on the array in future. 
3.2.8.2 Determination of feasibility of in-solution analysis/GFP-reassembly on array  
An additional demonstration of a cell-based in-solution binding assay in the array was 
carried out, using the GFP reassembly vectors described by Magliery et al. (2005). This 
method identifies the interaction between binding partners based on reassembly of dissected 
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fragments of GFP, fused to antiparallel leucine zipper peptides.  In the event of a positive 
interaction the “bait” and “prey” would bind to each other, the GFP fragments (N-terminal 
and C-terminal) will be brought together and a green fluorescence would be emitted. The 
potential application would involve fusion of one of these dissected fragments to a 
recombinant antibody library construct and attachment of the other fragment to the antigen 
of interest. The observation of fluorescent signal within the capillary would indicate a 
specific interaction between the binding partners (i.e. expressed antibody and antigen), as 
illustrated in Figure 3.28.  
 
 
Figure 3.28: Illustration of the proposed GFP Reassembly concept. As the two 
complementary proteins are brought together the dissected GFP is reassembled and emits a 
fluorescent signal. In the proposed screening format the antibody library would be loaded 
into the well along with the antigen, and on expression of a specific antibody, the interaction 
would be evidenced by the emission of fluorescence from the particular capillary.  
In order to demonstrate the potential of using this approach in array assays, the set of control 
vectors were obtained under MTA from the authors in Yale University. Initially the principle 
was confirmed to work by sequentially transforming both of the control vectors into the 
same cell. Throughout this study this embodiment, where both plasmids were contained 
within the one cell, was called ‘in vivo’. A number of the transformants were plated on 
screening media (solid and liquid), as described in section 2.3.14.  Following incubation, the 
fluorescence present in the cells was observed on a transilluminator at an approximate 
wavelength of 365nm, as shown in Figure 3.29.  Those cells containing both vectors 
fluoresced with a strong green colour and confirmed that the system was functional.  
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Figure 3.29: Demonstration of reassembly of GFP ‘in vivo’. The ‘in vivo’ samples had both 
plasmids (NZ and CZ) sequentially transformed into the same cell, allowing for GFP 
reassembly. The GFP reassembly was visualised on (A) Solid expression medium and in (B) 
liquid medium. Selection medium was LB containing 10 µM IPTG, 0.2% (w/v) arabinose, 
35µg/mL Kanamycin, 100µg/mL Carbenicillin. Cells have been pelleted by centrifugation at 
4,500 x g for 10mins and the supernatant removed. 
 
The vector set was then trialled, in what was deemed an ‘in vitro’ approach. This involved 
the co-incubation of the two control vectors, expressed singly in different cells, described in 
section 2.3.14. This would be akin to the final proposed screening format for use on the 
platform and it was hoped that as the cells grew and died, the dissected fragments would be 
released into the medium and would interact. The cells were loaded, in screening medium 
without antibiotic, into the microcapillary array and following two days incubation at 37°C 
the level of fluorescence was observed using a fluorescent microscope.  
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Figure 3.30: Determination of feasibility for GFP reassembly detection on array. Both ‘in 
vitro’ and ‘in vivo’ embodiments were loaded on to the array in discreet areas and 
visualised following incubation.  (A) Images obtained of microcapillary array with E. coli 
cultures harbouring split GFP fragments using a fluorescent microscope (B) Graphical 
representation of the fluorescent intensity values obtained images in Figure 3.30A.  
The level of fluorescence in each of the embodiments (CZ only, NZ only, ‘In vivo’ and ‘In 
vitro’) was compared, following observation under a fluorescent microscope. Based on the 
result obtained, shown in Figure 3.30, it appears that both the In vivo’ and ‘In vitro’ samples 
have performed as expected, with a level of fluorescence above the negative controls (CZ 
only and NZ only). The level of fluorescence is low and the implications of this, in terms of 
assay sensitivity, would be something to consider if moving forward with the approach.  
3.2.9 Summary for key challenge 3.2 
The purpose of this section was to develop a means to carry out assays using the 
microcapillary arrays. A chemical modification strategy, which will allow for assays to be 
performed in a reliable and robust manner on a PDMS surface, was identified. The use of the 
chemically modified surfaces means that assays with washing and secondary steps can be 
utilised in the process without non-specific binding or unfavourable signal-to-noise ratios. 
Standard assays carried out on the selected modified surface perform similarly to those 
carried out in microtitre plates.  A screening assay was then successfully carried out on the 
modified surface, allowing single cell analysis of the control recombinant antibody. Building 
on this the expansion of the functionality and performance of the microcapillary array assay 
process, through implementation of various assay embodiments, was explored.  For each of 
the different assay formats, a proof-of concept experiment was optimised and demonstrated. 
The possibility of carrying out ‘in-solution’ analysis on the array appears feasible based on 
the demonstration of GFP reassembly and the success of the FRET method in the array. This 
will mean that the need for an assay on a separate surface would not necessarily be required. 
This would serve to greatly reduce the overall time needed to carry out a screen and remove 
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any complications anticipated with alignment of the assay image to the physical array. 
Unfortunately it brings with it its own limitations in that only certain types of assay (i.e. 
homogenous formats with no washing steps), which may not be broadly applicable, can be 
performed. 
 
Key Challenge 3.3 Development of a method to accurately retrieve the contents of a 
target capillary.  
3.3.1 Experimental approach 
In order for the technology to be complete, a means to retrieve the cell producing the 
antibody of interest, for further analysis, is required. This portion of the technology 
development is concerned with the identification of an appropriate way to remove the cell of 
interest efficiently and reliably. It involves the design and building of a prototype device to 
allow single capillary contents to be retrieved. This required the integration of hardware and 
software elements, which were developed within the dedicated team of biologists (i.e. assay 
support and test reagents provided) and engineers. A means to relate the assay image to the 
location of the desired capillary in the physical microcapillary array was also developed and 
verified for use.  
3.3.2 Feasibility investigations for the removal of contents of capillaries using high 
pressure nitrogen.  
Initial investigations involved an experiment to determine if it was possible to remove the 
contents of a specific area of an array, without disturbing the surrounding areas, with high 
pressure nitrogen. The experiment, described in section 2.3.15, involved the removal of the 
contents from an exposed area of the array. A hole was burned in a piece of acetate and 
placed over the array, which was filled with liquid food dye. Nitrogen gas was then applied 
to the area exposed by the laser hole, and the array observed using a light microscope. The 
resulting image is shown in Figure 3.31.  
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Figure 3.31: Removal of the contents of an exposed portion of the microcapillary array. 
The contents of an area, comprising numerous capillaries, were blown out of the array using 
high-pressure nitrogen as described in section 2.3.15. (A) A laser was used to ablate an area 
of an acetate sheet. The hole in the acetate measured approximately 100 µm. (B) The acetate 
was placed over an array containing coloured liquid and air pressure was applied to remove 
the contents from those capillaries exposed by the ablated area. The clearance zone in the 
array was approximately 300 µm. Removal of the liquid was verified by observation of 
colour on the tissue paper which had been placed underneath. 
The image showed that it was entirely possible to remove the contents of designated area of 
the array. The area which was cleared of its contents was approximately three times larger 
than the laser hole (i.e. the laser hole measured 100 µm while the area of emptied capillaries 
had an approximate diameter of 300 µm). The reason for this was mostly the highly crude 
nature of the experiment, with the acetate not sealed to the array and the nitrogen blast 
applied by hand through a wide nozzle. The experiment did show that it was possible to 
remove contents of capillaries in a directed manner; however, the low level of accuracy 
meant that the development of a dedicated retrieval system was required. This work was 
undertaken by mechanical engineer Barry O’Donnell at the BDI and the working prototype 
developed is described in section 3.3.3.  
3.3.3 Design and production of a dedicated prototype device for removal of the contents 
of single capillaries in the microcapillary array.  
In order to achieve efficient single capillary removal, the development of a prototype for 
removal of the contents of a single capillary was undertaken by mechanical engineer Barry 
O’ Donnell. The prototype, shown in Figure 3.32, consisted of high precision XY stages for 
capillary alignment and a high powered laser for ablation of sealant above target capillaries 
and subsequent retrieval of capillary contents under a flow of high pressure nitrogen (Figure 
3.32B).  
The design of the DiCAST prototype was continually improved during testing to optimise 
the performance of the system. A wide variety of modifications were made to the system 
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including the introduction of a beam expander to reduce the laser spot size, inversion of the 
top XY stage to increase freedom of movement, the addition of an image system to allow in-
line viewing of the array and the introduction of a Z stage to enable focusing of the laser and 
image system. These improvements to the design of the prototype resulted in a reduction of 
the spot size of the laser from 100 µm down to 10 µm. The addition of an in-line viewing 
system allowed real-time observation of the laser ablations and extractions and allowed for 
accurate alignment of the system and these improvements helped to increase the reliability of 
recoveries and the overall efficiency of the system. 
 
 
Figure 3.32: DiCAST prototype system for cell retrieval. (A) Drawing of the setup with 
laser and dual high precision XY stages for array alignment. (B) The laser nozzle with 
nitrogen supply is placed close to the array for cell removal. Contents are collected in a 384 
well plate housed below the array.  
 
The prototype system was fully optimised to allow the removal of the contents of an isolated 
targeted capillary, as shown in Figure 3.33. The system is controlled by LabVIEW based 
software, custom written and implemented by electronic engineer Brian Manning. The 
software is further discussed in section 3.3.6.  
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Figure 3.33: Demonstration of single capillary removal. (A) Using the high powered laser, 
a ~30 µm hole was ablated in scotch tape (55 micron in thickness) which has been placed 
over a 40 micron array containing E. coli cells. The scotch tape seals the array and prevents 
removal of cells by air pressure. (B) Image of the array once the scotch tape has been 
removed. The dark capillaries represent those containing E. coli cells while the lighter 
capillary represents the one from which the contents were retrieved due to the laser ablation 
of the scotch tape. Scale bar is 25 µm.  
 
The viability of cells after incubation on and retrieval from the array has also been 
confirmed, as described in section 2.3.16. This was ascertained by removal of cells from the 
array, using the retrieval prototype, and their subsequent incubation overnight 
(37°C/200rpm). 
 
Figure 3.34: Bacterial growth recorded following removal from the microcapillary array. 
Following 18 hours incubation, cells were blown out of the array and captured in a 
microtitre plate beneath. The plate was then incubated at 37°C/200rpm overnight and read, 
using a spectrophotometer to determine cell density, on the following day. Blank is medium 
only. 
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Cell growth was recorded by spectrophotometer (OD 600nm) for twelve separate retrievals, on 
the following day, and is displayed in Figure 3.34. In addition to observing growth post-
removal from the array, the cells present were also enumerated to ascertain the portion of the 
capillary contents which are captured. In order to determine this, a solution of bacteria (9 x 
10
8
 cfu/mL) was added to the array and the contents of an individual capillary recovered into 
six different wells of a microtitre plate, containing 85 µL medium. Three were plated out 
immediately and three were allowed to grow overnight at 37°C/200rpm. A pipetted control, 
1.2 µL into 85 µL medium was also enumerated. Each capillary has a volume of 1.2 nL so 
the control would represent 1000-fold greater cell count.  
Table 3.2: Enumeration of bacteria following removal from the microcapillary array. 
Each of the cell counts represents an average of three different retrievals.   
Condition Cell count-0 hours Cell count-18 hours 
Stock 9 x 10
8
 cfu/mL N/A 
Removal (single capillary) 1 x 10
2
 cfu/mL 4 x 10
8
 cfu/mL 
Pipetted control (1000X) 1 x 10
7
 cfu/mL 5 x 10
8
 cfu/mL 
 
If the entire contents of the capillary had been retrieved then one would expect in the region 
of 1 x 10
3
 cfu/mL, allowing for the dilution factor of retrieving 1.2 nL into 85 µL of medium. 
The pipetted control performed as expected with the dilution factor imposed by retrieval 
(approximately 1 in 70) reflected in the overall numbers. The results, shown in Table 3.2, 
indicate that approximately one tenth of the total volume of the targeted capillary is retrieved 
and that following an eighteen hour incubation, the number of cells has reached saturation. 
From the results obtained it has been determined that the cells can grow, express a protein of 
interest and be retrieved from the array in a viable state. While some of the culture is lost on 
removal from the array, allowing the retrieval to grow overnight allows a stock to be 
obtained for further use.  
3.3.4 Development of a system for alignment of the array to the scanned image. 
In order for the software to accurately locate a capillary corresponding to a fluorescent spot 
on the assay image, there would need to be reference points present in each (i.e. the physical 
array and the image). A method to relate the position of a positive signal on the assay image 
to the corresponding capillary in the physical array was therefore devised. This was carried 
out by introducing a unique mark into the array and carrying out a control assay in this area 
to generate a pattern on the scanned assay image, as described in section 2.3.17. The unique 
mark was introduced using SU-8 photoresist polymer, by biomedical engineer Brian 
105 
 
O’Reilly. SU-8 is a viscous polymer, typically used in photolithography for the manufacture 
of microstructures. It remains in liquid form until exposed to light of a designated 
wavelength (i.e. UV at 365 nm) and subsequent curing. The SU-8 was added to the array in a 
defined pattern and the cross-linking and baking applied so that a permanent blockage of 
certain capillaries was achieved. By performing a control assay in this area, blocked 
capillaries would hopefully appear as dark areas (i.e. where the fluorescent protein could not 
pass through) and the surrounding area would consist of the regularly observed pattern.  
The scanned images obtained were compared with the patterns in the array to determine if 
the pattern can be used to accurately pinpoint the exact location of a selected capillary in the 
physical array. Images obtained show excellent correlation between the mark in the array 
and the corresponding fluorescent pattern, as demonstrated in Figure 3.35. 
.  
 
Figure 3.35: Strategy for alignment of physical array to the assay image obtained. (A) A 
unique mark was introduced into the array by sealing capillaries in a specific pattern with 
SU-8 polymer. (B) A pattern was then carried out by passing 2.5 µg/mL Cy5-labelled anti-
human IgG through the array in the area of the blocked capillaries and subsequently 
observing the image obtained. Scale bar is 100 µm.  
 
Based on these images it was shown that the alignment marks, introduced by blocking 
capillaries in a distinct pattern in discreet areas of the array, can be successfully used to 
assign unique coordinates to the spots of interest on the scanned image. 
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3.3.5 Dual assay for alignment 
In order for the full process to work, it is necessary to correctly identify the exact location of 
the capillary on the microcapillary array which relates back to the fluorescent spot on the 
image obtained after scanning. In order to make this possible an alignment system was 
devised. As shown in section 3.3.4, it involves the introduction of a physical feature (i.e. 
blocked capillaries in a highly defined pattern) in the microcapillary array which will also be 
present on the scanned image by implementation of a control fluorescent assay. The aim of 
this section is to ascertain whether it is possible to dual coat the surface with the reagents for 
the alignment assay along with the reagents for the screening assay without any negative 
effect on either assay’s performance, as described in section 2.3.18. 
 
Figure 3.36: Comparison of performance for single and dual coating systems on PDMS 
assay surfaces. The image demonstrates a dual coating system (A and B) in direct 
comparison with a single/separate coating system (C and D). The assay for alignment 
(corners) is a control anti-human IgG assay and the assay for screening (centre) is 
expressed anti-CRP scFv F8 detected by a fluorescently labelled HA-tag antibody.  
Both assay formats, compared in Figure 3.36, performed well in terms of the alignment and 
screening assays. While the single coating surface seems to have a clearer definition of the 
fluorescent spots the pattern obtained on the dual coated surface is acceptable for analysis by 
(C) 
(D) (B) 
(A) 
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the recognition software developed in-house by Brian Manning. There is a lower fluorescent 
signal seen on the screening assay. This is probably as a result of a lower level of CRP 
antigen being immobilised to the PDMS surface when in competition with the hIgG from the 
alignment assay. This can be overcome by altering the ratio of screening and alignment 
reagents in the coating solution. 
By directly comparing the single and dual coating system it can be concluded that the 
performance is not negatively affected by the more desirable dual coating approach.  Overall 
the use of a dual assay will make the process more streamlined by removing the need for a 
segregated surface and step-wise coating. In addition, the throughput for the final screens 
will be greatly improved as a greater area of the coated surface will be available for 
screening.  
3.3.6 Design and implementation of process control software. 
Dedicated LabVIEW software has been designed and developed by Brian Manning that 
allows for image analysis, alignment of the assay image to the physical array and instrument 
control. Additional functionality allows for  the  automated selection  of  lead  clones  
depending  on  user  selection  criteria such as signal intensity and dual signal data 
(positive/negative etc.). Multi-dye filters are incorporated allowing the user to design custom 
screening applications on the platform. The software has been tested thoroughly to ensure 
that the targeting and retrieval of capillaries is highly accurate and reproducible, as 
demonstrated in Figure 3.37 which shows the targeting efficiency of the software controlled 
prototype through 800 iterations.  
 
Figure 3.37: Demonstration of the accuracy of the DiCAST data analysis and recovery 
system. A total of 800 targets were analysed by the software, coordinates calculated and 
specific regions targeted with the recovery system. The average deviation from the centre 
was 3.6 µm and maximum deviation was only 8.6 µm from the centre. 
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3.3.7 Summary for key challenge 3.3 
This key challenge was concerned with the development of a means to allow for accurate 
retrieval of the contents of a desired capillary following screening. In order to achieve this, 
the dedicated team manufactured a retrieval prototype and designed several software 
applications which could both control the prototype and analyse the image to locate the 
capillary of interest. Furthermore the introduction of distinct patterns in the physical array 
was carried out with a view to providing a means by which each image obtained could be 
related to the microcapillary array. Without such a means of alignment, it would be 
impossible to identify and retrieve the contents of capillaries of interest (i.e. those containing 
a cell expressing an antibody with the desired characteristics). By relating the two patterns to 
each other, a mapping of the entire assay surface is possible and each capillary can be 
located accurately on the physical array and its contents removed for future use.   
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Conclusion and Significance: 
In this chapter the development of a single cell screening technology, now deemed the Direct 
Clone Analysis and Selection Technology (DiCAST), was brought from concept through to 
practice.  
DiCAST provides a miniaturised, ultra-high throughput method to screen millions of single 
cells in parallel without the need for enrichment, or without introducing bias towards fast 
growing or high expressing clones, typically seen in many traditional approaches. The 
technology is a novel approach for the identification of antigen-specific mAbs from millions 
of individual bacterial and mammalian cells using densely packed microcapillary arrays. By 
utilising dual detection surfaces, antigen-specific mAbs to multiple targets can be obtained in 
one single experiment. DiCAST incorporates the spatial addressing of single cells in 
individual microcapillaries with multiplex testing and automated data analysis and recovery 
in one system (Figure 3.38).  
The process involves analysing the supernatant from ASCs captured and cultured in 
microcapillaries ranging in volume from 80 pL to 1.2 nL per individual capillary. The 
capillaries are sealed at one or both ends with an antigen-coated and blocked surface that 
essentially forms a miniature removable assay surface for each capillary. Once removed the 
surfaces are washed and specific antibody, if present, is detected with fluorescently-labelled 
secondary antibody. Scanning the assay surface using a standard microarray scanner 
provides an image map of fluorescent spots corresponding to a positive assay signal. The 
image pixel coordinates are then interrogated to provide the location of the capillary 
containing the single cell producing the antibody to the target of interest. Using custom 
written software (coded by Brian Manning) for image analysis, alignment and instrument 
control, individual cells are recovered into 384 well microtitre plates using a high precision 
alignment setup. During this process, the densely packed capillary arrays containing the cells 
are sealed and loaded into the recovery instrument. The single capillary of interest is 
automatically located using the software and the contents of the capillary recovered by 
ablating a hole in the sealant to allow a flow of nitrogen to simply blow the contents in to a 
well of a 384 well plate positioned 1mm below the capillary array. Since all the coordinates 
are automatically calculated by the software, including full instrument control, one cell can 
be recovered every 3 seconds. 
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Figure 3.38: Schematic of DiCAST process. During the DiCAST process, single cells are 
captured in densely packed microcapillary arrays (A) and sealed reversibly to pre-coated 
assay surfaces to detect antibodies of interest. Cells which produce an antigen-specific 
antibody will be represented on the assay surface as a fluorescent spot when imaged, which 
can then be related back to the exact capillary containing the desired cell (B). A high 
resolution image of a fluorescent assay is generated and subjected to image analysis and 
processing (C). The coordinates for each spot on the image can then be used to find the 
corresponding capillary location on the physical array when loaded into the DiCAST 
instrument. Instrument control, image analysis, coordinate mapping and data processing are 
all controlled within the same user interface. Retrieval can be carried out with the custom 
recovery instrument to micron scale precision. 
 
In essence, the DiCAST process involves the integration of three key stages, Assay, Scan 
and Align/Recovery, as shown in Figure 3.38. In addition to complex integration challenges 
such as software and mechanical design, each individual process step presented important 
developmental hurdles that needed to be addressed before the technology could be employed 
for its final purpose.  
The primary portion of the chapter was concerned with the ability to incubate, grow and 
express a target protein from bacterial cells contained within the capillaries of the array. In 
addition because of the proposed embodiment for the DiCAST assays there was a 
requirement that the cells would remain viable throughout the incubation and removal 
processes. The employment of an auto-induction system was investigated as it would, if 
successful and comparable to traditional methods, allow for efficient expression and remove 
the need for addition of a secondary component to the array. The two auto-induction media 
formulations tested not only compared with but outperformed the standard IPTG induction 
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method usually employed within the laboratory (Figure 3.4 and Figure 3.5). Bacterial cells 
were visualised growing and expressing protein (GFP) in the capillaries of the arrays (Figure 
3.6) and viability of the cells, subsequent to retrieval from the array, was also confirmed 
(Figure 3.7).  Another area of interest in this section was the ability to dilute cells to allow 
for single cell analysis. This was carried out by analysing dilutions of GFP expressing E. coli 
in the capillaries of the array. It was evident from this analysis (Figure 3.8) that it is possible 
to dilute the cells to allow for single cell occupancy, based on a Poisson distribution. To 
accurately know the number of cells per capillary in a particular screen, the cells in the 
culture loaded onto the array would need to be enumerated and the culture diluted 
accordingly. More than one cell can be loaded into each capillary but on retrieval, additional 
processing steps would be required to ensure monoclonality of the cells.  
Following on from these investigations, the ability to carry out an immunoassay on the 
proposed assay surface (PDMS) was investigated. When it came to carrying out more 
complex assays that required extended incubation with culture, washing steps or multiple 
secondary assay steps the surface was not stable and could not be used. In light of this a 
campaign was undertaken to identify a suitable and reliable chemical modification strategy 
for the PDMS to allow assays on the surface. Testing of each modification was carried out to 
assess its potential, under conditions such as effect on sealing and performance with purified 
antibodies and expressed antibodies (Table 3.1). From the numerous strategies tested the 
APTES modification performed the best overall, as shown in Figure 3.11, and was selected 
for use going forward. Following this modification it was possible to obtain similar results, 
when directly comparing a modified PDMS surface and a microtitre plate, using purified 
antibodies in a sandwich format (Figure 3.12).  
Once the technology had been brought to a stage where an expressing assay could be carried 
out on the PDMS surface (Figure 3.15), a number of different assay formats were developed 
to improve the diversity within the DiCAST offering.  
Initially, the ability to carry out a multi-analyte assay was investigated. This approach 
involved the verification of two different criteria. The first was the ability to capture 
antibodies on the surface through an epitope tag (in this case the HA tag) using an antibody 
coated on the surface. The presence of specific antibody was then detected using 
fluorescently-labelled antigen. This essentially turns the assay, previously described, upside-
down and potentially means that responses to several antigens can be gathered 
simultaneously. The capture approach was shown to be possible (Figure 3.17) and the second 
requirement for multi-analyte, multiple fluorophore reading, was carried out. The Perkin 
Elmer microarray scanner has lasers for Cy3 and Cy5 detection installed. The excitation and 
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emission of these two fluorophores are well separated and although cross-talk was not 
expected its absence was confirmed by analysis on plate (Figure 3.18) and on array (Figure 
3.19). As final proof-of-concept for this approach an assay using an anti-CRP scFv was 
carried out, using the capture approach, and probed with CRP labelled with Cy 3 and Cy5 
(either singly or mixed) to observe response. The result (Figure 3.20) showed that it was 
possible to probe, and differentiate responses, with a mixture of alternately labelled antigens 
on the same assay surface.  
Following the development of the multi-analyte approach, two additional multiplexing 
approaches were tested. The first of these was the employment of a double-sided assay, 
which utilised the two open surfaces of the microcapillary array to carry out two different 
assays, on the same population of cells, simultaneously (Figure 3.22). The second involved 
the demonstration of a multi-lift approach, which allowed several assays to be carried out by 
sealing the array to multiple prepared surfaces sequentially (Figure 3.24). These additional 
multiplex approaches could be used as an alternative to the multi-analyte approach which is 
reliant on a common capture element. They could also be used in combination with the 
multi-analyte approach and each other to increase the number of “questions” asked of each 
antibody screened in the same iteration.  
The final assay format that was studied in this chapter was the possibility of applying a 
secondary solution to the top of the sealed array, and observing diffusion through the 
contents of the capillary. The benefit of this approach would allow for more complex assay 
systems, such as functional bio-assays which require addition of reagents after accumulation 
of antibody, to be performed on the array. The diffusion of a fluorescent-labelled antibody, 
through buffer loaded into the capillaries, was observed and shown to give excellent 
coverage over the area to which it was added (Figure 3.26).  
In addition to developing a stable surface approach, as described previously, several methods 
to analyse interaction in the actual capillaries were assessed. These methods, if successful, 
would offer the ability to carry out the assays on the array without the need for an external 
assay surface. This would remove the need to align the image to the physical array and 
would perhaps streamline and save time in the overall process. Both the FRET (Figure 3.27) 
and GFP reassembly (Figure 3.29 and Figure 3.30) approaches trialled proved to be 
amenable to use on the array, but it was thought that the low signals generated in both 
systems may affect assay sensitivity. This could likely be overcome by further optimisation 
of the assay and documentation systems employed.  
In the final section of this chapter the issue of retrieval was investigated. If the cell of interest 
cannot be accurately retrieved from the capillary in which it is housed, then the entire 
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DiCAST screening process becomes futile. The development of a system to reliably and 
accurately retrieve the contents of a desired capillary was undertaken by the DiCAST team, 
consisting of biologists and mechanical and electronic engineers. A custom built retrieval 
instrument (Figure 3.32) was designed and produced along with several software packages 
responsible for instrument control, image analysis and alignment of the assay image to the 
physical array. 
In terms of assay development within this area a method to relate the assay image to the 
physical array was devised. It involved the performance of an alignment assay in areas where 
distinct marks had been introduced into the array by blocking certain capillaries in a specific 
pattern (Figure 3.35). In this way the exact location of certain capillaries (those in the 
blocked pattern) was known, and could be extrapolated to identify the location of capillaries 
which contain antibodies of interest. It also involved carrying out an assay with dual coating, 
to allow for the alignment assay described above to be carried out in combination with the 
screening assay. If dual coating of the surface was not possible it would mean that sequential 
coating of different solutions in discrete areas of the assay surfaces would be required. This 
would make the entire process more complicated and most likely reduce the surface 
available for screening, neither of which would be ideal. Fortunately the dual coating process 
proved successful and when compared with single coating performed well, as shown in 
Figure 3.36.  
In all, this chapter has served to verify conditions and to develop and optimise procedures 
that allow the DiCAST technology to meet its full potential. The fully optimised technology 
will be employed and compared with traditional screening approaches in several campaigns, 
both bacterial and mammalian, in subsequent thesis Chapters 4 and 5, respectively. A 
detailed comparison of DiCAST and its advantages over existing technologies is provided in 
Chapter 7.  
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Chapter 4 
Phage-independent selection of lead antibody fragment 
candidates from bacterial antibody libraries using 
DiCAST 
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Hypothesis 
Presently, the major problem facing the antibody discovery space is not the ability to 
generate vast repertoires of antibodies but the capacity to test their potential and identify 
those with the unique characteristics required. Recent innovations in automation and 
miniaturisation of this process have resulted in the emergence of elegant techniques such as 
microengraving of miniature wells (Love et al., 2006; Ogunniyi et al., 2009; Sendra et al., 
2013), homogeneous cell spot assays (Jin et al., 2009) and microfluidic cell sorting (El Debs 
et al., 2012; Ryan et al., 2011; Wheeler et al., 2003). This chapter demonstrates the 
advantages of DiCAST for direct clone analysis and also provides a comparison between the 
newly developed DiCAST technology and the gold standard screening approach of phage 
display.  
Rationale   
Despite being the gold standard technology for screening bacterial antibody libraries for the 
last 30 years, phage display is not without limitations. Typically screening by phage display 
involves several rounds of bio-panning, as illustrated in Figure 4.1, gradually enriching the 
pool with high-affinity candidates.  It is a laborious technique, when compared with the 
DiCAST screening process, and commonly identifies high numbers of false positives, that 
can be attributed to non-specific binding of phage to reagents or consumables (e.g. 
polystyrene) and their subsequent propagation throughout each iteration (Hoen et al., 2012).  
The frequency of non-binders can often be reduced by employing multiple rounds of 
selection; unfortunately, this strategy can also result in the loss of rare or desirable clones 
(Buckler et al., 2008).  
Other complications that can occur when using phage display include poor or non-existent 
soluble expression subsequent to selection. This is often attributed to the presence of what 
are deemed “truncated” clones, with frame shifts or internal amber stop codons,  which fail 
to bind to the antigen following initial selection (Goldman et al., 2000; Shinohara & Fukuda, 
2002). In addition the reliance of display-based screening on competitive selection based on 
target affinity can result in the oversight of protein molecules with properties that are often 
incompatible with high affinity, such as agonists, partial agonists and antagonists, and 
modulators of target function (Mao et al., 2010).  
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Figure 4.1: Antibody Discovery Process using phage display. (A) A library of variant DNA 
sequences encoding antibody fragments are cloned and displayed on the surface of phage 
particles as fusions to the phage coat protein. (B) Bio-panning involves exposure of the 
phage library to the antigen of interest. Non-binding phage are washed away and the bound 
phage are eluted and infected into bacterial cells, allowing enrichment within the population 
of variants which bind the target antigen. Several rounds of bio-panning are typically 
carried out. (C) Following bio-panning monoclonal soluble ELISAs are carried out to test 
binding of variants from the output of the final round. (D) Those clones which exhibit 
binding, or a smaller subset depending on facility capacity, are taken forward for further 
characterisation studies that are relevant to the antibody fragments’ final use (e.g. 
specificity, affinity, functional effect).  
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As discussed in Chapter 3, DiCAST is a new spatial addressing technique (each cell is 
physically separated from each other in a microcapillary array) that allows the simultaneous 
analysis and selection of millions of individual cells in parallel. DiCAST can be used to 
identify ASCs from both bacterial and mammalian cells, reducing the time and resources 
required with current methods. As the cells are spatially addressed in individual 
microcapillary chambers, any bias or competition due to growth and expression levels is 
eliminated, preserving slow-growing or rare clones. Using DiCAST, heterogeneous 
populations of cells can be analysed to determine which cells are producing antibodies of 
interest. Once identified, the cells harbouring the desired antibody can be recovered from the 
array for further characterisation and use.  
When compared to phage display, DiCAST not only saves on time and costs but also 
circumvents the drawbacks of display systems by removing the competitive element from 
the selection as well screening fragments in soluble form (i.e. not on the surface of phage), 
enabling the discovery of novel and fit-for-purpose antibodies It also allows for multiple 
tests to be carried out, on the entire population of variants, simultaneously (Figure 4.2).  
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Figure 4.2: Antibody Discovery Process using DiCAST. (A) A library of variant DNA 
sequences encoding antibody fragments are cloned and expressed in soluble form in 
bacterial cells. (B)The library is diluted to achieve the equivalent of 1 cell per capillary and 
analysed using DiCAST. By utilising the multiplexing capabilities of the technology, 
discussed in Chapter 3, it is possible to carry out multiple, diverse tests on the entire library 
of variants simultaneously.  
In this chapter a series of bacterial screening campaigns utilising DiCAST, which was fully 
developed at DCU and the development of which is described in detail in Chapter 3, are 
discussed (Figure 4.3) 
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Figure 4.3: Schematic overview of thesis layout. Chapter 4 is concerned with 
demonstration of phage-independent selection of lead antibody fragment candidates from 
bacterial antibody libraries using DiCAST. 
To demonstrate the utility of the DiCAST system, over 1 million bacterial cells from an 
immune avian scFv library were directly analysed, in one experiment on a single cell basis, 
without enrichment by phage display. In addition to the standard screen multiplexing, 
experiments were carried out with the same immune library to illustrate the enhanced 
capabilities of the screening approach. To emphasise DiCAST’s utility further, antigen-
specific antibodies were also selected from a commercial naïve human single domain 
antibody library. Additionally a commercial evaluation of the technology was commissioned 
by a UK company, where a previously mined external library was screened using DiCAST 
and outputs returned and characterised in a blind test.  
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Key Challenges 
Key Challenge 4.1 C-Reactive Protein (CRP) in-house produced library- complete screen 
and comparison with phage display. 
4.1.1 Experimental approach 
CRP is a sensitive marker of inflammation and has been investigated as a prognostic marker 
for myocardial infarction (Ridker et al.,1998). Here the ability to select antibody fragments 
from a bacterial library without the need for traditional approaches of phage display and bio-
panning, illustrated in Figure 4.1, is demonstrated. 
4.1.2 Selection of scFv antibodies from E. coli without enrichment 
An immune avian scFv library, previously produced and screened against C-reactive protein 
(CRP) in the Biomedical Diagnostics Institute in DCU, was analysed for antigen-specific 
antibodies using the DiCAST platform. This library was previously well characterised by 
Biacore and generated a number of excellent lead antibodies making it a very good library to 
evaluate the potential of DiCAST. In fact, two of the best clones obtained from the library 
were licensed to two companies, one in the UK (Integrated Magnetics) and one in Portugal 
(BioSurfit), highlighting the quality of the library and the challenge was to see if selection 
could be pushed further with DiCAST.  
A total of 1.2 million clones from the original un-panned library were screened, for antigen 
(CRP) binding, on a single cell basis in a microcapillary array as described in 2.4.1. A 
selection (288 of 1631) of positive clones (Figure 4.4) were retrieved and confirmed as 
binding specifically to the antigen, as described in section 2.4.2 and shown in Figure 4.5. In 
total 98% of those retrieved were positive by subsequent ELISA analysis. A sub-set of those 
were then sequenced and unique sequences further investigated by ELISA, as described in 
section 4.1.3.  
 
121 
 
 
Figure 4.4: Selection of antigen-specific recombinant antibodies. An immune avian scFv 
library was screened to identify antibody fragments of defined specificity. (A) Scatter plot 
representing the precise location of the 1631 CRP-specific clones identified. (B) Enhanced 
portion from the scatter plot showing a particular set of spots each of which corresponds to 
a capillary containing an antigen-specific (CRP) clone. (C) Area of scanned image, 
corresponding to the highlighted portion of the scatterplot shown in Figure 4.4B, mirroring 
the exact pattern observed in Figure 4.4A and B.  
 
Figure 4.5: Confirmatory binding ELISA (CRP) of 288 clones selected and retrieved from 
analysis of avian anti-CRP scFv library on DiCAST. The 288 clones were randomly 
selected from the 1631 positives observed on the entire scan, and assayed using the direct 
on-plate methods described in section 2.4.2.  A total of 98% (283 out of 288) clones were 
positive binders subsequent to retrieval. The sample designated “B” represents a negative 
control consisting of medium only in place of expressed culture.  
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4.1.3 Characterisation of clones selected from the library using DiCAST.  
Following confirmation of binding to the antigen, as shown in Figure 4.5, a randomly 
selected sub-set (96) were sequenced, analysed and compared for assay sensitivity in 
competitive ELISA as detailed in section 2.4.4.  Sequencing of the clones allowed for the 
diversity of those clones retrieved to be assessed. In all there were 27 unique sequences 
identified following sequencing of 96 individual clones, shown in Figure 4.6 and Table 4.1. 
 
Figure 4.6: Sequence data for a selection of clones retrieved from the CRP library screen. 
A subset of the positive clones identified in Figure 4.4 and confirmed in Figure 4.5 were 
randomly selected (90/288) for sequencing analysis. In total 27 unique sequences were 
observed. Sanger sequencing was carried out by Source Bioscience. Sequences were 
translated to amino acids using the ExPASy translate tool (http://web.expasy.org/translate/) 
and aligned for similarities using multiple sequence alignment tool MultAlin 
(http://multalin.toulouse.inra.fr/multalin)(Corpet, 1988).  
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There was one predominant sequence, which had accounted for 45 of the clones as well as 
21 unique sequences among those sent for sequencing. The top four, highest affinity clones 
(F6, F8, H2 and G5) previously screened and selected using phage display and Biacore 4000, 
described in Leonard et al. (2007), are also represented within the groups (Table 4.1).  
Table 4.1: Sequencing diversity observed from 96 randomly selected clones from the 
anti-CRP library screen.  
Group Number of Clones 
Group 1 45 
Group 2 (incl. H2) 8 
Group 3 (incl. F6) 4 
Group 4  3 
Group 5 (incl. F8) 8 
Group 6 (incl. G5) 7 
Unique 21 
 
Each of the unique clones (27 in total) were then titered, as described in section 2.4.3,  to 
identify an appropriate dilution for competitive analysis (detailed in section 2.4.4). Assays 
were carried out for all clones and the data fitted with a 4-parameter equation using 
BIAevaluation software. Based on competitive ELISA analysis (Fig. 4.5) of the selected 
clones a range of antibody fragments were identified, the best of which (clone A6)  showed a 
55-fold improvement in IC50 value when compared to the best (i.e. in terms of affinity 
ranking results) perfoming clone selected previously using phage display (clone H2) 
(Leonard et al., 2007).  
 
Figure 4.7: Competitive ELISA analysis of a selection of CRP clones selected using 
DiCAST versus H2; the highest affinity clone obtained previously using phage display. 
Based on inhibitory concentrations of 50% (IC50) values, clone-A6 selected by DiCAST 
shows a 55-fold improvement over H2. IC50 values were calculated based on 4 parameter 
logistics equation, used to fit the data, and were determined to be H2-0.55 µg/mL, E6-0.23 
µg/mL, D8-0.03 µg/mL and A6-0.01 µg/mL.  
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4.1.4 Multiplexed analysis and selection of antigen-specific scFv.  
The ability to ‘multiplex’ offers huge advantages in the antibody screening process, as it both   
enables one to obtain more information in the same amount of time but to select antibodies 
which do not, or indeed do, cross-react with a particular antigen.  In terms of closely related 
targets this can be invaluable when introduced at the early screening stage.  
Multiplex analysis was performed on an immune avian scFv library, previously produced 
from chickens immunized with C-reactive protein (CRP) and Myeloperoxidase (MPO), on 
the DiCAST platform. MPO, like CRP, is a biomarker for use in the detection of 
cardiovascular disease (Zhang et al., 2001). By use of a capture format, antibodies from 3 
million antibody-secreting cells were analysed and then probed with multiple, alternately 
labelled antigens simultaneously. In this way three populations of antibodies could be 
identified. The first solely bound CRP while the second bound only to MPO. The third 
population were cross-reactive and bound both antigens. This was visualised as a ‘traffic-
light-like’ system, as shown in Figure 4.8, with each population identified by colour: CRP-
specific (Red/Cy5), MPO-specific (Green/Cy3) and cross-reactive (Yellow).  
 
Figure 4.8: Multiplexed analysis and selection of antigen-specific scFv. These include the 
performance of multi-analyte detection on the same surface using alternately labelled 
antigens. The surface was coated with a capture element (in this case an anti-HA antibody), 
all antibodies expressed in the microcapillaries were captured and secondary detection was 
carried out using two antigens with different fluorescent labels (Cy5-labelled CRP and Cy3-
labelled MPO). The number of antigen-fluorophore combinations employed is dependent on 
the scanner used. Analysis of the multi-analyte surface allowed identification of three 
different sets of antibodies: Those which bound CRP, those which bound MPO and those 
which cross-reacted with both proteins. In “Spot-viewer” mode, those spots which appeared 
green (Cy3) in the composite image represent an MPO-specific antibody and those which 
appeared red (Cy5) are specific to CRP, while those which appeared yellow in the composite 
view are capable of binding to both proteins.  
MPO             CRP       Both
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A sub-set of each population was retrieved using the DiCAST recovery system and further 
characterised by ELISA to confirm binding and specificity (Figure 4.9). Those clones which 
were labelled cross-reactive were streaked out and single colonies tested in on-plate ELISAs 
to ensure that the dual specificity was not a result of two different cells present in the 
capillary during the screen.  
 
Figure 4.9: Direct binding ELISA for a representative clone from each of the three sets of 
antibodies evident in the screen. Each clone was screened against both antigens. Clone N2-
E2 binds MPO only, clone F12-F3 binds CRP only and clone N2-E1 binds both MPO and 
CRP.  
Furthermore, the nature of the microcapillary array used in the DiCAST process very easily 
lends itself to the implementation of a ‘double-sided’ analysis. In this approach both sides of 
the array are sealed to an assay surface (Figure 4.10). Using the double sided approach it is 
possible to ask two distinct questions of a particular candidate. It offers an advantage over 
the ‘multiplex’ format in the fact that a common capture element is not required. In this way 
a large amount of information can be obtained for each antibody screened. For example, a 
library could be screened for both binding to a particular target and also for functional effect 
at the same time. The double-sided element of the microcapillary arrays used in the DiCAST 
screening process gives the technology a unique advantage over many other high-throughput 
screening approaches.  
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Figure 4.10: Double-sided assay using DiCAST. This can be used to carry out two separate 
assays on the same population of cells simultaneously. Two surfaces are coated with 
different antigens (MPO and CRP) and the array is sealed to each sequentially. Subsequent 
to incubation two distinct assays are performed and binders to each of the antigens 
identified and recovered. (A) A section of a scan for each antigen targeted in the screening 
process. The specific spots (40µm diameter), clearly visible, correspond to a capillary which 
contains a cell secreting an antigen –specific antibody in the physical array. Scale bar is 
100µm. (B) Competitive ELISA analysis of a typical clone from each antigen set selected.  
4.1.5 Summary for key challenge 4.1 
After a thorough interrogation of this recombinant library, in various embodiments (single 
antigen and multiplex), the advantages and performance quality of the DiCAST technology 
were evident. In a direct comparison with phage display, antibodies with enhanced 
sensitivity were identified by using DiCAST. In addition the ability to perform multiplex 
assays offers the opportunity to screen for several different traits of each antibody (e.g. cross 
reactivity) in one single experiment and gives the user access to a more powerful screening 
approach. It can also offer the benefit of streamlining the antibody discovery process and 
interrogating a library for several different antigens in a single iteration. This not only saves 
time but also has inherent savings on costs associated.  
The goal of this section was to demonstrate a direct comparison with phage display using the 
CRP library as a model library and to identify unique clones that were missed by phage 
display. A large number of positives were identified within the library and a number of 
Anti-CRP scFv 
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clones with improved binding could be observed. If there was a need to identify a higher 
sensitivity antibody more of the library and hits could have been screened and characterised, 
as necessary. Planned future work includes the incorporation of a method to affinity rank the 
clones detected, similar to strategies employed by MorphoSys (Poetz et al., 2005) or  as 
discussed in Watkins et al. (1998).  This will allow for enhanced information to be obtained 
for each clone versus direct binding screening.  
Key Challenge 4.2 Screening of commercially available naïve domain antibody (dAb) 
library 
4.2.1 Experimental approach 
As clones can be biased towards the target in immune library analysis, to further challenge 
the DiCAST process a commercially available, naïve, human domain (dAb) library (Lee et 
al., 2007) was screened using a number of different antigens (Transferrin, cTnI, cTnT and 
intact Jurkat T lymphocytes).  Model antigens available in the lab were chosen to provide a 
panel of protein and cell targets for the screening campaign.  
Transferrin is a plasma protein involved in the metabolism of iron and, monitoring of serum 
levels can  be indicative of anaemia, iron-overload conditions and diabetes mellitus among 
other conditions (Craig et al., 2001)
,
(Mabayoje et al., 2010). Cardiac troponins (cTnI and 
cTnT) are well established, standard biomarkers for the detection of myocardial damage and 
for the assessment of suspected cases of acute coronary syndrome (Apple & Collinson, 
2012). The cell screening, using Jurkat T lymphocytes, was included as a demonstration of 
the flexibility of the DiCAST system to use whole cells as a potential antigen. This is a 
desirable trait of any screening system, allowing the identification of antibodies which bind 
cell receptors, in their native form, as they are presented on the cell surface.   
4.2.2 Verification of the screening system using positive controls. 
Prior to screening of the library, the proposed assay format was tested using the supplied 
positive control (anti-β galactosidase dAb). There is a cMYC tag present on the expressed 
fragments for detection, and a monoclonal anti-cMYC antibody was used as the capture 
reagent. The positive control was expressed in small scale culture, as described in section 
2.2.2, and the supernatant (S/N) and lysate fractions tested by ELISA. The clone was also 
tested using the on-plate method described in section 2.4.2 (Guo et al., 2010). Finally once 
the clone was confirmed to work in ELISA (Figure 4.11A), it was tested in an array assay 
and performed well (Figure 4.11B).  
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Figure 4.11: Verification of library positive controls through ELISA and using the 
DiCAST platform. Control anti-β galactosidase dAb is provided with the library when 
purchased. The assay format and performance, in both ELISA (A) and using DiCAST array 
assay (B), was assessed prior to library screening. Capillaries measure 40µm in diameter. 
Scale bar represents 100µm.  
4.2.3 Screening of the domain library against multiple targets.  
Following the verification of the assay system for analysis, using the positive control 
supplied as described in section 4.2.2 and demonstrated in Figure 4.13, the library was 
screened. Without any prior exposure to any of the antigens 3 million clones were analysed 
for each one, this time at 10 cells per capillary, allowing a greater portion of the library to be 
analysed in each experiment.  
While positive responses were seen for all of the antigens, as shown in Figure 4.12, the 
binding response post-retrieval for the cTnI and cTnT and Jurkat screens was very low. The 
transferrin screen produced the highest number of positives and despite only sampling a 
fraction (0.1%) of the initial library a  high number  of transferrin-specific fragments were 
identified through the screen.  
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Figure 4.12: Scanned images from multiple screens carried out on the naïve dAb library. 
The library was screened with various different antigens including Transferrin, cTnI, cTnT 
and also intact Jurkat T lymphocytes (Clone E6-1 ATCC TIB-152) which were labelled with 
Cy5-labelled anti-EpCAM to allow visualisation. Capillaries measure 40µm in diameter. 
Scale bar is 100µm.  
A selection of positives (48) were subsequently retrieved from the microcapillary array, 
streaked out to obtain single colonies and further confirmed as antigen-specific by ELISA 
analysis (Figure 4.13). All fragments recovered maintained a certain level of antigen 
specificity post-retrieval, but appeared to have a degree of non-specific interaction with the 
blocking buffer (BSA). Attempts to express the clones exhibiting a desired binding profile, 
in large-scale culture, were not successful and lysates produced failed to bind the antigen in 
subsequent ELISAs. When sequenced the clones produced very poor reads, despite 
originating from a single colony.  
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Figure 4.13: Confirmation of binding post-retrieval of anti- transferrin dAb fragments. 
This analysis was carried out using the on-plate expression method described in section 
2.4.2. All clones were streaked out twice and single colonies analysed against the antigen 
(Transferrin) and unrelated protein (BSA).   
4.2.4 Summary for key challenge 4.2 
Overall, while thought to be a very useful tool to assess the power of the DiCAST platform 
the quality of the commercial dAb library (i.e. predominance of poly-reactive clones and 
lack of evident expression post-retrieval) did not allow for extensive screening to be carried 
out. Previous reports on single domain fragments have indicated a propensity for poor 
solubility and low levels of expression in certain cases and this may have been a contributing 
factor in this analysis (Holt et al., 2003). Additionally, during personal communication with 
Daniel Christ (who was part of the team that generated the library) the poor quality of the 
library, due to inadequate storage conditions, was mentioned.  
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Key Challenge 4.3 Commercial evaluation of DiCAST (anti-homoserine lactone library 
from an independent UK based laboratory) 
4.3.1 Experimental approach 
In order to assess and verify the performance of the DiCAST technology, a 100% industry 
funded evaluation of an externally sourced recombinant library was undertaken by the 
DiCAST team in DCU. The library, directed against a mixture of homoserine lactone (HSL) 
compounds (3-oxo-C12-HSL, 3-OH-C12-HSL & N-acyl-C12-HSL), had previously been 
generated and  screened by phage display, as described in Palliyil et al. (2014).  Homoserine 
lactones are used by a number of bacteria (e.g. Pseudomonas aeruginosa), to initiate cell-to-
cell communication, as quorum sensing signalling compounds. Antibodies which block this 
communication could offer a possible method to control infection of certain bacteria (Palliyil 
et al., 2014). An ideal antibody would cross react with the three compounds mentioned 
above, as well as an additional compound C4-HSL which is thought to potentially provide 
additional therapeutic effect (Palliyil et al., 2014).  
To be considered successful the evaluation of this external library would need to culminate 
in the identification of antibodies which bound to each of the three HSL compounds of 
interest at same, or better, affinity as was achieved by the original laboratory. In addition, the 
ability to cross react with C4-HSL was considered a point of interest. The screening 
conjugates (3-oxo-C12-HSL-BSA, 3-OH-C12-HSL-BSA and N-acyl-C12-HSL-BSA), the 
library and the positive controls (HSL2 and HSL4) were supplied by the independent UK 
laboratory. Unconjugated compounds were purchased to allow for functional sensitivity of 
antibodies to be ascertained by competitive analysis.  
 
4.3.2 Control Verification (On-plate and array) 
The proposed assay format for this screening campaign was a capture approach, using either 
the HIS tag or the c-MYC tag available on the fragments. Unfortunately the approach did not 
function as expected and no signal was seen using a capture approach (Figure 4.14 B and C) 
when compared to the use of antigen coated on the surface (Figure 4.14A). It was also noted 
that a much higher concentration of the antigen was required to obtain a positive signal in 
both ELISA and on array (4 µg/mL and 16 µg/mL, respectively). This was most likely due to 
the fact that in the case of this antigen (HSL-BSA conjugate) the predominant protein 
contributing to concentration reading was the carrier, BSA.  
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Figure 4.14: Verification of assay format on array, using control scFv (HSL4), on array 
and on plate. Two different screening assays (i.e. immobilised antigen Vs capture approach) 
were tested for performance using the anti-HSL scFv control prior to commencing 
interrogation of the library. The immobilised antigen approach coats the antigen, in this 
case one of the HSL conjugates, on the surface and uses an anti-tag antibody (anti-cMYC or 
anti-HIS) for detection. The capture approach uses the reverse approach by coating the anti-
tag or capture antibody on the surface and detecting presence of a specific antibody with 
fluorescently labelled antigen. Both formats were tested on array (A) and in ELISA (B) and 
their performance compared. TG1 cells, which did not contain any plasmid, were used as a 
negative control to assess any level of non-specific binding. 
4.3.3 Library Screening 
On identification and optimisation of the assay format to be implemented, using the positive 
controls, screening of the library was begun. In all, over 2.5 million scFv fragments were 
screened on a single cell basis throughout the study. There was a low number of positives 
(typically ~ 1 in 100,000 clones analysed were positive), and screens were carried out against 
each of the three compounds (3-oxo-C12-HSL-BSA, 3-OH-C12-HSL-BSA & N-acyl-C12-
HSL-BSA) to identify binders (Figure 4.15A). Post-retrieval each selected clone was tested 
for binding to each of the compounds (and the carrier protein, BSA) to ascertain cross-
reactivity, as shown in Figure 4.15B.  
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Figure 4.15: Sample post-retrieval confirmatory ELISA for clones against all conjugates. 
(A) A selection of chosen positive hits from library screens carried out throughout the 
project. The horizontal and vertical yellow bar intersect at the spot where a candidate 
antibody was chosen  (B) Each of the retrieved scFv fragments was tested for binding 
against each of the HSL conjugates (3OXO, 3OH, NAC and negative control BSA) following 
removal from the microcapillary array. Their binding was confirmed using the on-plate 
method, described in section 2.4.2 (Guo et al., 2010). All clones were also tested against the 
carrier protein (BSA). This graph represents a subset of clones (10) retrieved during several 
experiments.  
4.3.4 Characterisation of final selected clones 
Upon extensive screening of the library and further cross-reactivity testing against each of 
the three HSL compounds and the carrier protein, a final selection of twelve clones were 
chosen for assessment by the team in the UK-based laboratory. Each of the clones was 
expressed in large-scale culture (section 2.2.3), purified by IMAC (section 2.2.4) and 
compared against the two positive controls by competitive ELISA (section 2.4.4).  
Owing to the large number of clones, only the final eluent was visualised by SDS-PAGE 
analysis as described in section 2.2.1 and shown in Figure 4.17. In order to assess the level of 
specific antibody in each of the purification fractions, an ELISA was carried out, as 
described in section 2.4.5, and shown in Figure 4.16. For the purpose of illustration, Figure 
4.16 compares two of the purification profiles obtained. The purifications were successful 
and the eluent fractions for each were pooled and used in further characterisation 
experiments.  
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Figure 4.16: Confirmation of presence of antigen-specific scFv in each fraction of the 
IMAC purification. A qualitative ELISA was performed to identify the fractions which 
contained the antibody of interest. For the purpose of illustration only two of the final clones 
were compared in terms of purification profile. The purification was successful with only 
small amounts of the antibody lost in flow-through and wash fractions. The first two elution 
fractions were pooled, buffer exchanged for use in Biacore and competitive ELISAs. The 
purity of the final eluent was also assessed using SDS-PAGE (Figure 4.17).  
 
Figure 4.17: SDS-PAGE analysis of elution fraction for the final candidate clones. Each 
of the HSL clones were purified by IMAC, as described in section 2.2.1, and the final eluent 
visualised on a SDS-PAGE gel. The first gel (Lanes 1-6) contains HSL 1-6 in a consecutive 
manner. The second gel (Lanes 7-12) contains HSL 7-12 in a consecutive manner. The lanes 
designated ‘M’ contain the protein marker (PageRuler plus pre-stained protein ladder, sizes 
for each of the bands are indicated to the left of the gel picture). The expected size is 
approximately 27 kDa for each scFv. 
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On observation of the final eluent for each of the scFvs, it can be observed that some of the 
fractions would require concentration of the purified fraction in order to be visible on the gel. 
In the case of others there is clearly evident bands of greater size than was expected (typical 
scFv is approximately 27 kDa). The larger bands could indicate dimer- or trimerisation of the 
purified scFvs. 
It is important to note, at this point, that the stability of the HSL conjugates used throughout 
this study was a cause for concern. While all of the final selected antibody fragments bound 
to all three compounds in initial confirmation ELISAs, there are cases where they do not 
appear to bind some of the compounds in further investigations. Nevertheless, the functional 
sensitivity of each of the final clones was tested against each of the compounds (non-
conjugated), as described in section 4.3.4, prior to shipment of samples. The resulting data is 
displayed in Figure 4.18. Each of the HSL conjugates was coated on the plates and 
competition for binding against the free unconjugated compound assessed. In all, the 
analysis using 3-oxo-C12-HSL, shown in Figure 4.18A, was the most complete data set with 
all clones represented. The analysis for the remaining two compounds (3-OH-C12-HSL & 
N-acyl-C12-HSL), shown in Figure 4.18B and 4.18C respectively, was not complete and 
could only offer information on a subset of the clones.  It appeared based on the 3-oxo-C12-
HSL that a clone selected using DiCAST (Clone 4) offered superior functional sensitivity 
over the previously designated “best” clone, selected by phage display in the original 
screening campaign (HSL4).  
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Figure 4.18: Competitive analysis of final HSL clones against the three screening 
compounds. The graph shows the performance of DiCAST selected clones against the two 
controls provided by an independent UK based laboratory (HSL 2 and HSL 4), for each of 
the three screening compounds (3-oxo-C12-HSL, 3-OH-C12-HSL and N-acyl-C12-HSL). 
Each assay involved competition between the bound conjugate and free un-conjugated 
compound in solution. Outcomes following phage display of this library, reported in Palliyil 
et al. (2014), HSL4 was described as the best antibody identified. From competitive analysis 
of the DiCAST selected clones it appears that clone 4 outperforms HSL4 in functional 
sensitivity. 
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The final clones were also tested for functionality against an additional HSL compound C4-
HSL, as cross reactivity against this compound was considered to be of interest in the initial 
investigations of the library. This particular compound was not supplied as a screening 
conjugate as part of the evaluation; however, the unconjugated compound was purchased and 
tested in competitive analysis, using N-acyl-C12-HSL as the coating conjugate. Several of 
the final clones were functional, with lower sensitivity than other compounds, against this 
additional compound and once again DiCAST selected clone 4 demonstrated superior 
performance when compared to the controls (Figure 4.19).  
 
Figure 4.19: Competitive analysis of final HSL clones against additional compound C4-
HSL. The graph shows the performance of DiCAST selected clones against the two controls 
provided by an independent UK based laboratory (HSL 2 and HSL 4). The assay involved 
competition between the bound N-acyl-C12-HSL conjugate and free un-conjugated C4-HSL 
compound in solution. Outcomes following phage display of this library, are reported in 
Palliyil et al. (2014), HSL4 was described as the best antibody identified. From competitive 
analysis of the DiCAST selected clones it appears that clone 4 outperforms HSL4 in 
functional sensitivity. 
 
Upon sequencing of the twelve clones (ten DiCAST selected and two controls) it was found 
that DiCAST clone 4 matched the sequence of control HSL4 exactly. In all there was one 
predominant group which accounted for 6 of the final clones, the match to HSL 4 (DiCAST 
clone 4) and the remaining DiCAST clones were unique in sequence. The control HSL2 was 
not represented in the final selection. Biacore analysis was also carried out on the antibodies 
but, once again, due to instability of the screening conjugates the results added very little to 
the profile for each antibody. Finally, all selected purified antibodies were randomly 
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numbered and shipped to the independent UK based laboratory for blind testing. Following 
their analysis they delivered a positive response, describing several of the DiCAST selected 
clones as superior in performance to those they had selected previously, shown in Table 
4.2.This demonstrates that the DiCAST technology performs desirably in comparison with 
traditional methods and can identify specific antibody fragments from recombinant libraries 
without the need for enrichment.  
Table 4.2 Comparison of IC50 values obtained for DiCAST selected clones versus those 
selected using phage display. All analysis was carried out in a blind test by the original, 
independent UK-based laboratory.  
Clone 3-oxo-C12-HSL  3-OH-C12-HSL N-acyl-C12-HSL 
DiCAST Clone 2 4 nM 0.8 µM 40 nM 
DiCAST Clone 4 2 nM 0.8 µM 20 nM 
DiCAST Clone 5 275 nM Not determined 90 nM 
HSL 2 (scAb format)  3 nM 1.8 µM 500 nM 
HSL 4 (scAb format) 1.5 nM 0.8 µM 600 nM 
 
4.3.5 Summary for key challenge 4.3 
The ultimate aim of the evaluation undertaken in this section was to screen the library, 
supplied from an independent laboratory, and find the same (or better) clones than those that 
were selected using phage display. This particular aim was fulfilled with the identification of 
the best antibody, previously described (HSL 4). As such, the evaluation of the DiCAST was 
deemed successful by the UK-based company which had undertaken it.  
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Conclusion and Significance 
In this study, three separate bacterial antibody fragment libraries from immune and naïve 
sources were screened. Furthermore, the libraries were derived from avian (CRP), human 
(Dab) and sheep (HSL) highlighting the flexibility of the DiCAST platform. In the first study 
approximately 1.2 million single bacterial cells from a previously characterised avian 
immune single chain variable fragment library (Leonard et al., 2007) were analysed without 
any enrichment by phage display. Despite only sampling ~3% of the total library diversity, 
thousands of positive signals were observed (Figure 4.4), of which 288 were automatically 
selected by image analysis software and recovered for further testing using the prototype cell 
removal system. Using extremely high precision XY stages to identify microcapillaries 
containing target cells, 98% of the recovered cells gave a signal of twice the background or 
higher by direct ELISA. A selection of the recovered clones were sequenced and those found 
to be unique were tested in a competitive immunoassay to determine their sensitivity to C-
reactive protein (Figure 4.7). The best clone (clone A6), selected using DiCAST, had a 55-
fold improvement in assay sensitivity when compared to the best clone (clone H2) 
previously selected by phage display. The ability to screen significantly more cells on a 
single cell basis increases the probability of recovering a rare clone with unique 
characteristics that may be lost due to low expression on phage, diversity loss by panning or 
simply by not screening enough clones post phage selection. Any of these possibilities could 
account for clone A6 being missed when previously selected by phage display. While with a 
very large library it might be necessary to enrich the library before screening, DiCAST 
would reduce the selection steps required and allow a much larger number of clones to be 
analysed.  
 
To further demonstrate the flexibility and utility of the DiCAST method in selecting antigen-
specific mAbs to multiple different target antigens is one experiment, 3 million bacterial 
clones from an avian immune library generated from chickens immunised with C-reactive 
protein and myeloperoxidase were analysed. In this assay format, expressed scFv antibody 
fragments were captured on the anti-HA tag monoclonal antibody coated surface via a fused 
HA tag which is encoded on the pComb3X phagemid used to clone the variable heavy and 
light chain genes. A mixture of alternately labelled antigens was then added to the captured 
scFv surface to identify antibody fragments that bound CRP only, MPO only or cross reacted 
with both CRP and MPO (Figures 4.8 and 4.9). While these results show the use of two 
different fluorescent labels, the ability to screen for additional analytes is entirely possible 
based on alternative wavelengths becoming available in the scanner used and the selection of 
appropriate differential labels. 
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In addition to using multiple labels, DiCAST has two analysis surfaces, as demonstrated in 
Figure 4.10, which can be removed and replaced with additional surfaces allowing the 
analysis for multiple screening criteria all in one experiment. Ultimately the screening of this 
library produced antibodies which exhibited enhanced performance over those selected using 
the gold standard method of phage display. It also demonstrated the ability to identify 
antibodies specific to very distinct antigens simultaneously.  
 
With a view to increasing productivity in screening campaigns the testing of a naïve 
commercial library was also undertaken. The ability to use a non-immune library which can 
be used in all screening campaigns is highly advantageous as it removes the need for 
immunisations and subsequent library building, for each new target (Siegel, 2002). While 
screening using DiCAST was determined to be feasible (Figure 4.11 and 4.12), unfortunately 
the quality of the selected clones was not as expected and meant that a full assessment was 
not possible.  
 
Finally, in this chapter, an evaluation of the technology was commissioned by a UK-based 
multinational company. Utilising DiCAST a recombinant scFv fragment library, generated 
and previously screened in an independent laboratory, was analysed and the resultant outputs 
sent for blind testing in the original laboratory. Screening was hampered by two key factors, 
the first being that the library was not amenable to a capture-based screening approach, 
demonstrated in Figure 4.14, and as such limited the ability to identify and rank binders for 
retrieval. Alternative antibodies, surfaces and tags could have been evaluated but due to the 
extremely tight project deadlines imposed by the industry partner, a direct binding format 
was utilised, albeit not optimal for affinity screening. Due to the low number of positive 
clones present in each screen, this did not impact greatly on the final outcome because all 
positive hits were retrieved and ranking was not required. The second issue that arose was 
the instability of the conjugates supplied. This led to a number of variable results when using 
the same antibodies on consecutive days and resulted in an incomplete set of data following 
characterisation.  
Overall, approximately 2.5 million individual antibody-secreting cells were investigated for 
their binding status on a single cell basis. All were assessed for the desirable cross-reactivity 
profile and a final ten clones were selected as representative clones for external testing. Each 
of these ten clones, was purified and characterised by ELISA and Biacore in Dublin before 
shipping to the UK. All work, from receipt of library to final shipment of purified clones, 
was completed in six weeks. Using the traditional approach, the original lab had undertaken 
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a six month screening campaign to identify their best binder (HSL 4) which was also 
identified using DiCAST.  
Based on the studies discussed in this chapter, it can be concluded that the DiCAST 
technology offers a very attractive alternative to the traditional approaches applied to the 
mining of recombinant libraries, namely phage display. Due to the fact that the cells are 
spatially addressed in individual microcapillary chambers any bias or competition due to 
growth and expression levels is eliminated, preserving slow-growing or rare clones. It also 
offers the ability to multiplex which adds functionality, saves time and cost of reagents and 
provides the possibility of carrying out several antibody discovery campaigns 
simultaneously.  
Recent investigations into the process of phage display suggest that a reduction in the 
number of rounds of bio-panning might be advantageous in retaining diversity and allowing 
identification of clones which would otherwise have been lost (Buckler et al., 2008). They 
suggest that high-throughput automated systems or next generation sequencing be introduced 
to allow for screening of larger numbers of clones than would typically be analysed.  
One particular study, carried out by Hoen et al., emphasises the potential impact that the 
DiCAST technology could have when employed for selection from recombinant libraries. 
The authors carried out a deep sequencing campaign, which analysed the phage pool after 
one round of bio-panning on a naïve library (Hoen et al., 2012). From their findings, the 
authors suggest that 10 million sequencing reads would allow full characterisation of the 
round one output for this particular library. Due to this number being considered too large, 
they suggest that 1 million sequencing reads should represent the library sufficiently (Hoen 
et al., 2012).  By employing DiCAST the reduction in clones analysed to 1 million would not 
be required. All clones could potentially be analysed, not only in an antigen binding screen 
but with multiplexing options available. The technology provides a very promising 
alternative to currently used recombinant library screening approaches, both traditional (e.g. 
phage display) and more recent (e.g. next generation sequencing).  
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Chapter 5 
Mammalian cell screening using DiCAST 
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Hypothesis 
The screening of mammalian cells in typical antibody discovery approaches (e.g. Hybridoma 
cells, non-fused B cells or EBV transformed B cells) relies on the employment of cloning by 
limiting dilution. This involves spatially addressing cells in the wells of microtitre plates and 
monitoring the supernatant for specific antibody at several time intervals. In order to address 
the entire population of cells they are often plated with numerous (5-5000) cells per well. 
This can result in the potential loss of important antibody candidates due to overgrowth by 
fast-growing, non-specific cells. This chapter investigates the potential of using the newly 
developed DiCAST technology to screen mammalian cells, without the use of cloning by 
limiting dilution, for a non-biased, streamlined antibody discovery approach 
Rationale 
The development of the hybridoma technique by Kohler and Milstein, almost 40 years ago, 
revolutionised the antibody discovery space and remains today a commonly used method to 
generate monoclonal antibodies (Kohler & Milstein, 1975). The process which involves the 
fusion of a cell from an immunised source with a myeloma cell line has many desirable 
outcomes. These include the relatively simple procedure, the continuous production of the 
desired antibody and the antibody remaining in its native structure (Gorny, 2012).  The 
method is not, however, without its limitations as the fusion efficiency can be very low (i.e. 
PEG fusions can produce only one viable hybridoma from 10
5
 starting cells (Greenfield, 
2014) inferring that valuable B cells producing antibodies of interest could be missed. This 
inefficiency has led to the emergence of additional techniques such as EBV transformation, 
electro-fusion and single cell PCR, to overcome the loss associated with the traditional 
approach (Gorny, 2012).  
Regardless of the means in which the cells are treated (i.e. Hybridoma fusion, EBV 
transformation or native B cell) they are typically screened in the same way, i.e. by cloning 
by limiting dilution which was discussed in greater detail in Chapter 1. In order to overcome 
the limitations of traditional techniques a range of single cell analysis technologies have 
emerged in recent years. These include microengraving of miniature wells (Love et al., 
2006; Ogunniyi et al., 2009; Sendra et al., 2013), etched fibres (Biran & Walt, 2002), 
homogeneous cell spot assays (Jin et al., 2009) and microfluidic cell sorting (El Debs et al., 
2012; Diercks et al., 2009; Ryan et al., 2011; Singhal et al., 2010; Wheeler et al., 2003). 
DiCAST offers an attractive alternative to the traditional screening approaches typically 
employed by allowing all cells to be screened, on a single cell basis, in a very short time-
scale (i.e. antibody signal can be observed in as little as six hours but assays are typically 
incubated for up to 3 days to compensate for slow-growing or low expression clones ). The 
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utilisation of the multiplexing capabilities of the DiCAST technology could reduce the 
overall time to carry out a mammalian antibody screening campaign significantly, as 
illustrated in Figure 5.1, in addition to potentially finding superior antibody candidates. 
DiCAST also offers an enhanced option when compared with the other microtools currently 
under development as the throughput is much greater than many of them, which are typically 
limited to numbers close to 10
5
 single cells. Furthermore, the multiplexing options available 
are greater when using DiCAST and the retrieval of the target cell does not require the use of 
a micromanipulator which is often time-consuming and laborious.  
  
Figure 5.1: Antibody discovery process for mammalian cells using DiCAST. DiCAST 
process for both hybridomas and B cells. (A) Cells are fused with a myeloma cell line 
(hybridoma) or remain unmodified for screening (B cells) (B) The cells are diluted to 
achieve the equivalent of 1 cell per capillary and analysed using DiCAST. By utilising the 
multiplexing capabilities of the technology, discussed in Chapter 3, it is possible to carry out 
multiple, diverse tests on the entire cell population of variants, on a single-cell basis, 
simultaneously.  
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In this chapter the use of DiCAST to interrogate mammalian cells was investigated, as 
illustrated in Figure 5.2. Initial experiments determined the ability to detect antibody 
secreted from mammalian cells in the capillaries and their subsequent removal from the 
array. A means to capture the genetic information from each of the single B cells screened 
was developed to allow for recombinant cloning of the variable regions from cells showing 
desired binding or performance characteristics. Following on from that, a number of 
screening campaigns were carried out on single, non-immortalised B cells. As part of one of 
these screening campaigns, a single B cell was retrieved and the variable regions amplified, 
cloned and expressed as a scFv fragment. In addition to carrying out screening and retrieval 
of the genetic material from single B cells, a proof-of concept experiment for a functional 
bio-assay was also designed and executed on the array.  
 
Figure 5.2: Schematic overview of thesis layout. Chapter 5 is concerned with determining 
the feasibility of analysing mammalian cells using DiCAST.  
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Key Challenge 5.1 Determination of the feasibility of screening mammalian cells using 
DiCAST.  
5.1.1 Experimental Approach 
Due to the nature of the microcapillary arrays used in the DiCAST technology, they are not 
limited to the use of any one antibody-producing technology. In this section the ability to 
screen and detect antibodies secreted from mammalian cells was investigated. Firstly, the 
ability to specifically detect the antibody secreted from mammalian cells was confirmed, 
followed by the identification of an appropriate incubation time for cells of this type. Lastly 
a test screen was carried out using DiCAST. All initial experiments utilised a multiple 
myeloma, human IgE (hIgE)-secreting cell line to determine the criteria required to allow 
mammalian cell screening. 
 
5.1.2 Detection of IgE secreted from multiple myeloma cells which have been incubated 
on the microcapillary array. 
To determine whether mammalian cells can express protein in the capillaries of the array, the 
supernatant obtained from cells incubated on array was tested, via a sandwich ELISA, for 
detectable hIgE. The assay was carried out, as described in sections 2.5.1 and 2.5.2. Briefly 
cells were added to an area microcapillary array (i.e. 100 µL equals approximately 84,000 
capillaries), allowed to incubate for 2 days and then contents of the capillaries removed 
under nitrogen flow and assayed.  
From the ELISA result, it could be seen that there was hIgE present in the supernatant of 
cells removed from the array after 2 days incubation. When compared, as shown in Figure 
5.3, to supernatant from cells which were cultured under standard conditions the level of 
hIgE was low but this could be expected when the difference in culture volumes (i.e. 50 mL 
tissue culture flask versus 1.2 nL/capillary on array) in question are taken into account.  
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Figure 5.3: Sandwich ELISA analysis detecting levels of hIgE in the supernatant of 
multiple myeloma cells. The levels of hIgE present in the supernatant, Neat (N) and 1 in 50 
dilution,  taken from cells cultured under regular conditions and from cells cultured on array 
were assayed and compared. A medium blank (Media B) and a PBS blank (PBS B) were also 
included in the analysis to establish the level of background. 
Based on the analysis of supernatant taken from cells cultured on the array, the cells are 
capable of living and producing antibody in the capillaries of the array. The level of hIgE 
detected from the on-array sample is lower when compared to the cells cultured in a 50 mL 
tissue culture flask. This is most likely due to the significant decrease in medium volume 
when culturing (i.e. 50 mL culture Vs 100 µL in the array) as well as the loss of a portion of 
the supernatant on removal from the array under nitrogen.  
 
5.1.3 Establishment of appropriate incubation time for immortalised B-cells (multiple 
myeloma cell line) to detect secreted antibody. 
This experiment was used to identify a suitable incubation period for the cell line to produce 
detectable levels of hIgE, in a microtitre plate format, before transfer to the DiCAST array 
system. This was carried out on plate as outlined in section 2.5.3. 
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Figure 5.4: Time course using A 96 well plate FLISA for release of hIgE from multiple 
myeloma cells. Cells were enumerated and diluted before addition to the plate. The level of 
hIgE was detected using a sandwich FLISA on consecutive days, for three days.  
The FLISA results displayed in Figure 5.4 show that expression reached a maximum at 48 
hours and remained the same at 72 hours. In addition to this finding the lowest cell number 
from which hIgE could be reliably detected, above background, on standard microtitre plates 
was approximately 40,000 cells/mL. While this may appear slightly less sensitive than 
expected, the volume per capillary using DiCAST would be 1.2 nL, meaning that the 
sensitivity achieved is more than adequate (i.e. 40,000 cells/mL is equivalent to 0.05 
cells/1.2nL). As such, using the DiCAST platform to screen cells on a single cell level with 
the small culture volume of each capillary would allow for saturation of the supernatant, with 
secreted hIgE quite rapidly.  Thus, a single cell assay of the hIgE secreting multiple 
myeloma cells was attempted and is discussed in section 5.1.4 below.  
5.1.4 Single cell screening of multiple myeloma cells in capillaries of the microcapillary 
array.  
In order to assess the feasibility of screening mammalian cells using DiCAST, cells were 
incubated on array and detected using a sandwich anti-hIgE FLISA on an APTES treated 
layer of PDMS, in place of a microtitre plate, as described in section 2.5.4.  
 
 
-5000
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
1000000 40000 1600 64 2.56 0.1024
F.
U
. 
Cells/mL 
24hr
48hr
72hr
149 
 
 
Figure 5.5: Screening of hIgE-secreting U266 cells using DiCAST. Image showing 
expression and detection of hIgE secreted from multiple myeloma cells in individual 
capillaries. Cells (5 x 10
4
 cells/mL) were added to a 40 µm capillary diameter array, 
cultured for 4 days in CO2independent medium and expressed antibody analysed by 
sandwich FLISA. The bright (red) dots represent the antibody patterned PDMS from single 
capillaries that contained cells expressing antibody. Scale bar is 100 µm.  
At a dilution of 5 x 10
4 
cells/mL, which would equate to a cell present in every twenty 
capillaries,  a pattern of individual capillaries (40 µm) could be observed, as shown in Figure 
5.5. While some background is obtained from the APTES-modified PDMS, probably due to 
the extended incubation period in the humidified CO2 incubator, the capillaries which 
contain hIgE-secreting cells can be easily distinguished. This demonstrates the ability of 
DiCAST to screen and detect mammalian cells which secrete a protein of interest.  
5.1.5 Summary for key challenge 5.1 
The purpose of this section was to determine if mammalian cells could produce detectable 
levels of secreted protein in the capillaries of the microcapillary array. While it was proven 
possible to detect secreted protein from an immortalised multiple myeloma cell line, each 
new mammalian cell to be screened should be similarly assessed to ensure correct incubation 
durations are employed to allow for reliable detection. In addition, investigations into a 
supplemented medium (i.e. addition of cytokines, feeder cells etc.) could allow for enhanced 
survival and antibody production by the single cells in the capillaries.  
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Key Challenge 5.2 Establishment of a method for retrieval of mammalian cells from the 
capillaries of the array.  
 
5.2.1 Experimental approach 
Similar to the investigations carried out in Chapter 3, it is important to have the ability to 
retrieve the antibody-secreting cell of interest from the capillary in which it is housed 
subsequent to its identification. In bacterial experiments recovery of approximately 10 % of 
the capillary contents was achieved upon removal with the DiCAST prototype. Mammalian 
cells are larger, more fragile and do not replicate as quickly as bacterial cells and, as such, 
their successful retrieval from the array is complex.  
In this section, ways in which to best capture the contents of a desired capillary are 
investigated. In the first instance cells were removed from the array crudely under nitrogen 
flow and then retrieved from the capillaries using the DiCAST prototype. Finally, a means to 
capture the genetic information from cells once retrieved was devised and tested using the 
multiple myeloma cell line.  
5.2.2 Removal of intact cells from the microcapillary array.  
Due to the larger size of mammalian cells the ability to successfully pass them through the 
40µm capillaries of an array was tested, as described in section 2.5.5. A dilution (7.2 x 10
4
 
cells/mL) was added to the array and then removed using high pressure nitrogen gas. On 
enumeration of the cells subsequent to passage through the capillaries of the array very little 
loss in cell number was observed, with a cell number of 6.8 x 10
4
 cells/mL obtained upon 
collection of the cells. On visualisation the cells were present in high numbers and appeared 
healthy, as shown in Figure 5.6. The average size of the newly passaged cells, as determined 
by Millipore Sceptor, was between 12 to 18 µm in diameter.  
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Figure 5.6: Cells retrieved from the microcapillary array using nitrogen flow. A cell 
dilution of 7.2 x 10
4 
cells/mL was added to the array and cells, from several capillaries, were 
collected in the well of a 384-well microtitre plate. The image was captured using a light 
microscope at 20X magnification. Scale bar is 50 µm. 
 
Based on the success of this experiment, the prototype device was then used to carry out a 
retrieval of the cells loaded on the array, as detailed in section 2.5.6. On observation of the 
384-well plates, no cells were observed in target wells. The system parameters were then 
tested and improved using colorimetric tests (TMB and HRP) so that optimum settings were 
used for live cells retrievals. It was found that an increase of medium (50 µL increased to 85 
µL) in the 384 well plate allowed for a more accurate retrieval process using the colorimetric 
tests. The retrieval of mammalian cells was then repeated, as previously described. 
Subsequent to retrieval, using the optimised conditions, cells were observed in some of the 
target wells, as shown in Figure 5.7. Cells were not observed in all target wells and viability 
after retrieval was poor.  
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Figure 5.7: Visualisation of multiple myeloma cells retrieved into 384 well plates using 
the DiCAST prototype. Intact cells can be seen at (A) 10X magnification and (B) 20X 
magnification. 
While it is possible to retrieve intact mammalian cells using the prototype, there are several 
issues with the current set-up. Firstly, there is not a high level of accuracy, with cells seen in 
only 2 out of 40 target wells. This issue will be exacerbated when working at a single cell per 
capillary level. Secondly, the cells do not remain viable in the plates overnight. Options 
available to overcome this include (i) use of an enriched medium and/or companion cells to 
aid proliferation of the captured cells or, alternatively, (ii) the amplification of antibody 
genes from the target cell, allowing antibodies to be produced recombinantly. 
 
5.2.3 Amplification of genetic material from cells 
The success of the DiCAST process relies heavily on the successful removal of the cell of 
interest from the array. While it has proven possible to remove intact cells from the array, 
successful culturing of the cells post-retrieval may prove difficult. This concern is based 
predominantly on the fact that mammalian cells are rarely cultured at single cell level, due to 
their poor performance in the absence of other cells. Because of this an alternative method, 
which involves the amplification of antibody genes from the cell of interest, has been 
investigated as detailed in sections 2.5.11, 2.5.12 and 2.2.7. On observation of the gel a 
specific band could be seen at the correct size (350-400 bp), for dilutions ranging from 10
7
 to 
10
1 
cells/mL, as shown in Figure 5.8.  
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Figure 5.8: Analysis of PCR products, for the CH1 domain of anti-hIgE antibody, obtained 
from cDNA generated from multiple myeloma cells. Cell dilutions were analysed and the 
lowest cell dilution where detection is achievable is 10
 
cells/mL. Control reactions to ensure 
the product was not obtained from genomic DNA (PCR on the cell preparations, without the 
cDNA synthesis reaction) were carried out and did not contain a specific band. DNA Ladder 
is 1kb Plus Ladder from Life Diagnostics, CA, USA. 
Based on this result it can be concluded that it is possible to amplify antibody fragments, 
directly from cell preparations, with a low cell number (~10 cells/mL) as template. With 
such a sensitive detection rate it means that, theoretically, at a single cell per capillary level 
(1 cell per 1.2 nL) a PCR product can be obtained. This will mean that if cells cannot be 
retrieved and cultured directly that retrieval of the genetic information from a specific 
antibody of interest is a viable alternative.  
5.2.4 Summary for key challenge 5.2 
In this portion of the chapter the ability to remove the cell of interest from the capillaries of 
the array was determined. Unfortunately the process is highly inefficient and will need 
additional optimisation of the prototype to allow screens on mammalian cells carried out on 
DiCAST to be fully worthwhile. As the retrieval of intact, viable cells was not very efficient 
and an alternative approach was also investigated in this section. The ability to produce the 
antibody of interest by recombinant means was tested using dilutions of control cells. Based 
on this proof-of-concept data, it was thought feasible to amplify the genetic material from 
single cells removed from the array. A significant amount of development would be needed 
to produce a fully working system compatible with mammalian cells. However with a view 
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to confirming the utility of DiCAST for mammalian cell screening the ability to carry out 
direct screening of B cells, circumventing the need for the fusion process, was attempted and 
is discussed in Section 5.3.  
Key challenge 5.3 Native B cell screening, from non-immunised and immunised 
sources, using DiCAST.  
5.3.1 Experimental approach 
The ability to directly screen the B cell repertoire is of great interest in the development of 
human therapeutics, as the naturally produced/occurring antibody is thought to be more 
potent and, additionally, if produced from human B cells, can potentially have reduced 
adverse effects.  
In this section the ability to screen native B cells without any prior manipulation or 
immortalisation strategy, using DiCAST, will be investigated. In the first proof-of-concept 
experiment, B cells from the spleen of a non-immunised mouse were analysed for IgG 
secretion. Following that, a screen was carried out on the B cells of a mouse immunised with 
three different proteins in a multiplex format which allowed for responses for all three 
proteins to be analysed simultaneously.   
5.3.2 Screening of Naïve B cells from a non-immunised mouse.  
 
The initial investigation into screening B cells using DiCAST was carried out, using splenic 
B cells from a non-immunised mouse, to determine if individual B cells could secrete a 
detectable amount of antibody in the capillaries of the array. An assay for the detection of 
mouse IgG was carried out on the microcapillary array, as described in section 2.5.7. A 
specific response, to mouse IgG, can be observed in all dilutions. At higher concentrations of 
cells, all capillaries appear positive (Figure 5.9A).  
At a lower dilution (Figure 5.9B) where, theoretically, the density is less than 1 cell per 
capillary, single capillaries which contain B-cells expressing an antibody of interest (in this 
case, mouse IgG) can be differentiated.  
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Figure 5.9: Screening of murine splenic cells for mouse IgG. (A) Reponses obtained from 
serial dilutions of cells. When cells are loaded at too high a density no single capillaries can 
be differentiated. At 10
5 
cells/mL single capillaries containing specific cells can be identified. 
(B) Enhanced image of 10
5
 cells/mL dilution, showing single capillaries of 40µm diameter. 
Scale bar is 100 µm.  
 
This initial experiment served to prove that it was possible to detect antibody (IgG) secreted 
from individual B cells extracted directly from a non-immunised mouse spleen, without any 
prior manipulation.  
 
5.3.3 Screening of B cells from a mouse immunised with three different antigens. 
Following on from the successful analysis of naïve B cells in section 5.3.2, murine splenic B 
cells from a mouse immunised with 3 different antigens were analysed directly with 
DiCAST. Individual B cell responses to all 3 antigens were observed in one single 
experiment by multiplexing through dual surface and fluorescent label analysis.  
The assay format, as shown in Figure 5.10, involved a double sided assay which also 
incorporated a multiplex assay on one side. The analysis incorporated a direct antigen 
capture on the first surface for identification of the myoglobin-specific antibodies and an 
anti-mouse capture approach to allow multi-analyte (Transferrin and C-reactive protein-
specific antibodies) detection on the second surface of the assay.  
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Figure 5.10: Schematic of multiplex assay approach used for B cell screening. The assay 
performed involved a double-sided assay, in which one of the sides was used for multi-
analyte detection. (A) B cells isolated from the spleen of an immunised mouse were allowed 
to incubate and secrete IgG which were captured on each of the prepared PDMS surface. 
(B) Following incubation the array is removed and stored and secondary detection is 
carried out using fluorescently labelled detection reagents. Myoglobin specific antibodies 
were detected on Side 1, using an antigen coated surface. Transferrin and C-reactive protein 
antibodies were selected from Side 2, which employed an anti-mouse IgG capture approach 
and was probed with Cy5-labelled Transferrin and Cy3-labelled CRP.  
 
Capillaries which contained antigen-specific B cells could readily be identified on 
observation of the scan, shown in Figure 5.11A. When analysing the multi-analyte detection 
surface, separate images were obtained for each of the fluorophores and these were then 
overlaid to obtain a composite image, using the DiCAST software. A standard output from a 
multiplex format can be seen in Figure 5.11B, where those spots appearing green in the 
composite image represent a CRP-specific antibody and those appearing red are transferrin-
specific.   
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Figure 5.11: Output from multiplex B cell screening assay. (A) An example of a scan for 
one of three antigens targeted in the screening process. The specific spots (40 µm diameter) 
correspond to a capillary which contains a cell secreting an antigen-specific antibody in the 
physical array. Scale bar is 100 µm. (B) Multiplex surface 2 of the double-sided assay 
allows identification of capillaries (40 µm) which contain a cell secreting an antigen-specific 
antibody. In “Spot-viewer” mode, those spots which appear green (Cy3) in the composite 
image represent a CRP-specific antibody and those which appear red (Cy5) are specific to 
Transferrin.  
The contents of selected capillaries were then retrieved to allow for further analysis of the 
cells of interest. Cells were captured in a 384 well plate and incubated for 5 days at 37°C and 
5% CO2 before an ELISA analysis (Figure 5.12) of the supernatant was carried out. 
The 1.2 nL capillary volume containing the single murine B cell producing antibody to the 
target of interest was recovered into 85 µL of medium in a 384 well plate and, despite the 
large dilution factor, indicative binding signals could be observed 5 days later by ELISA 
(Figure 5.12).  
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Figure 5.12: ELISA results confirming antigen specificity of antibodies secreted from the 
retrieved cells. Supernatant from retrieved cells was assayed subsequent to 5 days post-
retrieval incubation at 37°C/5% CO2. For each of the three antigens screened (A) C-
Reactive protein (B) Myoglobin and (C) Transferrin there are a selection of cells, secreting 
antibody of interest, available for further characterisation. 
 
159 
 
5.3.4 Summary for key challenge 5.3 
The possibility of detecting target specific antibody producing cells against the three protein 
targets in a single iteration, using DiCAST has been demonstrated. While not carried out in 
this screen the recovered cells could have been immortalised by a variety of means such as 
PCR cloning (Yoshioka et al., 2012)(Yoshioka et al., 2011)(X. Jiang et al., 2006), EBV 
immortalisation (if human cells) (Steinitz et al., 1977) or by more recent improved methods 
(Traggiai et al., 2004). Additionally while this example demonstrates determination of 
binding for three antigens, the flexible nature of the technology can allow for a wide-range 
of assays to be carried out in parallel and thus determine a large amount of desired and 
relevant information for each of the cells analysed.  
Key Challenge 5.4 Determination of feasibility of whole cell screening (i.e. using whole 
cells as antigen). 
5.4.1 Experimental approach 
The ability to use cells as an antigen would allow for antibodies which bind an intact cell to 
be detected. This is an attractive approach in the development of monoclonal antibodies, for 
both therapeutic and diagnostic applications, where antibodies can be screened for binding to 
a particular cell based antigen in a relatively native state as opposed to a purified or 
recombinant version.  
In order to determine whether this approach was feasible for use with DiCAST, a number of 
experiments were designed and carried out using whole cells as antigens. Initially the ability 
of cells to bind specifically to the PDMS surface was ascertained, followed by DiCAST 
screening of B cells of a chicken which had been immunised with Jurkat cells.  
5.4.2 Confirmation of specific binding of cells to the PDMS surface.  
Before carrying out a screening campaign, the feasibility of using cells as an antigen in the 
DiCAST process was assessed. In order to determine whether cells could bind specifically to 
the PDMS surface, cells were captured on an anti-EpCAM-coated PDMS. Cells were added 
to areas of PDMS which had either been coated and blocked or blocked only, and following 
incubation and washing, the areas were imaged using a light microscope.  
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Figure 5.13: Capture of mammalian cells on an anti-EpCAM-coated PDMS surface. The 
PDMS surface was observed under a light microscope (10X magnification) to ascertain 
whether cells had bound to (A) An unmodified (blocked only) PDMS APTES surface and (B) 
A PDMS APTES surface coated with anti-EpCAM monoclonal antibody. Scale bar is 25 µm.  
Upon visualisation of the different areas it was evident that cells, as seen in Figure 5.13,  
were captured on the region where the anti-EpCAM antibody was coated and not in the area 
where only blocking solution had been applied. This indicated that it was possible to 
specifically capture cells on the surface of the PDMS.  
5.4.3 Screening campaign using whole Jurkat cells as the antigen 
Based on the results obtained in section 5.4.2, a screening campaign was undertaken which 
involved the screening of B cells taken from the spleen of a chicken immunised with intact 
Jurkat cells. The screen was carried out as illustrated in Figure 5.14 and involved the capture 
of antibodies secreted by the B cells on the PDMS surface followed by probing with 
fluorescently labelled Jurkat cells, as described in 2.5.10.  
 
161 
 
 
Figure 5.14: Schematic of the format used for the identification of cell-specific antibodies. 
(A) B cells isolated from the spleen of an immunised chicken were allowed to incubate and 
secrete IgG which were captured on the prepared PDMS surface. (B) Following incubation 
the array is removed and stored and secondary detection is carried out using intact Jurkat 
cells which had been fluorescently labelled with an Cy5-labelled anti-EpCAM antibody. 
Following this the surfaces were washed and scanned and detailed image analysis carried 
out to identify wells which contained a B cell which secreted Jurkat cell-specific antibodies. 
  
The purpose of this experiment was to determine if anti-cell antibodies could be screened on 
the DiCAST system. By analysing the images obtained, shown in Figure 5.15, the possibility 
to identify antibodies which were specific to the cells with which the animal had been 
immunised was determined.  
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Figure 5.15: Detection of Jurkat cell-specific antibodies from B cells of an immunised 
chicken using the DiCAST process.  Capillaries in the microcapillary array which contain 
a cell secreting an antibody of interest are indicated by a spot of fluorescence. Fluorescent 
signal should correspond to a specific antibody but a range of responses were observed from 
typical output (A) to those which appeared larger than the capillary diameter (B) and (D) 
and those which appeared smaller than the capillary diameter (C). Scale bar is 100 µm. 
 
Due to the complex nature of the antigen (i.e. intact cells) it was difficult to confidently 
identify positive hits, as the antigen solution was not a homogenous protein (as had been 
used in all other DiCAST screens). As a result, a range of signals were observed (Figure 
5.15) that differed in size and shape. This could be attributed to multiple cells binding to the 
same area and causing a larger, irregular shaped signal to be observed. In order for screening 
of intact cells to be reliable, the use of a scanner with the limited resolution demonstrated 
here would not be advised. A system that used a microscope set-up would greatly enhance 
the ability to select positive antibodies by allowing visualisation of the fluorescent cell at a 
much higher resolution.  
Despite the limitations of the scanner used a selection of potential positives were retrieved 
(250) using the DiCAST prototype. Plates were incubated overnight and single cell PCR was 
carried out on several of the wells, as described in section 5.4.4 below, on the following day.  
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5.4.4 Cloning and expression from a single B cell. 
From the 250 potential positives, mentioned in section 5.4.3, only 27 wells contained 
positives on the following day. While retrieval rates are typically poor with mammalian 
screening the low retrieval rate could also have been due to a number of factors, namely the 
uncertainty involved in identifying positives in the initial screen and the delay in processing.  
The positive wells were subjected to RNA extraction and cDNA synthesis, as detailed in 
section 2.5.11 and 2.5.12, respectively. The variable regions of the antibody were then 
amplified from the cDNA, purified and then combined by splicing overlap extension as 
described in section 2.5.13. An example amplification output is shown in Figure 5.16.  
 
Figure 5.16: Amplification of variable regions from single B cells. RNA extraction was 
carried out subsequent to retrieval. cDNA synthesis was carried out and variable regions 
(VH and VL) amplified by PCR. A splicing overlap extension (SOE) was then carried out for 
cloning. DNA ladder is HyperLadder 1kb Plus from Bioline.  
 
Of the 27 single cell RNA extractions carried out, first round PCR products were obtained 
from only 6. This could be attributed to low quality of the starting RNA. The samples which 
gave the greatest yields of product in first and second round PCRs were taken forward and 
the scFv fragments cloned into a pCOMB 3XSS vector, typically used for phage display, as 
detailed in section 2.5.14 and 2.5.15.  
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Following cloning, single colonies for each were expressed in small-scale culture to identify 
if the cloned scFv was present. The lysates were visualised by SDS-PAGE as described in 
section 2.2.1 and shown in Figure 5.17. Each of the lysates had a representative band, of the 
expected size (i.e. 27 kDa), present on observation of the gel.  
 
 
Figure 5.17: SDS-PAGE analysis of the expressed scFv fragments. Single colonies 
obtained from transformation plates were expressed in small-scale culture and the lysate 
fraction analysed by SDS-PAGE. Lanes 1-6 contain lysates expressed from six different 
single colonies, each representing a different B cell extraction, from the cloning 
transformation plates. The lanes designated ‘M’ contain the protein markers (PageRuler 
plus pre-stained protein ladder; sizes for each of the bands are indicated to the right of the 
gel picture). The expected size is approximately 27 kDa for each scFv. 
 
Following confirmation of expression of the scFv fragments, they were tested for maintained 
binding against the original target antigen (i.e. Intact Jurkat cells). This was carried out as 
described in section 2.5.16 and the resultant images are shown in Figure 5.18. 
M 1 M 3 4 5 6 2 
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Figure 5.18: Binding of the anti-Jurkat scFv to Jurkat cells. The variable regions were 
amplified from a single B cell and the scFv cloned and expressed for testing of maintained 
binding. (A) Assay performed with the cloned anti-Jurkat scFv (B) Assay performed with an 
unrelated scFv in place of the specific scFv (C) Assay performed with PBS in place of the 
specific scFv. Magnification is 10X. BF represents the brightfield view and Cy5 the 
fluorescent view. Scale bar is 25 µm.  
Based on the images obtained in Figure 5.18, it could be seen that one of the cloned scFvs 
did maintain binding to the intact Jurkat cells. It was compared with several controls (i.e. 
PBS in place of cloned scFv and an un-related scFv (anti-CRP) in place of the cloned scFv) 
to ensure binding was genuine and specific.  The remaining five clones did not exhibit any 
fluorescence upon visualisation. It was also noted that if clumps of cells were present in the 
control samples, they exhibited a low level of non-specific fluorescence. This should be 
considered in future screens and could possibly be eliminated by additional washing steps 
and reduction of clumped cells in the sample prior to visualisation.  
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5.4.5 Summary for key challenge 5.4 
The aim of this section was to determine if DiCAST was compatible with the use of whole 
cells as an antigen. The feasibility experiments showed that it was possible to bind cells 
specifically to the assay surface. A screening campaign was then carried out and while 
recovery rate was low, a specific antibody from a single B cell retrieved was successfully 
cloned, expressed and shown to exhibit maintained binding, as a scFv fragment, to its 
original whole cell antigen.  
Key Challenge 5.5 Functional Bioassay proof-of-concept 
5.5.1 Experimental approach 
The ability to detect functional effect in place of or alongside detection of specific binding to 
a target of interest is highly desirable in screening campaigns. Due to the complexity of 
functional assays, they are often incorporated late in the process and used only on final drug 
candidates, not the entire library/cell population. By including functional screening (e.g. 
induction of apoptosis) for the entire population, in the initial screen on DiCAST, candidates 
which may otherwise be discarded in earlier screening steps are also captured. This opens up 
the possibility for identifying unique, and most importantly therapeutically effective 
candidates, which may have been overlooked in standard screens based on other criteria.  
This section is concerned with the establishment and development of a functional assay 
(detection of apoptosis) and its execution using the microcapillary arrays. The majority of 
apoptosis assays rely on the detection of cell surface markers (e.g.  phosphatidylserine and 
Annexin V). While it is possible to execute this using the DiCAST system (with 
modifications to the standard methodology) it is more ideally suited to methods such as 
fluorescence activated cell sorting (FACS) or fluorescence microscopy. The method 
employed in this section describes the use of an assay system which allows for the detection 
of cell death (i.e. necrosis vs apoptosis) from the supernatant of target cells.  
5.5.2 Monitoring cell death in the microcapillary array. 
During apoptosis, vital intracellular proteins are cleaved by cysteinyl-aspartic acid proteases 
(caspases) that are expressed as zymogens and are activated by different apoptosis inducers. 
Once activated, a single caspase activates a cascade of caspases. Circulating full-length and 
caspase-cleaved cytokeratin 18 (CK18) are considered biomarkers of chemotherapy-induced 
cell death measured using a combination of the M30 and M65 ELISAs provided by Peviva, 
shown in Figure 5.19. The M30 ELISA measures caspase-cleaved CK18 produced during 
apoptosis and the M65 ELISA measures the levels of both caspase-cleaved and intact CK18, 
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the latter of which is released from cells undergoing necrosis. Previous studies have 
highlighted their potential as prognostic, predictive, and pharmacological tools in the 
treatment of cancer (Caulín et al., 1997; Hägg et al., 2002; Leers et al., 1999; Linder, 2011; 
Schutte et al., 2004).  
 
Figure 5.19: Schematic of assay approach for detection of apoptosis in target cells. Using 
commercially available monoclonal antibodies from Peviva it is possible to detect necrosis 
and/or apoptosis of epithelial cells. The M65® ELISA uses two anti-K18 mouse monoclonal 
antibodies of the IgG type and is primarily intended to be used together with the 
M30 Apoptosense® assay for detection of apoptotic cells. M30 Apoptosense® is an ELISA 
assay based on the M30 monoclonal antibody (Leers et al., 1999). This antibody specifically 
binds caspase-cleaved keratin 18 (ccK18, caspase-cleaved cytokeratin 18, ccCK18 or K18-
Asp396) but does not bind native, uncleaved, K18 (Hägg et al., 2002). 
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To demonstrate the detection of apoptosis using DiCAST a capture immunoassay, to 
measure total cell death (apoptosis and necrosis) of a Jurkat T cell line induced to undergo 
cell death with a monoclonal anti-Fas antibody, was performed. This antibody demonstrates 
cytolytic activity on human cells that express Fas (e.g. Jurkat). Binding of the Fas ligand 
(Fas-L) induces trimerisation of Fas in the target cell membrane. Activation of Fas causes the 
recruitment of Fas-associated protein with death domain (FADD) via interactions between 
the death effector domains (DED) of FADD and Fas. Procaspase 8 binds to Fas-bound 
FADD which in turn leads to the activation of caspase 8. Activated caspase 8 cleaves 
(activates) other procaspases, in effect beginning a caspase cascade that ultimately leads to 
apoptosis.  
In this study, Jurkat T cells were added to a 40 micron diameter microcapillary array and 
sealed with an analysis surface coated with an anti-keratin 18 monoclonal antibody (clone 
M6, binds intact and cleaved K18). A multi-analyte assay (Figure 5.20) was then employed, 
using alternately labelled monoclonal antibodies M5 and M30 to observe the occurrence of 
necrosis and apoptosis, induced by anti-Fas antibody present in the capillaries.  
 
Figure 5.20: Schematic for use of a multi-analyte assay detecting cell death in the 
microcapillary array. Utilising the Apoptosense ELISAs from Peviva, in a multi-analyte 
format, it will be possible to detect cells undergoing necrosis (Cy3-labelled M5) and 
apoptosis (Cy5-labelled M30) in the wells of the microcapillary array.  
On analysing the fluorescence signals from the assay Jurkat cells undergoing cell death can 
again be viewed as a ‘traffic-light system’ with Necrosis (Cy3 signal only), Apoptosis (Cy5 
signal only) and necrotic/late stage apoptotic cells (dual Cy3/Cy5 signal) all visualised 
simultaneously (Figure 5.21).  
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Figure 5.21: Measuring cell death on DiCAST using a combination of the M30 and M65 
fluorescence immunoassays. The M30 antibody specifically measures caspase-cleaved K18 
produced during apoptosis and M65 kit antibodies measure the levels of both cleaved and 
intact K18, the latter of which is released from cells undergoing necrosis. On DiCAST, 
multiplexed detection of anti-Fas-induced cell death of Jurkat cells was measured 
simultaneously in the microcapillary array. Scale bar is 100 µm.  
 
5.5.3 Summary for key challenge 5.5 
The aim of this section was to determine if it was possible to carry out a functional bio-assay 
in the capillaries of the array. A proof-of-concept approach with a commercial anti-Fas 
monoclonal antibody known to induce apoptosis in Jurkat cells was employed for this 
purpose. By utilising commercially available ELISA kits and employing them in a multi-
analyte format DiCAST assay it was possible to identify capillaries where Jurkat cells were 
undergoing necrosis, apoptosis or both. The use of such an assay in a screening campaign 
could offer greater insights into the functional activity of a greater portion of candidate 
antibodies much earlier in the screening process.  
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Conclusion and Significance: 
In this chapter the ability to analyse mammalian cells, using DiCAST, was assessed and 
shown to be achievable for both immortalised cell lines and for native B cells.  
Firstly the ability to detect antibody secreted from mammalian cells was tested by analysing 
the supernatant of multiple myeloma cells for secreted hIgE. Using a sandwich ELISA, the 
supernatant of cells which had been incubated on the array was compared with the 
supernatant from a flask of the same cells. While levels of hIgE were lower in the 
supernatant retrieved from the array, there was a detectable level present from the 84,000 
capillaries (Figure 5.3). This served to prove that the cells could survive in the reduced 
volume of the capillaries long enough to produce detectable levels of antibody in the 
supernatant.  
Following on from this a time-course for optimal incubation times of cells was carried out in 
microtitre plates, as shown in Figure 5.4.  While detectable levels of antibody were present 
after 24 hours, the 48 hour and 72 hour time-points produced similar and much higher levels 
of antibody. To allow for saturation of the surface and to ensure no slow-growing or low-
expression cells are captured, an incubation time of at least 48 hours will be used going 
forward.  
The time-course carried out on plate gave an indication of appropriate incubation time but 
was not directly transferable, so a single cell assay using the same assay components was 
carried out on the array. It was shown, by adding a concentration of cells that single cell 
analysis could be carried out (Figure 5.5) and that signals obtained from each single cell 
housed in an individual capillary were easily distinguishable above background.  
The second challenge of this chapter was to ascertain if it was possible to retrieve the desired 
cell from the target capillary. While shown to be possible to pass cells through the array 
(Figure 5.6), under nitrogen flow, with little loss of the overall cell number, retrieval of the 
contents of a single capillary was not highly successful. The alignment approaches and 
prototype, discussed in Chapter 3, were again employed but retrieval rates were shown to be 
very low when addressing a single capillary. This is not surprising given the results obtained 
using bacteria, where only 10% of the contents of each capillary were retrieved. Whereas 
bacteria can replicate quickly and a workable culture be obtained within hours, mammalian 
cells are larger, more fragile and divide at a much slower rate. Thus, the retrieval of 
mammalian cells proved highly difficult and unreliable.  An alternative retrieval prototype, 
designed specifically for the retrieval of intact mammalian cells, employing the use of a 
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liquid-liquid removal approach is currently in development and will hopefully greatly 
improve the yield of cells from the array.  
Due to the fact that retrieval of intact and viable cells was shown to be troublesome, a means 
to retrieve the genetic material of the cell and potentially build the antibody recombinantly 
was investigated. The RNA was extracted from varying dilutions of cells, the RNA reverse 
transcribed into cDNA and a specific region amplified from each dilution as a proof-of 
concept for the method. It was shown to be possible to amplify product from the range of 
cell dilutions down to the equivalent of approximately 10 cells/mL (Figure 5.8). The 
potential requirement of this approach would be amplification from one cell and while this 
would challenge the sensitivity of the approach described above it could possibly be 
improved by nested-PCR (Tickle et al., 2009) or other techniques described in the literature 
(Kurosawa et al., 2012; Kurosawa et al., 2011; Yoshioka et al., 2011).  
Despite requiring an improved method of retrieval, several screening campaigns using native 
B cells were carried out. Screening of B cells directly without the use of traditional 
immortalisation strategies is highly desirable as it negates the loss in the original population, 
caused by the inefficiencies associated with fusion and EBV transformation, and also 
reduces the time taken for screening (Lightwood et al., 2006). 
In the first instance, IgG secreted from the splenic B cells of a non-immunised mouse was 
carried out to ascertain if single B cells could produce a detectable level of secreted IgG to 
allow detection on DiCAST. Based on the miniaturised format and the high sensitivity of the 
microarray scanner it was not envisioned that there would be any issue in detecting even 
small amounts of antibody and this was shown to be the case (Figure 5.9).   
Following on from this initial experiment the ability to analyse a population of murine 
splenic B cells (300,000 at single cell per capillary occupancy), taken directly from an 
immunised mouse, without prior immortalisation or manipulation was demonstrated (Figure 
5.11). This screening campaign involved a multiplex format, which allowed the B cells 
obtained from a mouse which had been immunised with three different proteins to be 
screened, for antibodies specific to each of the proteins, simultaneously. This multiplexing 
capability offers advantages, not only in terms of cost and time-saving, but also in the 
reduction in animal use with multiple antigens immunised and screened from one animal.  
In an effort to add to the functionality of the DiCAST screening offering further, the ability 
to screen for cell binders using intact cells as the antigen was explored. The desire to select 
cell binding antibodies is driven by the fact that they can be used as very successful 
therapeutic and imaging reagents as well as potentially identifying cancer-specific markers 
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(i.e. present on cancer cells but not on regular cells) (Yoon et al., 2012). While cell markers 
can sometimes be identified and expressed recombinantly they do not remain in their native 
format, as they would appear on the cell, and lack the presence of potentially important post-
translational modifications (e.g. glycosylation) (Siva et al., 2008). All too often it does not 
prove possible to express the protein required and while whole cell panning has proven 
successful (Hoogenboom et al., 1999; Yoon et al., 2012) it has limitations in terms of non-
specific binding of phage and issues with washing steps which can result in the loss of the 
cells (Wang et al., 2011).  
To begin with, the ability of cells to bind specifically to an appropriately coated area of the 
PDMS surface was investigated. It was demonstrated to be possible (Figure 5.13) and, as a 
result, a screening campaign against whole cells was undertaken. The spleen cells of a 
chicken immunised with intact Jurkat cells were analysed using DiCAST. While proving 
difficult to identify positives with a high level of certainty, due to the irregular shape of the 
antigen (i.e. fluorescently labelled Jurkat cells), it proved possible to retrieve a number of 
cells from the array for further analysis. The rate of recovery was low and of those cells 
retrieved only six were successfully cloned and expressed.  
On testing of these cloned recombinant fragments, only one scFv maintained binding to the 
cell antigen (Figure 5.18). This loss in maintained binding is not unusual, with a number of 
authors describing  between 12 and 50% of cells originally selected producing a recombinant 
fragments which binds to the original antigen (Jin et al., 2009; Lightwood et al., 2006). 
While a worrying observation, if anything it highlights the need to screen more cells in a 
high-throughput manner to increase the chances of identifying and producing the desired 
antibody. The identification of a cell binding antibody was a successful result but 
improvements in the screening approach would absolutely be needed to progress with this 
approach. An enhanced imaging system (i.e. greater resolution), which would remove 
uncertainty in the identification of positives on the scanned image, would be a priority for 
development. 
As a final challenge in this chapter, the ability to carry out a functional bio-assay on array 
was examined. The majority of functional assays require visualisation of the cell, in addition 
to being complex and expensive. As a result they are only carried out on the small number of 
final selected antibodies at the end of a screening campaign. With actual functional effect 
being of such great importance for the success of a therapeutic antibody, the ability to 
incorporate functional screening at a much earlier stage could prove advantageous in 
identifying a greater pool of functionally effective candidates.  
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A bio-assay which detected functional effect in the supernatant of cells (i.e. induction of 
apoptosis) was identified, the assay components sourced and a proof-of concept experiment 
for ultra-high throughput functional screening attempted using DiCAST.  
By inducing apoptosis of Jurkat cells using a commercially available anti-Fas antibody, of 
known properties, it was shown to be possible to differentiate necrosis and apoptosis of the 
Jurkat cells in the capillaries of the array (Figure 5.21). The inclusion of an assay of this type 
on the entire population of cells, at such an early stage, could offer assurance to those 
developing potential therapeutics. Typically, using traditional methods, only the final 
candidate clones are tested for functional activity and there is a potential that investigators 
may have missed potent candidates because of reducing the pool in earlier steps based on 
non-ideal criteria (e.g. binding or expression level).  
Based on the findings of the experimental work carried out in this chapter, although not fully 
validated, DiCAST offers a very attractive alternative to the traditional methods employed 
for the screening of mammalian cells. The time, labour and cost-saving elements are only 
one consideration. The potential to find a unique antibody by screening all of the cells 
without bias is perhaps the greatest advantage of employing single cell technologies, such as 
DiCAST, in the place of the typically used cloning by limiting dilution approach.  
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Chapter 6 
Development of automated and high-throughput 
screening protocols 
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Hypothesis 
In the recent past the move towards the use of robotics and liquid handling systems, to 
increase screening throughput, has become more commonplace (Layton et al., 2012). The 
protocols once established and verified can help to reduce workload on operators and often 
mean that performance of the system, in terms of robustness and reliability, is improved. 
Typical screening approaches attempt to reduce the number of clones for characterisation 
(e.g. binding properties, on-rate, off-rate and affinity) to a manageable number. This 
approach potentially means that important antibodies can be lost early in the selection 
process. This chapter demonstrates the development of automated and high throughput 
screening protocols for antibodies 
Rationale 
The ability to build large highly diverse repertoires of monoclonal antibodies (mAbs) 
increases the likelihood that an antibody with the desired characteristics will be generated. 
The challenge is finding the requisite unique antibody, which can often be both costly and 
time consuming. Antibodies and their derivatives are increasingly important as 
biotherapeutics, precision diagnostics, and essential tools for biological research. Techniques 
to screen and characterize large numbers of antibodies and provide confident selection of the 
best candidates for development are therefore essential. As discussed extensively in 
preceding subject areas of this thesis, the move towards miniaturisation, single cell 
interrogation and technologies such as DiCAST are becoming the leaders in the field for 
successful screening of large populations of monoclonal antibodies, from multiple sources.  
 
While the initial selection using these “microtools” can screen thousands, up to millions in 
the case of DiCAST, of clones simultaneously the screening campaign can often result in 
thousands of desirable clones. This is evidenced by the outcome of the C-Reactive protein 
library screen, described in Chapter 4, where 1631 positive hits were obtained. While the use 
of a more restrictive antibody selection screen might be useful to reduce the number of 
finally selected clones, there still exists a requirement for final characterisation and 
deployment of the selected antibodies. 
 
The aim of this chapter is to develop a set of protocols (automated ELISA and high-
throughput SPR) which can be employed to improve on traditional methods of screening and 
characterisation for a particular set of antibodies (Figure 6.1).  In this first portion of this 
chapter, the design and implementation of a set of protocols to efficiently carry out an 
automated, plate-based sandwich ELISA on a laboratory liquid handling workstation was 
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undertaken. The assay, against CRP, was fully optimised and tested with true clinical 
samples to determine its suitability for purpose.  
In the second part of this chapter, a high-throughput screening campaign for a set of 
antibodies (960) which had been previously selected, against cardiac Troponin I (cTnI), by 
phage display were interrogated using the Biacore 4000. The antibodies were first ranked 
based on binding stability and the top ten percent were then brought forward for kinetic 
characterisation. In addition an epitope mapping experiment was employed to identify 
binders to highly specific regions of the target antigen. All screening was designed to be both 
time and cost efficient, as well as delivering the most appropriate antibodies for the specific 
project.  
 
Figure 6.1: Schematic overview of thesis layout. Chapter 6 explores the establishment of an 
automated ELISA screening system using the Biomek 2000 and the development of protocols 
for efficient high-throughput SPR analysis, using the Biacore 4000.  
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Key Challenges 
6.1 Key Challenge 1-Development of an automated anti-CRP sandwich assay using the 
Beckman Coulter Biomek 2000 laboratory automation workstation. 
6.1.1 Experimental Approach 
The use of the Biomek 2000 allows for a more robust assay system and reduces the time 
spent by the user on completing tasks such as dilution series and washing steps. The 
workflow for the design of programmes on the Biomek 2000 begins with defining the layout 
of the work surface, shown in Figure 6.2A. This involves placing all pipetting tools (single-
channel, multi-channel or wash heads) and required pipette tips, reservoirs, microtitre plates 
and tube racks for all operations to be carried out. Once all lab ware has been selected and 
placed in an appropriate layout, the second step in the process is to define the functions to be 
carried out from the function palette (Figure 6.2B) such as filling plates with coating, 
blocking or washing solutions and serially diluting samples. All pipetting steps are carried 
out as detailed in the pipette transfer tab, as shown in Figure 6.3. This allows for exact 
conditions to be replicated between methods and days, helping to improve the precision, 
reproducibility and robustness of assays carried out.  
 
Figure 6.2: Beckman Coulter Biomek 2000 laboratory automation workstation work 
surface and function definition user interfaces. The work surface tab (A) allows definition 
of location for each of the required elements (i.e. pipetting tools, buffer reservoirs, pipette 
tips, microtitre plates etc.) from the defined list in the lab ware bar. The function palette (B) 
allows for precise definition of operations (i.e. serially dilute, transfer, fill etc.) within the 
work surface. 
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Figure 6.3: Beckman Coulter Biomek 2000 laboratory automation workstation pipette 
transfer function tab. Each criterion of the particular pipetting step is specifically defined 
within this tab including; source and destination lab ware items, tools used, volumes to be 
transferred, pattern of transfer, tip change requirements, mixing etc.  
A range of programmes were designed and tested, on the Biomek 2000, to allow for the 
development and validation of an assay which would detect levels of C-Reactive protein 
(CRP) in human serum. CRP is used as a sensitive marker for systemic inflammation and 
elevated levels have been linked to risk of future myocardial infarction (Ridker et al., 1998). 
The sandwich assay for detection was optimised and its accuracy and precision determined. 
The recombinant anti-CRP scFv A6 selected using DiCAST in Chapter 4, was used in 
combination with a commercially available polyclonal antibody. Because of the high 
sensitivity of the recombinant scFv the range of detection for the plate assay was well below 
typical levels of CRP normally detected in serum, which are between 1 and 5mg/L in healthy 
individuals and >10mg/L for individuals with inflammation (Food and Drug Administration, 
2005). This meant that the sample could be diluted quite significantly for use which might be 
useful in the case of sample taking (i.e. finger prick in place of actual blood draw). In 
addition, while the antibody might prove to be too sensitive in a plate assay, the use of such a 
highly sensitive antibody could be beneficial in non-typical devices such as the mobile phone 
assay device developed in the BDI. Due to the limited nature of the detection system on the 
phone a more sensitive antibody could help in the improvement of assay function. The 
developed assay could also be useful if employed for the detection of high sensitivity 
(hsCRP) or cardiac CRP (cCRP). Cardiac CRP assays, like hsCRP assays, have 
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measurement ranges that extend below the measurement range typical of most conventional 
CRP assays, typically ≤1mg/L (Food and Drug Administration, 2005). 
 
6.1.2 Purfication of anti-CRP scFv A6 using immobilised metal affinity 
chromatography (IMAC).   
Purification of the filtered bacterial lysate was performed by immobilised metal affinity 
chromatography (IMAC), as described in section 2.2.4 IMAC works by interaction between 
specific amino acid side chains on the protein of interest and a transition metal ion, in this 
case Ni
2+
, immobilized on a matrix (Bornhorst & Falke, 2000). The pCOMB 3XSS vector in 
which the anti-CRP scFv A6 is expressed contains a 6X histidine fusion tag. Histidine has a 
strong interaction with Ni
2+
 metal immobilized on the matrix due to the formation of 
coordination bonds between the immobilized transition metal and the electron donor groups 
on the histidine imidazole ring (Bornhorst & Falke, 2000). Those proteins which contain 
consecutive histidine residues are retained within the IMAC column matrix; washing with 
buffers containing lower levels of free imidazole allows for non-specifically or loosely 
bound proteins to be removed from the column. In addition, wash buffer A, detailed in 
section 2.2.4, contains glycerol, sodium chloride and Triton-X100 which serve to reduce 
hydrophobic interactions between non-specific proteins and the column matrix allowing for 
fewer contaminants in the final eluted protein. The desired protein can then be eluted from 
the column by adding a buffer with a higher level of free imidazole. Imidazole is a histidine 
analogue and its addition competitively elutes the His-tagged protein from the purification 
column. An aliquot of each of the fractions from the purification process was retained and 
analysed by SDS-PAGE, as detailed in section 2.2.1.  
6.1.3 Characterisation of purified anti-CRP scFv A6 by SDS-PAGE.  
The purity of the anti-CRP scFv A6 was analysed by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE). SDS-PAGE allows the separation of 
proteins according to their size. A picture of the SDS-PAGE gels is presented in Figure 6.4 
and shows the high level of purity obtained from the IMAC purification. The expected size 
of the desired protein is approximately 27 kDa. The final eluent was buffer exchanged into 
PBS, concentrated, aliquoted and stored at -20⁰C until further use. 
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Figure 6.4: SDS-PAGE analysis of IMAC purification for anti-CRP scFv A6. Lanes 
designated ‘M’ contain the protein marker (PageRuler plus pre-stained protein ladder, sizes 
for each of the bands are indicated to the left of the gel picture). The desired band is 
highlighted on the image, in both the lysate and elution fractions. Lane 1 contained the crude 
lysate of scFv A6, generated as described in Section 2.2.2. Lane 2 represents the flow-
through from the IMAC column, containing all proteins that did not bind to the IMAC 
column. Lane 3 contained Wash A, which removes non-specifically bound proteins to the 
column. Lane 4 contained Wash B which removes any additional non-specific proteins. Lane 
5 contained the eluted, IMAC-purified scFv A6 (expected size is approximately 27 kDa).  
6.1.4 Optimisation of anti-CRP sandwich assay. 
The process of optimisation is integral to the development, and possibly validation, of any 
assay. It will allow for a more reliable assay and gives confidence to the user that the assay 
will perform as expected throughout all operations.  To optimise this indirect sandwich 
ELISA, a series of checkerboard ELISAs were carried out to determine the optimal 
concentrations of the reagents used.  
A checkerboard titration involves the dilution of two reagents against each other to examine 
the interactions between all resultant combinations (Crowther, 2000). For any checkerboard 
investigation the maximum number of reagents that can be varied per assay is two 
(Crowther, 2000). As a result two separate checkerboard ELISAs were carried out to 
optimise this sandwich assay, as described in sections 2.6.2 and 2.6.3. The first was utilised 
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to determine the correct coating concentration of the polyclonal anti-CRP antibody as well as 
the appropriate range of CRP to use and the second assay was used to determine the optimal 
dilution of primary detection antibody (scFv A6). Throughout the assay development the 
secondary detection antibody (HRP labelled anti-HA) was used at a 50 ng/mL dilution, as 
recommended by the manufacturers.  
Based on the initial checkerboard, which is shown in Figure 6.5, the optimal coating 
concentration for the assay was determined to be 4 µg/mL. This was based on the fact that 
there was little difference between the higher concentration of 20 µg/mL. The titer and the 
overall absorbance levels were non-optimal below 4 µg/mL.  
In terms of the range of CRP which could be reliably detected using the assay, there was a 
plateau effect evident after approximately 0.6 µg/mL of CRP and there was still a response 
above background at 0.001 µg/mL. A range of 1-0.0001 µg/mL CRP was determined at 
optimal for the assay going forward.  
 
Figure 6.5: Checkerboard ELISA for the determination of appropriate coating 
concentration of the polyclonal anti-CRP antibody. The coating antibody was diluted in 
series (1 in 5) and a sandwich assay carried out using a range of CRP concentrations (15 
µg/mL to 0.0001ug/mL; 1 in 5 series). The recombinant scFv A6 was used as the primary 
detection antibody at a concentration of 1.04 µg/mL and secondary detection was carried 
out using 50 ng/mL anti-HA tag antibody which was HRP labelled.  
 
In the second checkerboard ELISA (Figure 6.6) the dilution of primary detection antibody 
was investigated. Three different dilutions were employed, as described in Section 2.6.3. 
Based on the responses obtained a concentration of 1.04 µg/mL appears to be optimal by 
giving sufficient absorbance values while also titering well.  
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Figure 6.6: Checkerboard ELISA for the determination of appropriate concentration of 
primary detection antibody (anti-CRP scFv A6). The coating antibody was used at 4 µg/mL 
as determined in section 6.1.4. The recombinant scFv A6 was used as the primary detection 
antibody at a range of dilutions (1in 100 (5.2 µg/mL), 1 in 250 (2.08 µg/mL) and 1 in 500 
(1.04 µg/mL)) and secondary detection was carried out using anti-HA tag antibody which 
was HRP labelled, as per manufacturer’s instructions.  
 
6.1.5 Determination of the performance of the optimised sandwich assay.  
In order to measure the accuracy of the immunoassay, intra-day assay variability studies 
were performed. Three sets of standards were prepared and assayed as per section 2.6.4.  The 
results were plotted and are shown in Figure 6.7. The standard deviations, for each of the 
points of the standard curves, were expressed as error bars on the graph.  
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Figure 6.7: Intraday assessment of the standards used in the CRP sandwich assay. The 
error bars indicate the deviation in the absorbance over three separately prepared standard 
curves assayed on the same day. Each standard curve was carried out on a separate plate 
and was composed of three replicates for each standard. The % CV values ranged from 1.12 
to 6.12% which is within the accepted ranges for this type of analysis (DeSilva et al., 2003).  
To measure the intermediate precision (precision of repeated measurements, taking into 
account sources of variation such as runs, days, reagents etc.), inter-day assay variability 
studies were performed using the optimised assay. The assay was carried out, as described in 
section 2.6.4, on three separate days using freshly prepared reagents for each day. The results 
obtained are displayed in Figure 6.8, where once again the standard deviations are shown for 
each point of the standard curve using error bars. While it is evident that there was a larger 
degree of variance interday than intraday, it could be expected that this would be the case.  
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Figure 6.8: Interday assessment of the standards used in the CRP sandwich assay. The 
error bars indicate the deviation in the absorbance over three separately prepared standard 
curves assayed on the three different days. Each standard curve was carried out on a 
separate day and was composed of three replicates for each standard. The % CV values 
ranged from 0.92 to 16.83%. While this is still within the accepted guidelines for precision 
(DeSilva et al., 2003) some of the values were on the higher end of the scale. This was 
predominantly evident in the lower end of the curve where any deviation would represent a 
higher percentage of the mean absorbance for that standard.  
To further evaluate the accuracy of the assay, spiked samples were prepared at a 
concentration of 0.001 µg/mL, in both buffer (PBS with 1% (w/v) BSA) and serum, and 
subsequently assayed using the optimised ELISA method. The concentration of 0.001 µg/mL 
was chosen as a potential LOQ for the developed assay, by observation of the standard 
curve. The results obtained were plotted using BIAevaluation software and a four parameter 
logistic equation fitted to the data. The four parameter function provides an accurate 
representation of the sigmoidal relationship between the measured response and the 
logarithm of concentration observed for many immunoassays (Findlay et al., 2000) 
The concentration for each of the spiked samples was then back-calculated based on the 
standard curve obtained. This was carried out for 10 separate spiked samples on each of 
three consecutive days. The data obtained from this analysis is summarised in Table 6.1 
(intraday) and Table 6.2 (interday). The method proved to be very accurate in both the cases 
of intra- and inter-day analysis, with calculated concentrations for all samples (buffer and 
serum) ranging between ~88 and 103% recovery. The precision of the method was also well 
within acceptable ranges, with % CV for each set of data being below 7%. For analysis of 
this type a % CV that is ≤20% tends to be considered acceptable (DeSilva et al., 2003). It 
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could be noted that, while within acceptable values, the analysis in serum was slightly less 
accurate and precise, most likely due to the more complex nature of the matrix.  
Table 6.1: Inter- and Intra-day data for back calculations and % recoveries for both buffer 
and serum spiked samples. Actual spiked concentration is 0.001 µg/mL CRP. Samples were 
assayed alongside a standard curve, values for each of the samples were then calculated 
based on the standard curve (four parameter logistic fit).  
Intraday Absorbance 
(450nm) 
Calculated conc. 
(µg/mL) 
 
Recovery 
(%) 
Buffer    
1 0.3289 0.000934 93.37 
2 0.3317 0.000947 94.70 
3 0.3325 0.000951 95.08 
4 0.3454 0.001012 101.22 
5 0.3300 0.000939 93.89 
6 0.3305 0.000941 94.13 
7 0.3247 0.000914 91.37 
8 0.3419 0.000996 99.55 
9 0.3244 0.000912 91.22 
10 0.3311 0.000944 94.41 
    
Summary    
Mean 0.3321 0.000949 94.89 
SD 0.0067 3.19E-05 3.19 
CV (%) 2.02 3.36 3.36 
    
Serum    
1 0.3232 0.000943 94.28 
2 0.3327 0.000989 98.94 
3 0.3227 0.000940 94.04 
4 0.3306 0.000979 97.90 
5 0.3217 0.000936 93.55 
6 0.3121 0.000889 88.92 
7 0.3162 0.000909 90.89 
8 0.3284 0.000968 96.82 
9 0.3188 0.000922 92.15 
10 0.3085 0.000872 87.21 
    
Summary    
Mean 0.3214 0.000935 93.47 
SD 0.0078 3.8E-05 3.80 
CV (%) 2.43 4.06 4.06 
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Table 6.2: Interday data for back calculations and % recoveries for both buffer and serum 
spiked samples. Actual spiked concentration is 0.001 µg/mL CRP. Samples were assayed 
alongside a standard curve. Values for each of the samples were then calculated based on 
the standard curve (four parameter logistic fit). The interday values are representative of the 
mean and standard deviation from 10 replicates assayed on three separate days. 
Interday Calculated 
conc. (Mean) 
Calculated 
conc. (SD) 
Recovery 
Mean 
(%) 
Recovery 
SD 
(%) 
CV 
(%) 
Buffer      
Day1 0.000932 4.29827E-05 93.19 4.29 4.61 
Day2 0.000958 5.55126E-05 95.76 5.55 5.79 
Day3 0.000950 5.67111E-05 94.96 5.67 5.97 
      
Summary 0.000946 1.31862E-05 94.64 1.31 1.39 
      
Serum      
Day1 0.000921 4.64978E-05 92.13 4.64 5.04 
Day2 0.001032 5.94022E-05 103.22 5.94 5.75 
Day3 0.000965 6.73871E-05 96.50 6.73 6.98 
      
Summary 0.000973 5.58901E-05 97.29 5.58 5.74 
  
6.1.6 Analysis of clinical samples using the optimised CRP assay  
In order to assess the performance of the assay for its final purpose, a number of clinical 
samples of known CRP concentration were analysed with fully optimised assay. The samples 
were obtained from the Mater Misericordiae University Hospital, Dublin. They were 
previously analysed using Abbott ARCHITECT c16000 Clinical Chemistry Analyser, in a 
turbidometric assay format.  The samples were then titered and assayed, as described in 
section 2.6.6. Once again the results obtained were plotted using BIAevaluation software and 
a four parameter logistic equation fitted to the data, which is displayed in Figure 6.9.  The 
values for each of the dilutions were then back-calculated using the standard curve, as shown 
in Table 6.3, with the aim of identifying a dilution which allowed for accurate calculation of 
the CRP levels in the clinical samples. Due to the wide range of samples concentrations (2-
21 mg/L or µg/mL) for the clinical samples it was important to identify a single dilution that 
could be applied to all samples/unknowns that would allow for their accurate and precise 
quantitation, in an actual blind analysis. On observation of the titer, carried out as detailed in 
section 2.6.6, for the clinical samples (Figure 6.9) it can be seen that the greatest 
differentiation between samples of different concentrations can be seen at roughly a 1 in 
3125 dilution.  
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Figure 6.9: Titer of clinical samples in sandwich format. The serum samples (containing 
21, 16, 9, 3 and 2 mg/L or µg/mL, as determined in the hospital clinic) were each diluted in 
series (1 in 5) to determine a dilution which will allow for all concentrations to be 
accurately quantified using a standard curve, as previously described. On observation of the 
curve it can be seen that the greatest differentiation between samples can be seen at a 1 in 
3125 dilution.  
The back calculation of sample concentrations from the curve provides a more detailed 
analysis of the data and identifies the most accurate dilution ranges, highlighted within Table 
6.3, for all of the clinical sample concentrations. The higher concentration samples appear to 
have a wider range of suitable dilutions for accurate quantitation while the lower 
concentration samples (2 and 3 µg/mL) are only accurate within a narrower range (1 in 625 
to 1 in 3,125).  
Table 6.3: Determination of correct dilution factor to allow accurate quantification of 
CRP levels in clinical samples. Each of the values from the standard curve were used as 
hypothetical samples and the CRP level calculated based on the standard curve. The 
accuracy of the calculation was then determined and the ideal dilution range for each 
sample concentration defined (highlighted in blue in the table). 
Sample 
 
Dilution 
 
Actual Conc. 
(µg/mL) 
Absorbance 
(450 nm) 
Calc. Conc. 
(µg/mL) 
Accuracy 
(%) 
21 2 10.50 1.5565 ND ND 
 5 4.2 1.5680 ND ND 
 25 0.84 1.4267 0.0259 3.0943 
 125 0.168 1.4205 0.0250 14.9031 
 625 0.0336 1.4697 0.0354 105.5860 
 3125 0.0067 0.9783 0.0061 91.3808 
 15625 0.00134 0.3933 0.0014 111.4070 
 78125 0.0002 0.1507 0.0002 104.5423 
 390625 5.38E-05 0.1154 5.00E-05 92.9363 
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 1953125 1.08E-05 0.0965 ND ND 
 9765625 2.15E-06 0.1022 ND ND 
      
16 2 8 1.5739 ND ND 
 5 3.20 1.3781 0.0200 0.6253 
 25 0.64 1.4612 0.0330 5.1665 
 125 0.128 1.4266 0.0259 20.2942 
 625 0.0256 1.4473 0.0297 116.3430 
 3125 0.00512 0.8857 0.0050 98.0280 
 15625 0.001024 0.3239 0.0011 112.2518 
 78125 0.000205 0.1520 0.0002 140.7955 
 390625 4.1E-05 0.1129 2.61E-05 63.7881 
 1953125 8.19E-06 0.0994 ND ND 
 9765625 1.64E-06 0.0998 ND ND 
      
9 2 4.5 1.5658 ND ND 
 5 1.8 1.5583 0.2534 14.0799 
 25 0.36 1.4231 0.0254 7.0636 
 125 0.072 1.4262 0.0259 35.9901 
 625 0.0144 1.2608 0.0127 88.3996 
 3125 0.00288 0.6206 0.0028 97.3701 
 15625 0.000576 0.2301 0.0006 119.9788 
 78125 0.000115 0.1370 0.0002 174.1953 
 390625 2.3E-05 0.1114 8.11E-06 35.1898 
 1953125 4.61E-06 0.1038 ND ND 
 9765625 9.22E-07 0.1004 ND ND 
      
3 2 1.5 1.5906 ND ND 
 5 0.6 1.3665 0.0189 3.1609 
 25 0.12 1.4374 0.0278 23.1910 
 125 0.024 1.3543 0.0179 74.8939 
 625 0.0048 0.8605 0.0047 99.0625 
 3125 0.00096 0.3534 0.0012 134.9635 
 15625 0.000192 0.1506 0.0002 146.0643 
 78125 3.84E-05 0.1164 5.86E-05 152.5355 
 390625 7.68E-06 0.1124 2.07E-05 269.2913 
 1953125 1.54E-06 0.1052 ND ND 
 9765625 3.07E-07 0.0999 ND ND 
      
2 2 1 1.6393 ND ND 
 5 0.4 1.5638 0.5972 149.3205 
 25 0.08 1.4979 0.0471 58.9053 
 125 0.016 1.22 0.0112 70.1658 
 625 0.0032 0.6321 0.0028 90.0220 
 3125 0.00064 0.236 0.0007 112.5089 
 15625 0.000128 0.1246 0.0001 94.1025 
 78125 2.56E-05 0.1027 ND ND 
 390625 5.12E-06 0.0985 ND ND 
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 1953125 1.02E-06 0.0974 ND ND 
 9765625 2.05E-07 0.0996 ND ND 
 
Based on the detailed accuracy analysis, discussed above, the clinical samples were all 
diluted 1 in 2000 (ten replicates for each sample) and assayed as described in Section 2.6.7.  
 
Figure 6.10: Standard curve for determination of clinical serum sample CRP 
concentration. The curve was generated as described in section 2.6.4, and the data fitted 
with 4-parameter equation using BIAevaluation software. Absorbance values from the 
diluted clinical samples were calculated based on this standard curve. The result of the 
analysis can be seen in Table 6.3. Error bars denote the standard deviation from the mean of 
three replicates for each standard.  
A standard curve was generated using the BIAevaluation software (Figure 6.10), as 
previously discussed, and was used to quantify the level of CRP in the clinical samples. The 
results of this quantification, for ten replicates of each clinical sample, are detailed in Table 
6.4. Overall there was an extremely high level of accuracy (Mean accuracy ranged from 100 
to 105%) and precision (% CVs for the ten replicates for each sample ranged from 1.22 to 
3.61%) for all of the samples analysed. 
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Table 6.4: Calculation of CRP levels in clinical patient samples using the optimised 
sandwich assay. Samples were diluted 1 in 2000, which was determined as the optimal 
dilution range from Table 6.3. Each sample was assayed 10 separate times, the 
concentration calculated based on the standard curve (Figure 6.10) and the sample 
concentration corrected for dilution factor before calculating the recovery and precision 
values. All performed very well and had low % CV, indicating a very high level of precision 
when calculating the amount of CRP in clinical samples. 
Actual Conc. 
(µg/mL) 
Abs 
(450nm) 
Calculated Conc. 
(µg/mL) 
Dilution corrected 
(x 2000) 
% Recovery 
     
21 1.189 0.010 20.55 97.84 
 1.198 0.011 21.07 100.34 
 1.200 0.011 21.20 100.97 
 1.199 0.011 21.13 100.62 
 1.201 0.011 21.22 101.05 
 1.199 0.011 21.12 100.60 
 1.193 0.010 20.78 98.94 
 1.189 0.010 20.54 97.81 
 1.211 0.011 21.87 104.14 
 1.196 0.010 20.92 99.63 
Mean 1.197 0.011 21.04 100.19 
SD 0.006 0.00019 0.39 1.84 
CV (%)    1.84 
     
16 1.092 0.008 15.98 99.89 
 1.098 0.008 16.21 101.34 
 1.099 0.008 16.24 101.49 
 1.089 0.008 15.87 99.21 
 1.099 0.008 16.26 101.62 
 1.099 0.008 16.25 101.57 
 1.099 0.008 16.25 101.55 
 1.101 0.008 16.33 102.09 
 1.108 0.008 16.60 103.77 
 1.099 0.008 16.25 101.58 
Mean 1.098 0.008 16.23 101.41 
SD 0.005 0.00010 0.19 1.22 
CV (%)    1.2 
     
9 0.838 0.005 9.06 100.70 
 0.846 0.005 9.22 102.42 
 0.840 0.005 9.09 101.04 
 0.859 0.005 9.48 105.35 
 0.844 0.005 9.17 101.89 
 0.837 0.005 9.04 100.46 
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 0.851 0.005 9.32 103.54 
 0.850 0.005 9.30 103.30 
 0.842 0.005 9.14 101.59 
 0.851 0.005 9.31 103.47 
Mean 0.846 0.005 9.21 102.38 
SD 0.007 0.00007 0.139 1.540 
CV (%)    1.50 
     
3 0.390 0.001 2.96 98.66 
 0.396 0.002 3.02 100.61 
 0.390 0.001 2.96 98.76 
 0.401 0.002 3.07 102.35 
 0.399 0.002 3.06 101.91 
 0.390 0.001 2.96 98.59 
 0.401 0.002 3.07 102.42 
 0.401 0.002 3.08 102.56 
 0.399 0.002 3.05 101.81 
 0.389 0.001 2.95 98.32 
Mean 0.396 0.002 3.02 100.60 
SD 0.005 0.00010 0.05 1.82 
CV (%)    1.81 
     
2 0.299 0.001 2.05 102.54 
 0.300 0.001 2.07 103.37 
 0.309 0.001 2.15 107.43 
 0.313 0.001 2.22 111.21 
 0.290 0.001 1.97 98.30 
 0.310 0.001 2.16 108.02 
 0.299 0.001 2.06 102.84 
 0.299 0.001 2.05 102.69 
 0.310 0.001 2.16 108.17 
 0.301 0.001 2.07 103.67 
Mean 0.303 0.001 2.10 104.82 
SD 0.007 0.00004 0.08 3.78 
CV (%)    3.61 
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6.1.7 Summary for key challenge 1.  
The objective when approaching key challenge 1 was to develop an automated, highly 
sensitive, accurate and precise assay for the detection of CRP in clinical samples, utilising 
the liquid handling workstation Biomek 2000.   
The accuracy and precision of the method were thoroughly investigated through intra- and 
interday analysis. Once deemed to be within acceptable limits the assay was applied to 
clinical samples of known CRP concentration for verification of the assay. An ideal dilution 
factor was also identified to allow for accurate quantitation of a varied range of CRP 
concentrations, in true clinical samples. Based on the data described above it can be seen that 
the objective has been achieved with an optimised and robust assay tested and proven with 
actual clinical samples.  
 
6.2 Key Challenge 2- Development of a high-throughput SPR screening protocol using the 
GEHC Biacore 4000. 
6.2.1 Experimental Approach 
High-quality antibodies are key components in diagnostic and therapeutic applications. 
Today, secondary screening of recombinant antibodies or fragments (e.g., scFv and Fabs) 
from different selection platforms is often an analysis bottleneck due to large datasets of low 
quality. In this section, the Biacore 4000 equipped with Biacore 4000 Antibody Extension 
Package was used for rapid screening, characterisation, and ranking of antibodies against a 
marker for cardiovascular disease (troponin I) as detailed in Figure 6.11.  
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Figure 6.11. Schematic overview of the process for selecting recombinant antibodies for 
diagnostic use. Biacore 4000, used for secondary screening, has the throughput required to 
resolve the analysis bottleneck and provides high quality binding, specificity, and kinetic 
data. 
 
The antibodies were initially developed to be incorporated into a point-of-care (POC) 
diagnostic device for the detection of cTnI in patients with suspected, recent myocardial 
infarction (MI). To serve as high quality diagnostic reagents for POC applications, ideal 
antibodies should have a high specificity and a high affinity that is temperature-stable. 
Additionally, the antigen of interest may require a very stringent screening protocol to ensure 
that the correct antibodies are selected for further characterisation and promotion to 
validation in appropriate assays and/or devices.  
 
In this study the antigen to be studied was cardiac Troponin I (cTnI) which exists in vivo as 
part of a complex. The Troponin complex is a heteromeric protein playing an important role 
in the regulation of skeletal and cardiac muscle contraction. It consists of three different 
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subunits – troponin T (TnT), troponin I (TnI) and troponin C (TnC). Each subunit is 
responsible for a part of troponin complex function (Gomes et al., 2002). 
Human troponin I is presented in cardiac muscle tissue by a single isoform with molecular 
weight 23,876 Da and it consists of 209 amino acid residues. The cTnI molecule contains 
two serine residues in the 22 and 23 positions. Both amino acid residues can be 
phosphorylated in vivo by protein kinase A, so four forms of protein – one dephospho, two 
monophospho and one bisphospho – can coexist in the cell. Phosphorylation of cTnI changes 
the conformation of the protein and modifies its interaction with other troponins as well as 
the interaction with anti-TnI antibodies (Zhang et al., 2011). 
Because of the complexity of the antigen this section will not only develop a high throughput 
screening protocol for the identification of specific, high-affinity recombinant fragments but 
also identify the epitopes bound by each of the antibodies in a high throughput epitope 
mapping experiment.  
 
6.2.2 Screening of scFv fragments based on stability 
The antibodies screened throughout this section were selected from a large immune antibody 
library of 10
9 
clones, described in section 2.2.5, using phage display. The library was panned 
against cardiac Troponin I (cTnI) and the plates screened contained monoclonal stocks from 
output plates obtained after four rounds of panning. All plates were obtained from the 
Applied Biochemistry Group (ABG) in DCU.  
The antibody panel screened, analysed using the set-up depicted in Figure 6.12., consisted of 
ten 96-well plates of crude bacterial extracts, expressed from the stocks as described in 
section 2.6.8, containing avian-derived scFv antibody fragments. 
The polyclonal anti-HA antibody was covalently immobilized to spot 1, 2, 4, and 5 in all 
four flow cells on Series S Sensor Chip CM5 with amine coupling to a level of 
approximately 7000 RU. Each of the crude cell lysates were centrifuged, diluted 1:4 in HBS-
EP+ buffer, and captured onto spots 1 and 5 of each flow cell. A solution of troponin I (50 
nM) was injected over all spots. During each cycle, 8 individual scFv samples were analysed 
simultaneously.  
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Figure 6.12: Biacore 4000 assay setup for screening of scFv fragments based on stability.  
The anti-HA capture antibody is immobilised by amine coupling to the CM-dextran surface 
of the sensor chip. The scFv fragments are then passed over the surface (Spot 1/5), followed 
by the antigen cTnI at 50nM (All spots). This set-up allows for a high level of referencing 
(both anti-HA and CM-Dextran surface controls for non-specific antigen binding are 
inherently included) and removal of any responses as a result of non-specific binding. The 
surface is then regenerated using 20mM NaOH, removing the scFv and cTnI complexes 
entirely and making the surface available for the next cycle.  
 
The antibody capture responses ranged from 0 to 890 RU depending on the antibody 
expression level and antigen responses varied between 0 and 210. 
The sensor surface was regenerated using 20 mM NaOH and the surface was used for 120 
cycles without any loss of binding activity. Ranking of binding stability was evaluated based 
on report points, placed early (stability_early) and late (stability_early) during antigen 
dissociation.  A selection of sample sensorgrams (120, representing all scFvs passed over 1 
of the 8 available analysis spots) with the report points indicated as coloured bars are shown 
in Figure 6.13. 
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Figure 6.13: Ranking of anti-cTnI scFv fragments based on complex stability. 
Sensorgrams shown represent those samples (120) passed over one particular analysis spot 
during each of the analysis cycles.  Complex stability is determined by expressing the 
response units at the stability_late (Red) time as a percentage of the response units at the 
stability_early point (Blue).  
 
Typically those antibodies which exhibit a higher complex stability are those which are the 
most desirable. The scatterplot, shown in Figure 6.14, displays report points stability_early 
plotted against stability_late and allows the ranking of scFvs based on binding stability. The 
figure shows two main groups of scFvs, non-binders close to the origin and binders higher 
along the diagonal.  
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Figure 6.14: Scatterplot for identification of stable binders from a population of clones 
screened. The plot is obtained by graphing Stability_early vs Stability_late. The dotted grey 
line denotes a 100% left (i.e. no dissociation once injection of antigen ceases) which would 
represent a very strong binding event. Those clones (blue squares) which are close to the 
100% left line exhibit high binding stability and have a very slow ‘off-rate’. Those clones 
denoted as green squares exhibit binding to the antigen but are less stable.  
 
The best binders, with a high binding stability and slow dissociation, are shown as blue 
squares. In total, 960 samples were analysed and ranked with respect to binding stability in 
27 h. Response levels early and late in antigen dissociation are plotted on the y-axis to show 
the quality of the interaction of captured scFv with antigen. Those clones which exhibit poor 
binding are distinguished from the best clones (close to the dashed lines) which have the 
greatest binding stability (slow off-rates). Importantly, Biacore analysis of antibodies and 
their fragments allows both the expression levels of the clones and quality of the antibodies 
to be measured simultaneously.  
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Figure 6.15: Ranking of scFvs based on antibody expression and antigen binding. Antigen 
binding stability, stability_early (top) and stability_late (bottom), is plotted against capture 
level in spot 1 (left) and spot 5 (right). Wells without scFv binding (blue squares), with 
significant capture (red squares), and scFvs showing a stable antigen response (red circles) 
are displayed. The green box indicates scFvs that are captured, but do not exhibit antigen 
binding. The best scFv clones show high capture level and high binding stability (circled in 
blue). 
Alternative methods to analyse each antibody is shown in Figure 6.15,  which gives an 
example of how report point data from the scFv screen  can provide an excellent overview of 
the performance of different clones. It correlates binding levels to the initial capture level 
(related to level of expression) of the scFv. In certain cases a scFv with high production rates 
might be desirable and may alter those clones selected for further characterisation. These are 
important criteria when selecting high quality antibodies and antibody fragments for further 
development. In this study the method of ranking by complex stability was employed and 
used to select the scFvs for 2-over-2 kinetic characterisation, which is discussed further in 
Section 6.2.3.  
 
6.2.3 Affinity ranking of scFv fragments by employment of 2-over-2 kinetics on Biacore 
4000. 
The top 10% binders (96) from the screening experiment, discussed in Section 6.2.2, were 
analysed using 2-over-2 kinetics. The Biacore 4000 Antibody Extension Package enables the 
setup of 2-over-2 kinetics using an additional spot-addressing functionality.  
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The assay setup, shown in Figure 6.16, involved the immobilisation of anti-HA antibody at 
two different levels (~4000 RU on spots 1 and 5, and ~2000 RU on spots 2 and 4) across 
each flow cell. The scFvs in cell lysate were diluted 1:4 and captured on spots 1+2 and 5+4. 
The antigen (cTnI) diluted to 100nM, 25nM and 0nM in HBS-EP+ was injected over the 
captured surface for 1 minute with dissociation monitored for 10 minutes. Data from the 
reference spot during each cycle were subtracted and each antigen response was then double 
referenced by subtracting the buffer response (zero antigen concentration) for each antibody 
tested, using the dedicated Biacore 4000 evaluation software. The analysis was performed at 
both 25°C and 37°C. 
 
Fig 6.16:    Biacore 4000 assay setup for “2 over 2” kinetic screening of scFv fragments. 
Two densities of capturing molecule are immobilized on the spots in each flow cell half 
(higher density on spots 1 and 5, lower density on spots 2 and 4). This enables capture of 
two levels of antibody in each flow cell half. The 2-over-2 kinetics analysis requires 3 
antigen cycles, 2 antigen concentrations plus a blank per antibody. The data are then 
combined and evaluated together for generation of the kinetic constants. 
Obtaining kinetics data early in the development process enables better-informed selection, 
since kinetic properties have consequences for both therapeutic and diagnostic agents. The 2-
over-2 kinetics approach is particularly suitable for providing kinetic information already 
during screening, as the data can be obtained in half the time using significantly fewer 
reagents and smaller sample volumes. Evaluation was performed with the kinetic evaluation 
tool in the Biacore 4000 Evaluation Software, by combined kinetic fitting of the sensogram 
data from spots 1-2 and 4-5, respectively. The evaluation combines the different surface 
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densities with the different analyte concentrations in one fit. To investigate temperature 
stability of the binding, all samples have been analysed at 25°C (Fig 6.17A) and 37°C (Fig 
6.17B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.17: Kinetic fits for a selected anti-cTnI clone (4E3). The overlay plots compare 
the performance of the same clone using a 2-over-2 kinetics run at two different 
temperatures to investigate stability of scFv/Troponin binding at 25°C (A) and 37°C (B) 
During a ‘2 over 2’ kinetics experiment, two levels of antibody are captured in each flow cell 
half and two concentrations of antigen are injected over the captured antibody. The data are 
then combined for the kinetic evaluation. A global fit of a 1:1 interaction model to the 
response data is shown; the black lines represent the global fit to the response data (blue 
lines). The performance of the 2-over-2 approach to a traditional ‘full’ kinetic (C) shows 
that the method provides an appropriate alternative to full kinetics screening and is a 
beneficial method for increasing throughput in screening campaigns.  
 
 
 
 
-20 
0 
20 
40 
60 
80 
100 
120 
140 
-100 0 100 200 300 400 500 600 700 
4E3 
Time (s) 
RU 
 KD = 3.38E-10 
 
 
-20 
0 
20 
40 
60 
80 
100 
-100 0 100 200 300 400 500 600 700 
4E3 
Time (s) 
RU 
 KD = 6.98E-10 
-5
0
5
10
15
20
25
-100 100 300 500 700 900
cTnI
Tim e s
R
e
s
p
o
n
s
e
RU
                            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                     
  
  
  
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
 
 
  
  
  
 
 
  
  
  
 
                                                                                                                                                                                                                                                                                                                                                                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                      
  
    
   
   
    
    
    
    
   
   
    
   
   
   
    
                                                                                                                                                                                                                                                                                                                                                                     
  
     
       
       
       
       
       
                                                                                                                                                                                                                                                                                                                                                                             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                      
4E3-Full Kinetic (25⁰C) 
4E3- ‘2-over-2’ Kinetic (37⁰C) 
4E3- ‘2-over-2’ Kinetic (25⁰C) 
KD = 4.276E
-10
 
High  
Low  
High  
Low  
 
 
cTnI Conc. 
Spot 1/5 
Spot 2/4 
High  
Low  
High  
Low  
 
 
cTnI Conc. 
Spot 1/5 
Spot 2/4 
cTnI Conc. 
1 in 2 series 
A 
B 
C 
201 
 
The data was also compared in a kinetic distribution plot (Figure 6.17C) which shows the 
association rate versus the dissociation rate, over the range of temperatures analysed. 
Temperature-stable, high-affinity scFvs were identified in Spotfire using on/off-rate maps 
(Fig 6.18). Due to licencing issues all Spotfire analysis was carried out in GEHC and was 
kindly shared with DCU.  
 
 
Figure 6.18: On/off-rate map for scFv antibodies specific to troponin I. The group with 
temperature-stable high affinities is most likely to be robust, and preferable for use in 
diagnostic analyses run at varying temperatures. 
 
All of the antibodies displayed in Figure 6.18 have high affinities in the sub-nanomolar 
range. However, two groups of antibodies displaying different kinetic behaviour were 
identified. One group compensated for an increase in off-rate at increased temperature by a 
parallel increase in on-rate, thereby displaying a temperature-stable affinity, while the other 
group showed weaker affinity at higher temperature. Because the analyses are typically 
performed between room temperature and 37°C on this diagnostic platform, suitable reagents 
must behave similarly at both temperatures. Temperature analysis is considered important as 
an antibody which is sensitive to temperature fluctuations may cause variation in the final 
assay, dependent on the environment in which the analysis is carried out. Those antibodies 
which exhibit stable binding affinity over a range of temperatures, and as such are not 
susceptible to fluctuations in ambient temperature, are the most desirable (Leonard et al., 
2011).  
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In less than 11 h, close to 100 samples were characterized with regards to on/off-rates and 
KD. Using the 2-over-2 kinetics approach, the best candidates, which showed temperature 
stable affinity, were quickly identified and could be advanced rapidly to the next stage of 
characterisation. 
 
6.2.4 Epitope Mapping of cTnI scFvs  
Cardiac Troponin I (cTnI) is considered a gold standard marker for damage and death of 
cardiac muscle. A great number of diagnostic tests have been developed and deployed but 
there did exist, at least initially, a large discrepancy in the results obtained for the same 
sample when analysed across multiple test methods. This was often attributed to the 
heterogeneity of cTnI forms in human blood and the difference in the epitope specificity of 
the antibodies utilized in different assays. This means that results obtained using different 
assays can differ greatly (Apple & Collinson, 2012).  
Often the concentration of cTnI measured with different assays could be found to vary by 
orders of magnitude (10-1000 fold), for the same sample (Tate et al., 2010).  Through efforts 
between national and international organizations, scientists, clinical practitioners and 
industrial assay manufacturers, the discrepancies observed are currently far less (Tate et al., 
2010). 
During the standardisation process of the cTnI assays there were two important factors 
identified and addressed. These included the introduction of the international cTnI standard 
(SRM 2921) developed by the National Institute of Standards and Technology (NIST) and 
also a gradual “standardisation” of the epitopes detected in commercial assays. Most assays 
now utilise antibodies which are specific to three regions of the cTnI molecule: 23–43, 41–
56 and 83–93 (Apple & Collinson, 2012). These regions are illustrated in Figure 6.19, which 
was kindly provided by BDI researchers following its generation using a protein modelling 
program, Deepview.  
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Figure 6.19: Human cardiac Troponin I (cTnI) ribbon structure. The structure was 
modelled, using the amino acid sequence, in the DeepView molecular graphics program. The 
regions from where the three peptides used for cloning were selected are highlighted and the 
amino acid numbers indicated. 
6.2.4.1 Cloning of cTnI peptides 
The cloning strategy, described in Section 2.6.12, involved the cloning of a cTnI peptide-
GFP gene fusion into pET28b vector using BamHI and HindIII. The peptides listed in Table 
6.5 were incorporated into the 5ˈ primer to yield the following construct 6xHis-T7 tag-
Peptide-GFP-6xHis-STOP. The same back primer was used for all peptides with the forward 
primer (encoding peptide) changing for each peptide.  
 
Table 6.5: Details of cloned cTnI peptides. The amino acid sequence for each of the cloned 
peptides is included as well as the location of the peptide within the native antigen. The 
specific antibody listed is the clone name of the commercially available Hytest antibody.  
Peptide Name Amino acid sequence Location Specific antibody (Hytest) 
Peptide 1 KISASRKLQLKT 39-50 19C7 
Peptide 2 NYRAYATEPHAKKKSKI 24-40 228 
Peptide 3 QPLELTGLGFAELQ 80-94 560 
 
Each of the peptides was confirmed to be present, by pick-PCR (section 2.2.12 and Figure 
6.20) and expressing correctly by small scale expression (2mL culture) of the clone and 
observation of the green colour obtained from expression of the GFP, prior to large-scale 
expression and purification. 
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Figure 6.20: Colony pick-PCR for confirmation of insert present in transformation 
colonies following cloning. This involved carrying out PCR on individual colonies, from the 
transformation plates, to confirm that that particular clone contained the gene of interest. 
Three colonies were investigated for each of the cloned peptides and all colonies contained 
the appropriately sized insert (~750bp). Marker used is TrackIt™ 1 Kb plus DNA Ladder 
(Invitrogen). B represents a PCR reaction which contained no colony material (i.e. template 
DNA). 
 
6.2.4.2 Expression and purification of cTnI peptides 
Each of the three cTnI peptides was expressed in large-scale culture, as described in section 
2.2.3. The level of purity obtained for each was assessed by SDS-PAGE analysis, as 
described in section 2.2.1, and one of the images obtained (Peptide 3-GFP) is shown as an 
example in Figure 6.21. Purified proteins were buffer-exchanged and concentrated using a 
Vivaspin column with a 10KDa MWCO. The protein concentration of each sample was then 
quantified at 280nm, using a Nanodrop instrument and they were aliquoted and stored at -
20⁰C for future use.  
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Figure 6.21: SDS-PAGE analysis of the IMAC purification of cTnI peptide 3-GFP. Lanes 
designated ‘M’ contain the protein marker (PageRuler plus pre-stained protein ladder, sizes 
for each of the bands are indicated to the left of the gel picture). The desired band is 
highlighted on the image. Lane 1 contained the crude lysate of cTnI peptide 3- GFP, 
generated as described in Section 2.2.3. Lane 2 represents the flow-through from the IMAC 
column, containing all proteins that did not bind to the IMAC column. Lane 3 contained 
Wash A, which removes non-specifically bound proteins to the column. Lane 4 contained 
Wash B which removes any additional non-specific proteins. Lane 5 contained the eluted, 
IMAC purified cTnI peptide 3- GFP which had been buffer exchanged and concentrated 
(expected size is approximately 28 kDa).  
6.2.4.3 Screening of anti-cTnI scFv fragments against cloned and purified cTnI 
peptides. 
Each of the purified cTnI-derived peptides was immobilised, through amine coupling, to a 
single spot in each of the four flow cells of a series S sensor chip. In order to test the 
performance of the immobilised surface, the commercial Hytest antibodies specific to each 
of the peptides were passed over the surface. The resulting binding profiles can be seen in 
Figure 6.22. In case of the Hytest anti-peptide 1 antibody there was a very large level of 
binding to immobilised peptide 1 (1382 RU), a certain amount of binding to peptide 2 
(190RU) and no binding to peptide 3. This cross reactivity could easily be expected as the 
region of cTnI that the antibody targets is adjacent to peptide 1. In terms of the both the anti-
peptide 2 and anti-peptide 3 commercial antibodies, their binding performance was as would 
be expected, showing no cross-reactivity with any of the non-targeted peptides.  
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Figure 6.22: Verification of peptide binding to commercial antibodies on Biacore 4000. 
The graph depicts the binding response (RU) for each of the commercial antibodies against 
the three cTnI peptides. This analysis was carried out prior to epitope mapping experiments 
on anti-cTnI in-house generated scFvs. Each of the peptides was immobilised to a CM5 
sensor chip and the Hytest monoclonal antibodies passed over the surface. The peptide 1-
specific antibody was 4T21-19C7, the peptide 2-specific antibody was 4T21-228 and the 
peptide 3-specific antibody was 4T21-560. 
The 960 anti-cTnI scFv fragments, from the high throughput stability screen, were tested 
against the immobilised peptides. Crude lysate for each fragment was passed over the entire 
flow cell, allowing four antibodies to be analysed in parallel, as shown in the raw sensogram 
in Figure 6.23. Binding levels for each of the peptides against each antibody were obtained 
following evaluation with the Biacore 4000 evaluation software.  
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Figure 6.23: Raw sensogram taken from the Biacore 4000 epitope screen. This view 
represents one scFv passing over one flow cell (FC1) with each spot/peptide represented by 
a different colour sensogram as detailed in the key at the bottom left. This particular clone 
solely binds to peptide 3.  
The binding to native antigen, obtained from the initial 10 plate screen data described in 
Section 6.2.2, was combined with the data obtained from the peptide screen to provide an 
epitope binding profile for each of the 960 antibodies screened. The resulting breakdown of 
binders can be seen in Figure 6.24.  
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Figure 6.24: Epitope mapping of 960 anti-cTnI scFvs against three cTnI-derived peptides 
and the native antigen using the Biacore 4000. Each of the antibody fragments was 
screened against 3 antigen derived peptides as well as the native antigen. All data was 
combined and the trend of binding profiles plotted. The predominant group appears to 
comprise those fragments which bind peptide 1 and 2 as well as the native antigen (472).  
Of the 608 fragments which bound the native antigen, the peptide specificity of each of the 
fragments could be defined. The data provide a detailed breakdown of the antibodies present 
within the library. In terms of value, this screen can be very useful in identifying the correct 
antibodies for a potential assay while quickly discounting a large number of unsuitable 
fragments (e.g. cross reactive with peptide 1 and peptide 2). What is perhaps most interesting 
to note is that when this library was screened using traditional methods (phage display 
followed by monoclonal ELISA analysis) the library was thought to be hugely biased 
towards peptide 3 specific fragments as those in the final selected clones were all directed 
toward that region. By looking at this screen one can see that peptide 3 binders account for 
only 76 of the total 960. What is interesting when seeing the full analysis is that peptide 3 
binders show very high levels of capture on the surface (related to antibody expression), 
explaining why they may be have selected as the “best” binders in ELISA. In addition only 
peptide 3 binders have a level of binding which exceeds 250 RU (up to a maximum 
2000RU); the majority of other binders have a response close to 100RU for their respective 
epitopes. This point helps to reiterate the need to carry out high-throughput screens, of this 
type, on larger numbers of antibodies early in the screening and selection process to ensure 
rare and/or valuable antibodies are not overlooked.  
1/cTnI (2)
1/2/cTnI (472)
2/cTnI (58)
3/cTnI (76)
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6.2.5 Summary for key challenge 6.2 
The high capacity of Biacore 4000 allowed sampling of a large diversity pool from phage 
displayed combinatorial antibody libraries. In just over 27 hours, 960 samples were screened 
and ranked based on binding stability. The top 10% from this analysis were then taken 
forward for 2-over-2 kinetic analysis which provided on-rates, off-rates, and affinity for 96 
scFvs in approximately 11 hours. Crude sample preparations were analysed without the need 
for purification, saving both time and resources. The capture-based approach minimizes 
assay development time and allows the convenient analysis of multiple analytes or antibody 
batches in a single analysis. The results show that kinetic data enables better-informed 
selection of antibody fragments. Off-rate-based screening for initial selection and rapid on- 
and off-rate mapping for characterisation, over a range of temperatures, are the keys to 
success in antibody development. In a separate epitope mapping experiment of 960 scFv 
fragments, carried out in just over 14 hours, a valuable insight into the specific binding 
properties of each of the individual fragments was provided. All this taken together 
demonstrates that the Biacore 4000 can provide the throughput and data quality needed to 
resolve the analysis bottleneck typically observed in the screening workflow of this type. 
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Conclusion and Significance: 
In this chapter two key research challenges were addressed, both concerned with 
demonstrating the benefit of utilising improved methods (i.e. Automated or high-throughput) 
in the selection and characterisation of recombinant antibody fragments.  
The first challenge involved the use of Beckman Coulter Biomek 2000 laboratory 
automation workstation for completion of a standard ELISA. Typical ELISA analysis can be 
both labour intensive and prone to human error or variation. By automating the process it 
was hoped that these factors could be reduced or even eliminated. The entire assay 
development was carried out by implementing specifically written programmes on the 
Biomek 2000. Each programme was designed to utilise the dedicated workspace and labware 
in the most simple and efficient way. All programmes were also tested several times with 
buffer prior to use with actual reagents to ensure that all operations performed as expected 
over multiple iterations. The workstation was used to perform all filling (coating, blocking), 
dilution (serial dilutions for standard curves) and washing steps, significantly reducing the 
required input from the end user and allowing for a high level of robustness overall from the 
assay.  
The accuracy and precision of the method were thoroughly investigated through intra- and 
interday analysis and found to be suited to the final application for the assay (i.e. 
determination of CRP levels in serum). The precision of the standard curve generated was 
tested and performed within recommended guidelines in terms of intraday (1.12 to 6.12% 
CV) and interday (6.92-16.83% CV) precision, Figures 6.7 and 6.8, respectively. The 
accuracy of the method was also investigated by testing the ability to correctly quantify the 
level of CRP in spiked samples using the standard curve generated. In terms of accuracy the 
method performed particularly well, in both buffer and serum, with values shown in Table 
6.1 and Table 6.2. The accuracy of calculation for intraday analysis in buffer were between 
4.61% and 5.97%, with interday values at 1.29 % based on three different analysis days. In 
serum, while slightly less accurate than in buffer, the assay also performed at a high level in 
both intraday (5.04-6.98%) and interday (5.74%) analysis.  
Once both the programmes and assay had been completely optimised and verified, as 
described above, the assay was employed for use with clinical samples. These samples were 
obtained from the Mater Misericordiae University Hospital in Dublin. Prior to their arrival in 
DCU they were analysed as per standard clinic practices, and the levels of CRP determined, 
using Abbott ARCHITECT c16000 Clinical Chemistry Analyser in a turbidometric assay 
format.  
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Due to the high-sensitivity of the CRP sandwich assay developed in this chapter and the 
wide range of CRP levels (2-21 mg/L) in the samples, it was necessary to carry out 
preliminary investigations on the level of dilution required to allow for accurate quantitation 
of the levels of CRP in future “unknown” clinical samples. By carrying out this analysis it 
was possible to identify a dilution factor (between 1 in 625 and 1 in 3125) which would 
allow for use of the assay for all CRP levels (Table 6.3). The samples were then diluted to a 
value within this range (1 in 2000), tested and the CRP levels quantified. The assay 
performed particularly well in this set of experiments and the quantitation of CRP across the 
range was highly accurate (100-105 %) and precise (1.2-3.78 % CV), as shown in Table 6.4.   
Based on the findings of this study, the use of the anti-CRP recombinant scFv A6 combined 
with the Beckman Coulter Biomek 2000 laboratory automation workstation helped to deliver 
a highly precise, accurate and robust assay for the determination of CRP levels in serum 
samples of patients.  
The second challenge addressed in this chapter was to establish a high-throughput screening 
protocol, for recombinant antibody fragments, utilising the Biacore 4000. A set of 
antibodies, against cardiac troponin I, were analysed throughout the study. The ultimate goal 
of the analysis was to develop a method for high throughput screening that could be used to 
streamline the antibody discovery process irrespective of target analyte. With this in mind 
the screening campaign was designed to provide the greatest amount of information, for each 
individual antibody, in the most efficient manner.   
In terms of this particular analysis, desirable qualities of antibodies would include a high 
level of binding stability (fast on-rate and slow off-rate), high affinity and binding to specific 
areas within the native antigen. The analysis involved the ranking of 960 scFv fragments 
based on their binding stability (Figure 6.13), the top ten percent of those ranked (96) were 
then affinity ranked utilising a “2-over-2” kinetic screen which proved much faster than a 
traditional kinetic screen while providing a similar output in terms of kinetic constant values 
for each of the clones (Figure 6.17).  Due to the high-throughput nature of the “2-over-2” 
approach it was carried out over several analysis temperatures (Figure 6.18), further 
narrowing the number of clones which behaved in a desirable fashion (i.e. affinity and 
on/off-rates remained stable despite a shift in analysis temperature). All antibodies 
demonstrated picomolar affinity for the native antigen at 25⁰C and ranged from high 
nanomolar to picomolar affinity when analysed at 37⁰C.  
In addition to ranking and definition of the affinity of the antibodies, an epitope mapping 
experiment was carried out to identify exactly where on the antigen the scFv fragment 
bound. This involved the cloning and expression of three different cTnI-derived peptides, 
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described in section 2.6.12, and their subsequent immobilisation on a Biacore sensor chip. 
The scFv lysate were then passed over all the peptides and their specificity profiles 
determined (Figure 6.24). It was interesting to note that, when compared with the typical 
screening approach usually undertaken in the laboratory (i.e. predominantly ELISA 
characterisation with Biacore kinetic analysis for a small number of clones), the clones 
identified were more diverse in their binding properties.  
In addition to the advantage of a greater level of knowledge obtained for each individual 
clone, all of the screening programmes mentioned were carried out in relatively short time 
frames. There is a minimal time commitment from the user once programmes are designed 
and reagent and sample plates prepared and loaded to the instrument, as the analysis does not 
require any additional input until evaluation. In all, the entire screening campaign, taking 
into account the need to immobilise three different chips to allow for the analysis, could 
theoretically be completed within a week. This offers a very attractive alternative to the 
traditional ELISA-based approaches which can often take considerable time and effort to 
complete effectively.  These and further anti-cTnI antibodies developed at the BDI were 
screened, using this very tailored approach, by the dedicated cardiac biomarker team and the 
best antibodies licensed to industry. This further development and characterisation was 
reported in Conroy et al. (Conroy et al., 2012).  
Overall, the two key challenges of this chapter have been rigorously investigated. The 
establishment of suitable screening protocols, automated (Biomek 2000) or high-throughput 
(Biacore 4000), for each set of equipment was completed. The use of these protocols and 
procedures could easily be implemented for all users to allow for a higher degree of certainty 
of finding and accurately characterising the optimal antibody for each individual application 
or project. Also noteworthy is the higher level of repeatability afforded by the introduction of 
robotics/liquid handling allowing for more reliable results and improved efficiencies within 
traditional screening approaches.  
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Chapter 7 
Overall Conclusion 
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Monoclonal antibodies are now the largest class of biological drugs with at least 36 
monoclonal antibody drugs approved by the FDA, and are currently responsible for almost 
40% of the market (Aggarwal, 2014) . With the antibody discovery field expanding year on 
year, in the area of biological therapeutics, and hundreds of potential new antibody drugs in 
clinical trials it is expected that antibodies will drive in excess of 50% of total market growth 
within the pharmaceutical industry over the next 3-4 years.  
The numerous ways by which to generate monoclonal antibodies have been discussed in the 
earlier chapters of this thesis and it can be said that there are a plethora of options available 
to the community, each with advantages and disadvantages associated. The two gold 
standards have been phage display and hybridoma technology coupled with cloning by 
limiting dilution. They have demonstrated through their uptake across the general 
community that they are amenable to use in all research situations, whether based in 
commercial, industrial or academic laboratories. 
In comparing DiCAST with the traditional methods, the benefits of utilising a single cell 
screening tool of its type are clear as discussed further below.  
The disadvantages of phage display as an antibody selection tool, such as the potential high 
level of non-specific phage and the presence of truncated clones, have been discussed in 
Chapter 4 and provide evidence of the need to establish new approaches for the screening of 
antibody libraries which have been generated recombinantly and are expressed in bacteria. 
DiCAST offers this option, by allowing the spatial addressing of millions of individual 
bacterial cells each secreting a monoclonal antibody. A direct comparison of the two 
approaches is shown in Table 7.1.  
In terms of recombinant screening, the ability to address cells on a single cell basis is highly 
novel. The large size and diversity of the libraries generated means that only ultra-high 
throughput methods, such as DiCAST, FACS, next generation sequencing or micro-droplet 
platforms, can screen the number of cells required to properly probe any given library. 
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Table 7.1 Comparison of phage display and DiCAST for recombinant screening.  
Recombinant Screening 
Antibody Source Bacterial antibody fragment library 
No. of starting cells  1 x 10
8 
 - 1 x 10
10
 
Method Phage display method DiCAST method 
Selection process 2 to 4 rounds of enrichment by 
biopanning 
0-1 round of enrichment by 
biopanning 
Time (days) 3 – 8  0 – 2   
No. of wells per plate 96-384 wells 950,000 - 10 million capillaries 
No. of single cells per plate 96-384 ~300,000 – 3 million 
Primary screening assay type  Binding Binding, cross reactivity and/or 
functional in one screen 
No. of surfaces for analysis 1 2 or more 
Min. time for mAb detection 1 day <6 hours 
Antigen required per plate 24 – 48 µg 1 – 4 µg 
Test volume per well  75 – 200 µL 80 pL – 1.2 nL 
 
As discovered in Chapter 4 (Section 4.1.2) it is entirely possible to find the same as well as 
superior antibodies from a particular library, in a much improved time frame, when 
comparing DiCAST to phage display. An additional advantage is the fact that antibodies 
which are selected are suited to soluble expression, which is important when moving on to 
characterisation and potentially large-scale expression. Furthermore, all antibodies can be 
addressed without a bias towards those which are more suited to expression on the surface of 
a bacteriophage.  
Practical considerations such as the amount of antigen required for screening and the 
opportunity to increase the numbers of assays carried out simultaneously by harnessing the 
unique multiplexing features available also make DiCAST a favourable alternative to the 
traditional approach of phage display.  
In terms of screening of mammalian cells, which include hybridoma cells, immortalised cells 
or native B cells, the traditional approach that is often taken is cloning by limiting dilution 
which has been described in Chapter 1. While progress in areas of laboratory automation and 
liquid handling robotics have allowed for the laborious and time-consuming nature of this 
method to be addressed, there are still questions pertaining to the overall effectiveness of 
plating cells at densities which tend to favour those that grow quickly without any preference 
for those that are secreting a desirable antibody. 
When comparing the DiCAST approach for screening of mammalian cells with the typical 
cloning by limiting dilution method (Table 7.2) it is not difficult to identify the distinct 
advantage that microtools, such as DiCAST, present. The first distinct advantage is the time 
taken for screening. Because of the need to grow cultures for between 2 and 3 weeks per 
round of cloning and the fact that several rounds of cloning are typically required, DiCAST 
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provides a highly attractive substitute to the traditional approach. When this is coupled with 
the added improvements in areas of throughput and multiplexing as well as reduction in 
antigen required and overall footprint in terms of laboratory space (i.e. A microscope slide 
sized microcapillary array is equivalent to 10,000 x 96 well plates) the use of DiCAST for 
mammalian cell screening can be seen as an much more efficient method. 
Table 7.2 Comparison of cloning by limiting dilution and DiCAST for mammalian cell 
screening.  
Mammalian screening 
Antibody Source Heterogeneous mix of hybridomas, native B cells or immortalised 
cells 
No. of starting cells  1 x 10
5 
 - 1 x 10
8
 
Method Traditional method DiCAST method 
Selection process Culture of thousands of cells 
per well followed by 1-3 rounds 
of cloning by limiting dilution 
Direct immunoanalysis of 
single cells in microcapillaries 
Time (days) 14-56 1-3  
No. of wells per plate 96-384 wells 950,000 - 2.5 million capillaries 
No. of single cells per plate 96-384 ~300,000 – 900,000 
Primary screening assay type  Binding Binding, cross reactivity and/or 
functional in one screen 
No. of surfaces for analysis 1* 2 or more 
Min. time for mAb detection 3 – 7 days <6 hours 
Antigen required per plate 24 – 48 µg 1 – 4 µg 
Test volume per well  75 – 200 µL 300 pL – 1.2 nL 
*Supernatant from each well could technically be analysed multiple times in separate ELISA-based 
assay but is limited by the amount of supernatant available from each well and the labour intensive 
nature of the screening.  
 
Despite its limitations, the use of cloning by limiting dilution and other microtitre plate-
based screens continue to be utilised, alone or in combination with other techniques, to 
screen antibody-secreting cells for antibody discovery. Indeed several companies which are 
leaders in the field (e.g.  AdiMab, AiMM Therapeutics, Anaptys Bio, Biotem, Humab 
Biomed, Immunome, Novimmune, Fabrus, Theraclone, Trellis Bioscience and UCB) utilise 
some form of microtitre plate based method as part of their screening programme. It should 
be mentioned that each of these companies hold their own unique selling points and have 
amended and improved the typical process in one way or another.  
For instance UCB Pharma, carry out an initial ELISA-based screen on a particular B cell 
population, plated at a high density of cells per well, to identify cells which contain a B cell 
clone of interest. Once identified the well is screened using what is termed the fluorescent 
foci method, which involves placing the cells on a glass slide with a labelled antigen (e.g. an 
antigen immobilised on a bead or a surface bound receptor on a cell) and allowing them to 
incubate together for approximately 2 hours (Lightwood et al., 2013). As the B cells begin to 
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secrete IgG, those producing antibody specific to the labelled antigen will develop a halo of 
fluorescence. These individual cells are then removed, and the genes captured by RT-PCR, 
using a micromanipulator (Clargo et al., 2014). UCB Pharma also employs a high level of 
automation within their screening facility to enable efficient initial screening (Presentation 
given by Daniel Lightwood at HAH conference in 2014).   
Another interesting approach is that used by Trellis Biosciences, who employ their 
CellSpot™ assay, which utilises beads with a number of different biological components 
attached in a highly multiplexed manner. Cells are placed on a membrane and overlaid with 
a semi-solid medium effectively immobilising them in the well. The antibody secreted from 
each cell is captured on an antibody-coated slide beneath the membrane and is probed with 
multiple labelled beads. Cells of interest are allowed to reach a colony of approximately 10-
50 cells and are retrieved for processing by micropipette (Harriman et al., 2009).  
While these traditional approaches have stood the test of time and remain in use today, there 
has been a shift in the focus of the community towards increasing the throughput, sensitivity 
and information garnered for each antibody-secreting cell screened. As single cell analysis 
has become more commonplace, novel ways in which to screen and interrogate each cell 
within a population have emerged and are now becoming the cornerstone technologies and 
platforms of leading companies in the antibody discovery space, either replacing or 
complementary to traditional approaches (Table 7.3).  A number of these single cell, high 
throughput techniques are discussed in greater detail below.  
FACS has developed from its conception in 1969 (Hulett et al., 1969) into a very well 
established and supported technology for the high-throughput analysis of heterogeneous cell 
populations from various sources (e.g. blood, tissue, antibody-secreting cells). It is widely 
used alone or in combination with complementary methods by a number of antibody 
discovery companies (e.g. AdiMab, AiMM Therapeutics, Anaptys Bio, Biotem and 
ImmunoQure among others) and with sorting times as fast 10,000 cells per second it is not 
difficult to see why it is so popular.  
The major advantage of using FACS is the ability to sort a very large number of cells on a 
single cell basis in a relatively short space of time. The technology is also very amenable to 
multiplexing, with typical analysis capturing up to 20 different criteria (e.g. cell size/shape, 
nucleic acid content, membrane integrity, cells undergoing apoptosis etc.) in a highly 
sensitive and efficient manner. The limitations of the technology as a means to screen 
antibody libraries tends to focus on the sensitivity of the method, with loss of potentially 
interesting clones often attributed to high levels of noise (Harriman et al., 2009). In addition 
the ability to detect secreted products is somewhat limited, as reliable detection is generally 
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carried out using intracellular or cell surface based targets. A previous disadvantage of 
FACS arose in the retrieval of cells, as cells are typically collected as bulk populations and 
would require subsequent characterisation of the sorted populations. Machines which allow 
single cell retrieval are now available and have begun to negate this issue. 
The relatively recent emergence of novel microtools to circumvent the limitations of 
traditional screening approaches has led to the discovery of many very interesting antibodies 
and also has allowed a much more in-depth analysis of the immune system (Ogunniyi et al., 
2009; Varadarajan et al., 2012). 
All microtools, irrespective of their classification (i.e. microwell, microdroplet or 
microfluidic chamber) have inherent advantages such as lower consumption of reagents, 
shorter analysis time (attributed to faster accumulation of detectable target in the reduced 
volumes), compatibility with multiple cell types, amenability to multiplexing and the all-
important ability to screen cells on an individual basis.  The different classifications each 
present their own advantages and disadvantages when compared to each other in Table 7.3, 
and as discussed below.  
Microtools utilising microwells, described in Chapter 1, involves the seeding of individual 
cells into a chip containing microengraved wells and analysing their response either directly 
in the well or by capturing secreted proteins on a slide sealed to the chip. Once identified 
cells of interest are retrieved using a micromanipulator and are either expanded in culture or 
the genetic information captured by RT-PCR. Some approaches, such as those carried out by 
the company Single Cell Technologies (http://www.single-cell-technology.com/) lyse the 
target cell in the microwell and carry out RT-PCR in situ. The variable regions in each well 
are then sequenced and the antibody sequence related back to the response obtained in the 
assay.  
A number of successful applications of this approach are described in the literature. For 
instance, the ISAAC (Immunospot Array Assay on a Chip) method described by Jin et al. 
describes the use of microwells for the discovery of biological therapeutics and is the 
cornerstone technology of the antibody discovery company Valneva (Jin et al., 2009). 
Valneva markets a vaccine against Japanese encephalitis which was approved in the 
U.S., Europe, Canada, Hong Kong, Singapore, and Israel under the trade name 
IXIARO
®
 and in Australia and New Zealand, where it is marketed as JESPECT
® 
(http://www.valneva.com/). 
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Table 7.3 Comparison of microtools currently available 
Notes: All technologies are utilised for single cell screening. All technologies are amenable to multiplexing assays. All technologies can be used to screen native B cells, 
immortalised cell lines and hybridomas with DiCAST and the droplet technologies also capable of screening bacterial cells (mostly due to throughput required). (* Surfaces 
can be removed and replaced with additional prepared surfaces to allow for added assay throughput and functionality).  
Name Microtool 
Category 
Throughput Assay format  No. of assay 
surfaces 
Assay Type Cell recovery Publication/Website 
DiCAST Microcapillaries  
(80 pL - 2 nL) 
1-10 million 
capillaries per chip 
Surface 
Homogenous 
≥2 * Binding 
Functional 
Automated (every 3 
seconds); Single cell 
Fitzgerald et al. (2015). Analytical 
Chemistry; 87, pp 997-1003 
HiFiBio Droplets  
(50 pL) 
>1000 droplets per 
second 
Homogenous N/A Binding  Collected as sorted by 
FADS; Bulk or single 
cell 
Mazutis et al. (2013) 
Nature Protocols; 8 (5), pp 870-
891 
Sphere Fluidics Droplets  
(pL to nL) 
Up to 1 billion 
droplets per screen 
Homogenous N/A Binding 
Functional 
Collected as sorted by 
FADS; Bulk or single 
cell 
http://www.spherefluidics.eu/index
.php 
Enumeral 
Biomedical Inc. 
Microwells  
(100 pL- 1 nL) 
25,000-234,000 per 
chip 
Surface   ≥1 * Binding Micromanipulator (>1 
minute); Single cell 
Love et al. (2006)  
Nature Biotechnology 24 (6); 
pp703-7 
Single cell 
technologies 
Microwells 
(100 pL- 1 nL) 
30,000 cells per 
chip 
Surface ≥1 * Binding 
Functional 
RNA extraction 
carried out on chip; 
single cell (VH and 
VL paired) 
http://www.single-cell-
technology.com/ 
Valneva Microwells  
(100 pL- 1 nL) 
62500 wells per 
chip 
Surface 1 Binding 
Functional 
Micromanipulator (>1 
minute); Single cell 
Jin et al. (2009) 
Nature Medicine; 15 (9), pp1088-
1092 
Abcellera Microfluidic 
chambers  
(4.1 nL) 
8092 chambers per 
chip 
Homogenous N/A Binding 
Functional 
Automated 
micromanipulator (>1 
minute); Single cell 
Lecault et al. (2011). Nature 
Methods; 8 (7), pp 581-586 
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The numerous papers from Christopher Love’s laboratory describe the utilisation of 
microwell arrays for the interrogation of not only antibody-secreting cells (Love et al., 2006; 
Ogunniyi et al., 2009; Story et al., 2008) but also the dissection of the immune response by 
profiling the T cell population on a single cell basis (Varadarajan et al., 2012). Their work 
formed the basis for the company Enumeral, who are currently generating novel antibody 
immunotherapies, or immunomodulators, targeting checkpoint proteins (e.g. PD-1, OX40 
and Lag3) (http://www.enumeral.com/).  
In comparison with DiCAST the microwell approach has several disadvantages, of which the 
main element is throughput, as chips must be fabricated and the number of wells is currently 
limited to approximately 90,000 or fewer individual microwells. The ISAAC method is 
limited to only one analysis surface, as the halo of fluorescence is detected on the chip, 
which again negatively effects throughput and information that is obtained from each screen.  
Microdroplets are another microtool approach which has been applied to the discovery of 
antibodies in recent years. It involves the isolation of individual cells by capturing them in 
two-phase droplets which range in volume from picolitre to nanolitre (Mazutis et al., 2013). 
They can be used for single cell analysis in a range of applications from antibody and 
cytokine secretion to gene expression or enzymatic activity (Love et al., 2013). Droplets are 
sorted by FADS (Fluorescence activated droplet sorting) which works on the same principle 
as FACS but overcomes the limitation of detection of secreted product as the secreted 
product is also contained within the droplet. Interestingly, passive droplet fusion, electro-
coalescence, and pico-injection have all been utilised to allow addition of  reagents at a 
certain time point which adds to the diversity of assays which can be carried out in droplets 
(Mazutis et al., 2013). Desirable features of this screening approach include the highly rapid 
analysis (i.e. >1000 droplets per second) and also the diversity of analyses that can be carried 
out in the droplets, including the ability to lyse the cell in the droplet and carry out RT-PCR 
in situ (Hatch et al., 2011).  
In comparing the approach with other microtools there are a number of disadvantages when 
adopting the use of microdroplets for screening of antibody-secreting cells. The approach is 
only compatible with homogenous assays which can be carried out in solution without the 
need for washing steps. Additionally the generation and manipulation of the droplets requires 
very precise conditions and cells are typically collected in bulk as they are sorted, likely 
requiring additional rounds of screening to isolate  the desired monoclonal antibody.  
Nevertheless, El Debs et al. describe the use of micro-droplets to successfully screen 
approximately 300,000 individual hybridoma cells against ACE-1 which is associated with  
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blood pressure regulation  and the development of vascular pathology and remodelling (El 
Debs et al., 2012).  
There are also a number of companies which describe the use of microdroplets in biological 
discovery. HiFi Bio offer a range of screening options that include antibody discovery 
(Droplet mAb) as well as other interesting application of microdroplets such as whole 
genome chromatin DNA mapping from a single cell (Droplet ChIP-seq) and single cell, high 
fidelity dose response screening (http://www.hifibio.com/).  
Another company, Sphere fluidics, offer a service model which can either carry out the 
discovery project for a customer or facilitate the design of a specific analysis biochip. They 
also supply a number of off-the-shelf products including specialised chemical reagents and 
polymer picodroplet biochips to facilitate single micro/picodroplet screening 
(http://www.spherefluidics.eu/index.php).  
The use of microchambers constitutes the third microtool category that is currently available 
for single cell screening. It involves the capture and of single cells in microchambers, linked 
by a microfluidic system, and the performance of bead-based assays to detect specific 
antibodies produced.  This approach, while limited to utilising homogenous assays, 
overcomes the associated lack of sensitivity seen in microdroplet or in situ microwell assays 
by allowing washing steps to be incorporated. Additionally, medium exchange can be carried 
out, if required, facilitated by the unique microfluidic valve system.  
Some disadvantages associated with this approach when compared to other methods include 
the requirement for manufacture of highly specialised chips. To scale-up such a complex 
device would be difficult, if possible at all, and the chip size is currently limited to 
somewhere in the range of 10
3
 chambers per chip (Lecault et al., 2011). Other limitations 
include the difficulty of single cell seeding as the chambers are linked and also that manual 
visualisation of the chip is required to detect a specific response. This factor slows down the 
overall processing time and ultimately reduces throughput.  
Microchambers  have been extensively employed for diverse uses such as antibody 
discovery and affinity ranking (Singhal et al., 2010), stem cell proliferation (Lecault et al., 
2011), cell signalling (Ricicova et al., 2013), RT-qPCR of single cells (White et al., 2011) 
and miRNA analysis of single cells (Petriv et al., 2010). These studies, among others, have 
led to the establishment of the company Abcellera which offers an antibody discovery model 
through collaboration with pharmaceutical companies using their microchamber platforms 
(http://abcellera.com/).  
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Our newly developed Direct Clone Analysis and Selection Technology (DiCAST) represents 
a new class of microtool and delivers fully customisable deep screening of cell libraries. By 
isolating, culturing and interrogating up to 10 million antibody-secreting cells in a nanoscale 
self-contained environment per experiment, the screening avoids any bias typically 
introduced in traditional methods, which analyse cells in bulk, and is applicable to both 
prokaryotic and eukaryotic library systems.  
DiCAST represents the first described incidence of screening single antibody-secreting cells 
using microcapillaries (PCT Patent Application No: PCT/EP2011/062015) and is entirely 
novel in that respect. DiCAST offers an enhanced option when compared with the other 
microtools currently described, within the industry as a whole, as the throughput is much 
greater than many of them (i.e. they are typically limited to numbers close to 10
5
 single cells) 
and the analytical output has the potential to also exceed those of close competitors.  
 
The DiCAST technology has several advantages over its direct competitors including the 
fact that microcapillary arrays are an off-the-shelf product available commercially, meaning 
that capillary size and density can be varied, making it highly scalable to increase 
throughput. The straw-like nature of the arrays also offers up unique advantages in two 
respects. The first is the ease of retrieval, with contents easily removed by application of 
force on an opening and capture of the ejected contents on the opposite side. The second is 
that dual openings lend themselves to very efficient multiplexing with the associated 
methods (i.e. multi-analyte, multi-Lift and especially double-sided analysis) which have been 
described in Chapter 3.  
Apparent disadvantages such as the requirement for high precision alignment, a custom 
prototype for accurate retrieval of the contents of a single target capillary, the need for 
specialised software for interpretation of data and the ability to carry out complex assays on 
a hydrophobic surface have all been overcome in the process of developing the technology.  
This demonstrates that they were not insurmountable and that the unique advantages 
afforded by the use of microcapillaries for antibody discovery far outweigh any potential 
limitations.  
In screening such a high number of antibody-secreting cells the final number of selected, 
interesting antibodies can also be high. Through clever design of the screening assay on 
DiCAST, by building in several assays through the multiplexing options available, it is 
possible to select only those antibodies which meet a very specific list of criteria. It is hoped 
by screening in this way that the number of antibodies that will be taken forward following 
this initial selection round will be kept to a manageable level. Even so during the course of 
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this work a number of high throughput and automated approaches for antibody 
characterisation to fully complement the DiCAST screening process have been developed. 
 
The first approach was the development and testing of protocols for the implementation of 
high-throughput Biacore screening. Biacore has become the household name for SPR 
analysis and their range of instruments cater to users of varied requirements (i.e. low 
throughput research instruments amenable to troubleshooting and fine-tuning as well as high 
throughput instruments with standardised reagents kits allowing ease of use and a high level 
of reproducibility). The techniques discussed in Chapter 6 allow for an efficient and 
informative analysis of a large number of clones (960) in a relatively short period of time, 
utilising the high throughput Biacore 4000 instrument. The use of crude lysates for both 
binding and kinetic analysis, using a capture format, allows for the antibodies to be screened 
without the need for any complicated or laborious purification procedures, further reducing 
the time to select and characterise antibodies of interest.   
 
The second involved performing assay development using a Beckman Coulter Biomek 2000 
laboratory automation workstation.  Optimisation of programmes for automated platforms 
such as this gives the opportunity to further streamline the entire process by removing the 
need for users to carry out ELISA-based methods manually. The correct use of automation, 
implementing fully optimised protocols, can also allow for a greater level of precision and 
reduces the variability often encountered between different users and laboratories. Its 
description within this thesis aimed to demonstrate that automation, in this case of an assay 
for C-reactive protein in clinical samples, helped to provide a robust and reliable assay for 
potential clinical use.   
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Table 7.4 Comparison the antibody discovery technologies from companies generating monoclonal antibodies for therapeutic use.  
Name Disease Area Approach Additional Offerings 
Abcellera 
 
As requested (service model) Microfluidic Chamber single cell 
screening 
 
Adimab As requested (service model) Yeast Display (Surface/FACS or 
Secretion/ELISA modes available) 
Ultra HT FACS (10, 000 cells per second) 
AiMM Therapeutics Cancer  
Infectious diseases 
FACS/ELISA Proprietary immortalisation method 
AIMProve (Improve affinity/stability) 
AIMLink (Develop bispecifics or ADCs) 
Anaptys bio Cancer 
Inflammation  
FACS/ELISA SHX-XEL (In Vitro somatic hypermutation platform) 
Arsanis Biosciences Infectious Diseases 
Toxins (S.aureus toxin, E.coli, Shigella) 
Hybridoma/Yeast Display  
Enumeral Biomedical Inc. Checkpoint proteins (PD-1, OX40 and 
Lag3) 
Microwells single cell screening  
Fabrus/Sevion Cancer 
Autoimmune diseases 
Chronic pain 
Diabetes 
FACS/ELISA FAST (Fabrus arrayed screening technology) arrays the 
members of their in-house library (Fab with longer 
CDR3 regions) in the wells of microtitre plates for 
screening. 
Genmab/Medarex Cancer 
Autoimmune diseases 
CNS diseases 
Infectious diseases 
Not stated Duobody® platform (bispecifics); Unibody® platform 
(silencing effect); Hexabody® platform (increased 
potency) 
HiFiBio As requested (service model) Droplet single cell screening Single cell whole genome chromatin DNA mapping, 
Single cell, high resolution dose response screening 
Humab Biomed Cancer 
Infectious disease 
inflammatory disease  
CellClone (EBV immortalisation with 
HT Microwell screening) 
 
Immunome Inc. Cancer Hybridoma (proprietary cell fusion 
method) 
 
Intrexon (mAbLogix) Not specified (Service provided) LEAP® (Laser enabled analysis and 
processing) 
 
Kenta Biotech Hospital acquired infection Hybridoma (MabIgX platform with 
unique specific heteromyeloma fusion 
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cell line ) 
Mabvax therapeutics Cancer Not stated  
Morphosys Cancer 
Inflammatory diseases 
Autoimmune diseases 
Phage Display (HuCal  high content 
library) 
Yscreen (Robotic liquid handling and screening); 
Slonomics (Genetic engineering platform) 
NovImmune Cancer 
Inflammatory diseases 
Autoimmune diseases 
Phage Display/ELISA screening  Fully human bispecific IgG generation using 'Kappa-
Lambda' body 
Patrys Cancer Not stated Optimised expression and purification of IgM in Per.C6 
cells  
Single cell technologies As requested (service model) Microwells single cell screening, cells 
lysed and RT-PCR carried out in situ 
Affinity Ranking available 
Sphere Fluidics As required (technology model) Droplet single cell screening Alternative analysis available includes bacterial cell 
screening (antibiotic resistance etc.) 
Theraclone Biosciences Cancer 
Infectious diseases 
Single cell ELISA screening   
Trellis Bioscience Cancer 
Infectious diseases 
Proprietary CellSpot platform 
(multiplexed probes on latex beads)  
Single cell screening in plates 
UCB  CNS and immunology disorders ELISA screening  SLAM (Selected Lymphocyte antibody method) and 
Fluorescent foci method. High level of automation 
available 
Vaccinex Cancer 
Multiple sclerosis 
Recombinant cDNA libraries in Vaccinia 
virus (panning/cell sorting screened) 
 
Xbiotech Infectious Disease  Microwells single cell screening Competency in vaccine development (EB66 cell line for 
production, IC31 approved adjuvant) 
Note: Where fields remain blank information is not readily available. 
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Future Outlook: 
In terms of future work there are several areas of development and validation that are 
required for DiCAST to reach its full potential. The first of these is in the identification, 
optimisation and implementation of a number of other assay offerings, such as affinity 
ranking on array.  
The second is concerned with the modification and improvement of the retrieval device to 
increase the rate of successful retrieval for mammalian cells. Due to their fragile nature a 
new approach using liquid-liquid retrieval where a small jet of buffer or medium is used in 
place of the high pressure nitrogen gas is envisioned and will hopefully become a realised 
entity in the coming year. In connection with this, a microscope-based imaging system is 
being considered which will help to increase the throughput of the system in two ways, the 
first being the ability to use larger arrays, where the sample size will not be limited to a 
microscope slide size (as is currently the case with the microarray scanner). The second way 
being that the enhanced resolution of this type of imaging system will mean that the capillary 
size and the distance between capillaries can both be reduced. 
The final element that will be enhanced in the DiCAST process is the software packages for 
ranking, sorting and correlation of the data. Employing this type of data mining generates a 
very powerful tool to select unique subsets of antibodies from potentially tens of thousands 
of hits.  
Once these new amendments have been incorporated the ultimate aim is to begin to utilise 
the technology to screen human B cells, ideally isolated from patients who are recovering 
from diseases such as cancer or have been recently exposed to infectious agents. This will 
help researchers to decipher the way in which the immune system fights off these attacks and 
will hopefully lead to the discovery of much needed future medicines. 
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